[go: up one dir, main page]

NZ711657B2 - Cftr mrna compositions and related methods and uses - Google Patents

Cftr mrna compositions and related methods and uses Download PDF

Info

Publication number
NZ711657B2
NZ711657B2 NZ711657A NZ71165714A NZ711657B2 NZ 711657 B2 NZ711657 B2 NZ 711657B2 NZ 711657 A NZ711657 A NZ 711657A NZ 71165714 A NZ71165714 A NZ 71165714A NZ 711657 B2 NZ711657 B2 NZ 711657B2
Authority
NZ
New Zealand
Prior art keywords
mrna
cftr
seq
lung
hcftr
Prior art date
Application number
NZ711657A
Other versions
NZ711657A (en
Inventor
Frank Derosa
Braydon Charles Guild
Michael Heartlein
Christian Plank
Carsten Rudolph
Lianne Smith
Original Assignee
Ethris Gmbh
Shire Human Genetic Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethris Gmbh, Shire Human Genetic Therapies Inc filed Critical Ethris Gmbh
Priority to NZ751462A priority Critical patent/NZ751462A/en
Priority claimed from PCT/US2014/028849 external-priority patent/WO2014153052A2/en
Publication of NZ711657A publication Critical patent/NZ711657A/en
Publication of NZ711657B2 publication Critical patent/NZ711657B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/03—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
    • C12Y306/03049—Channel-conductance-controlling ATPase (3.6.3.49)

Abstract

Materials, formulations, production methods, and methods for delivery of CFTR mRNA for induction of CFTR expression, including in the mammalian lung are provided. The present invention is particularly useful for treating cystic fibrosis.

Description

CFTR MRNA COMPOSITIONS AND RELATED S AND USES RELATED APPLICATIONS This application claims priority to US. Provisional Application Serial No. 61/783,663, filed March 14, 2013, the disclosure of which is hereby incorporated by reference.
BACKGROUND The present invention relates to cystic fibrosis embrane tor (CFTR) mRNA compositions, uses of same, and methods of making and using same.
Cystic fibrosis is an autosomal inherited disorder resulting fiom mutation of the CFTR gene, which encodes a chloride ion channel ed to be ed in regulation of multiple other ion channels and transport systems in epithelial cells. Loss of function of CFTR results in chronic lung disease, aberrant mucus production, and dramatically reduced life expectancy. See generally Rowe et al., New Engl. J. Med. 352, 1992-2001 (2005).
Despite cloning of the CFTR gene in 1989, ive therapy for replacing CFTR for the ent of cystic fibrosis has yet to be developed. The literature has documented numerous difficulties encountered in attempting to induce expression of CFTR in the lung. For example, viral vectors comprising CFTR DNA triggered immune responses and CF symptoms persisted after administration. Conese et al., J. Cyst. Fibros. 10 Suppl 2, S114-28 (2011); Rosenecker et al., Curr. Opin. Mol. Ther. 8, 439-45 (2006). ral delivery of DNA, including CFTR DNA, has also been reported to r immune responses. Alton et al., Lancet 353, 947-54 (1999); cker et al., J Gene Med. 5, 49-60 (2003). Furthermore, non-viral DNA vectors encounter the additional problem that the ery of the nuclear pore complex does not ordinarily import DNA into the nucleus, where transcription would occur. Pearson, Nature 460, 164-69 (2009).
Another source of difficulties in inducing CFTR sion in the lung is the lung environment itself. Pulmonary surfactant has been reported to reduce transfection efficiency for cationic lipid transfer vehicles such as Lipofectamine (DOSPA:DOPE).
Page 1 of121 2014/028849 Ernst et al., J. Gene Med. 1, 331-40 (1999). Also, Rosenecker et al., 2003, supra, identified multiple inhibitory components present in the airway surface liquid which can ere with either polymer-mediated or lipid-mediated transfection. Messenger RNA therapy has been proposed as a general approach for inducing expression of a therapeutic or ement protein.
The concept of uction of messenger RNA (mRNA) as a means of protein production within a host has been ed previously (Yamamoto, A. et al. Eur. J. Pharm. 2009, 71, 484-489; Debus, H. et al. J. Control Rel. 2010, 148, 334-343). However, apparent lung-specific difficulties have been reported for mRNA delivery using certain lipoplexes formulations. For example, a comparison of in vitro and in viva mance of lipoplexes carrying mRNA or DNA revealed that even though the mRNA composition gave higher expression in cultured cells, measureable expression was detected only with the DNA composition when administered intranasally to mouse lung. Andries et al., Mol. Pharmaceut. 9, 2136-45 .
It should also be noted that CFTR is a relatively large gene ve to model or reporter genes such as firefly luciferase (FFL). Compare the lengths of the ype CFTR coding ce (SEQ ID NO: 2) and the FFL coding sequence (SEQ ID NO: 7). The difference in length can impact stability under some stances, and therefore whether and how much protein expression any given dose ofmRNA will produce. Furthermore, although in vitro synthesis ofmRNA is generally preferable to synthesis by cells due to the absence of normal cellular mRNA and other cellular components which constitute undesirable contaminants, in vitro synthesis ofmRNA with a long coding sequence, such as CFTR mRNA, is substantially more difficult to achieve than in vitro synthesis ofmRNA with a relatively short coding sequence such as FFL.
PCT patent publication WO2007/024708 and US patent publications US2010/0203627 and US201 l/0035819 discuss the eutic administration of CFTR mRNA but provide neither a trated reduction to practice of production of functional CFTR in the lung following administration of CFTR mRNA or sufficient guidance for overcoming the difficulties associated with inducing CFTR expression in the lung using in vitro-transcribed CFTR mRNA. These include difficulties with achieving in vitro synthesis of the mRNA and difficulties specific to the interactions ofmRNA compositions with lung-specific substances that investigators such as Andries et al., supra, have found to render mRNA compositions ineffective Page 2 of 121 for induction of expression even while corresponding DNA-based compositions did provide some level of expression.
Thus, there is a need for improved materials, formulations, production methods, and methods for delivery of CFTR mRNA for induction of CFTR expression, ing in the mammalian lung, for the treatment of cystic fibrosis.
SUMMARY OF THE INVENTION The present invention is based, in part, on the development of formulations of CFTR mRNA and non-naturally occurring CFTR mRNA and methods of administration f that can induce functional CFTR expression in vivo. The compositions, methods, and uses according to the invention can provide CFTR expression in the lung of a large mammal with a favorable safety profile suitable for effective treatment of cystic s.
Thus, in one aspect, the present invention provides a method of in viva production of CFTR, in ular, in the lung of a subject (e.g., a mammal) in need of delivery by ring an mRNA encoding a CFTR protein. In some embodiments, the mRNA encoding a CFTR protein is red directly to the lung of the subject. As used herein, a “CFTR protein” encompasses any full length, fragment or portion of a CFTR protein which can be used to substitute for naturally-occurring CFTR protein activity and/or reduce the intensity, severity, and/or frequency of one or more symptoms associated with Cystic fibrosis. For example, a le CFTR protein according to the present invention may have an amino acid sequence identical to the wild-type human CFTR protein (SEQ ID NO: 1). In some embodiments, a le CFTR protein according to the present invention may have an amino acid sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the wild-type human CFTR protein (SEQ ID NO: 1).
In one embodiment, the invention provides a method of inducing CFTR expression in epithelial cells in a lung of a , the method comprising ting the epithelial cells in the lung of the mammal with a composition, wherein: the composition is a pharmaceutical composition comprising an in vitro transcribed mRNAgthe in vitro ribed mRNA comprises a coding sequence which s SEQ ID NO: 1. In another embodiment, the Page 3 of 121 WO 53052 in vitro transcribed mRNA comprises a coding sequence which encodes an amino acid sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1.
In one ment, the invention provides a method of inducing CFTR expression in a mammalian target cell, the method comprising contacting the mammalian target cell with a composition, the composition comprising an in vitro transcribed mRNA encoding the amino acid sequence of SEQ ID NO: 1. In another embodiment, the in vitro transcribed mRNA comprises a coding sequence which encodes an amino acid sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1.
In another embodiment, the ion provides a non-naturally ing mRNA molecule sing a coding sequence, a 5’-UTR, and a 3’-UTR, n the coding sequence encodes the amino acid sequence of SEQ ID NO: 1 and the coding ce is at least 80% identical to SEQ ID NO: 3. In another embodiment, the coding sequence encodes the amino acid sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1 and/or the coding sequence is about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 3.
In another embodiment, the invention provides a non-naturally occurring mRNA le comprising a coding sequence, a 5’-UTR, and a 3’-UTR, wherein the coding sequence encodes the amino acid sequence of SEQ ID NO: 1 and the coding sequence comprises at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of the non-wild-type bases listed in Table l at the positions of the coding sequence listed in Table 1 relative to the wild-type coding sequence of SEQ ID NO: In another embodiment, the invention provides a non-naturally occurring mRNA molecule comprising a coding sequence, a 5’-UTR, and a 3’-UTR, wherein the coding sequence encodes the amino acid sequence of SEQ ID NO: 1 and the coding sequence comprises at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of the ld-type bases listed in Table 2 at the corresponding positions of the coding sequence listed in Table 2 ve to the wild-type coding sequence of SEQ ID NO: 2.
Page 4 of 121 In some embodiments, the ion provides a non-naturally occurring mRNA molecule comprising a coding sequence for a signal peptide. In a particular embodiment, the invention provides a non-naturally ing mRNA comprising a coding ce for a growth hormone leader sequence. In certain embodiments, the invention provides a non-naturally occurring mRNA sing a coding sequence of SEQ ID NO:l8 or SEQ ID NO: 19. In some embodiments, the invention provides a non-naturally occurring mRNA comprising a coding sequence at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% to SEQ ID NO:l8 or SEQ ID NO:l9.
In some embodiments, the invention provides a non-naturally occurring mRNA molecule sing a sequence of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 l, SEQ ID NO:12, SEQ ID NO:l3, SEQ ID NO:l4, SEQ UD NO:l5, SEQ ID NO:l6, or SEQ ID NO:l7.
In some embodiments, the invention provides a non-naturally occurring mRNA molecule comprising a ce at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% to any of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:ll, SEQ ID NO:12, SEQ ID NO:l3, SEQ ID NO:l4, SEQ UD NO:l5, SEQ ID NO:l6, or SEQ ID NO:l7.
In another ment, the invention provides a polynucleotide comprising a sequence complementary to the sequence of an mRNA according to the invention.
In another ment, the invention es a composition comprising the polynucleotide according to the invention, an RNA polymerase, and nucleoside triphosphates.
In another embodiment, the invention provides a pharmaceutical composition comprising an mRNA according to the ion.
In another embodiment, the invention provides a nebulization or aerosolization apparatus loaded with a pharmaceutical composition according to the invention.
In r embodiment, the invention provides a cultured cell comprising an mRNA according to the invention and functional CFTR expressed from the mRNA.
In another embodiment, the invention provides a use of a pharmaceutical composition according to the invention for the induction of expression of functional CFTR.
In another embodiment, the ion provides a method of inducing CFTR expression in epithelial cells in a lung of a mammal, the method comprising contacting the Page 5 of 121 epithelial cells with a composition, wherein the composition is a pharmaceutical composition comprising an mRNA according to the invention.
In another embodiment, the invention provides a method of inducing CFTR sion in a ian target cell, the method sing contacting the mammalian target cell with a composition, the composition comprising an mRNA according to the invention.
In another embodiment, the present invention es a method of treating cystic fibrosis by administering to a subject in need of treatment an mRNA encoding a CFTR protein as described herein. In one embodiment, the mRNA is administered to the lung of the subject. In one embodiment, the mRNA is administered by inhalation, nebulization, intranasal administration or aerosolization. In various embodiments, administration of the mRNA results in expression of CFTR in the lung of the subject.
In a ular embodiment, the present invention provides a method of ng cystic fibrosis by administering to the lung of a subject in need of ent an mRNA comprising a coding sequence which encodes SEQ ID NO: 1. In some embodiments, the present invention provides a method of treating cystic s by administering to the lung of a subject in need of treatment an mRNA comprising a coding ce which encodes an amino acid sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the wild-type human CFTR protein (SEQ ID NO: 1). In another particular embodiment, the present invention es a method of treating cystic fibrosis by administering to the lung of a subject in need of treatment an mRNA comprising a coding sequence of SEQ ID NO:3. In some embodiments, the present invention provides a method of treating cystic fibrosis by administering to the lung of a subject in need of treatment an mRNA sing a coding sequence at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID N03.
In yet r aspect, the present invention provides methods for making an mRNA encoding a CFTR protein as described herein. In one embodiment, the invention provides a method of making CFTR mRNA in vitro, sing contacting an isolated polynucleotide with an RNA polymerase in the presence of nucleoside triphosphates, wherein: the isolated cleotide and RNA polymerase are not contained within a cell; the isolated polynucleotide is a template for the RNA polymerase; the isolated polynucleotide comprises a Page 6 of 121 2014/028849 promoter operably linked to a template sequence; the template ce comprises a coding sequence complement which is complementary to a sequence encoding SEQ ID NO: 1; and: (a) the te sequence comprises fewer cryptic promoters than the complement of SEQ ID NO: 2, (b) the template sequence comprises fewer direct and/or inverted repeats than SEQ ID NO: 2, (c) the template sequence comprises complements of fewer disfavored codons than SEQ ID NO: 2, or (d) the GC content of the coding sequence complement is lower than the GC content of SEQ ID NO: 2.
In another embodiment, the invention provides a method of making CFTR mRNA in vitro, comprising contacting an isolated polynucleotide ing to the invention with an RNA polymerase in the presence of nucleoside triphosphates, wherein: the isolated polynucleotide and RNA polymerase are not contained within a cell; the isolated polynucleotide is a template for the RNA polymerase; and the isolated polynucleotide comprises a er operably linked to a template ce, and the RNA polymerase synthesizes mRNA comprising a coding ce encoding SEQ ID NO: 1.
In some embodiments of such uses and methods of treatment, the in vitro transcribed mRNA is a naturally occurring or wild-type mRNA ng human CFTR (SEQ ID NO: 2) modified to include non-naturally occurring UTRs. In other embodiments, the in vitro transcribed mRNA is a non-naturally occurring mRNA as described above.
Additional obj ects and advantages of the ion will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. The objects and advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended It is to be tood that both the foregoing general description and the following detailed description are ary and explanatory only and are not restrictive of the invention, as claimed.
The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several embodiments of the invention and together with the description, serve to explain the principles of the invention.
Page 7 of 121 BRIEF DESCRIPTION OF THE GS The foregoing aspects and advantages of this ion may become apparent from the following detailed description with reference to the accompanying drawings.
Figure 1A. Detection of mature “C” band for human CFTR protein 24 hours after transfection with human CFTR mRNA. Successful protein production was observed for both fied and modified (SNIM) mRNA (comprising 25% of 2-thiouridine and 5- methylcytidine). precipitation was performed using R&D Systems MAB25031 antibody and detection using AbS 70.
Figure 1B. n Blot analysis of CFTR KO mouse lungs 24 hour post- exposure of PEI/unmodified human CFTR mRNA rticles. Mice were treated via nebulization (Pari Boy jet nebulizer) over the course of approximately one hour.
Immunoprecipitation of human CFTR protein derived according to provided methods was performed. Mature “C” band is detected in all treated mice while unobserved in control mice.
Figure 2. t-voltage plot of 8-Br-cAMP evoked ts of treated (4 ug hCFTR mRNA) and untreated HEK293T cells. A large current is induced within the hCFTR mRNA transfected cells as compared to the untreated cells. Treated cells that were d to a specific CFTR protein inhibitor, CFTRinh-l72, show a marked reduction (~89%) in Cl- ion current flow.
Figure 3. Histogram plots of 8-Br-cAMP evoked currents of treated (4 ug hCFTR mRNA) and ted HEK293T cells upon application of a +80mV membrane potential. A large current is induced within the hCFTR mRNA transfected cells as compared to the untreated cells. Treated cells that were exposed to a specific CFTR protein inhibitor, CFTRinh-l72, show a marked reduction (~89%) in C1- ion current flow.
Figure 4. t-voltage plot comparing profiles ofHEK 293 cells of native, forskolin and GlyH-lOl exposure. No significant changes in current were observed in any scenario.
Figure 5. Current-voltage plot of forskolin-evoked currents of treated (4 ug hCFTR mRNA) and untreated HEK293 cells. A large current is induced within the hCFTR Page 8 of 121 mRNA transfected cells as compared to the untreated cells. d cells that were exposed to a specific CFTR protein inhibitor, GlyH-lOl, show a marked reduction (~95%) in Cl- ion current flow as demonstrated in the step plot (+100 mV) on the right side of the graph.
Figure 6. In situ hybridization of human CFTR mRNA in untreated (PBS) (left) and treated (right) CFTR KO mouse lungs. Mice were exposed to 30 ug of encapsulated unmodified hCFTR mRNA in PEI nanoparticles via intratracheal administration. Substantial positive staining is observed throughout both lungs at 24 hours dministration.
Figure 7. In situ hybridization of human CFTR mRNA treated CFTR KO mouse lungs at ent magnification views (up to 20x magnification). Mice were exposed to 30 ug of encapsulated unmodified hCFTR mRNA in PEI nanoparticles via intratracheal administration.
Figure 8. High magnification (40x) representative lung section trating in situ hybridization of human CFTR mRNA treated (right) CFTR KO mouse lungs. Human CFTR mRNA was detected in the apical cytoplasm of target ial epithelial cells 24 hours post stration. Mice were exposed to 30 ug of encapsulated unmodified hCFTR mRNA in PEI nanoparticles via intratracheal administration.
Figure 9. Comparison of in situ hybridization staining of human CFTR mRNA treated CFTR KO mouse lungs at six hours (left) and 24 hours (right) dministration. Mice were exposed to 30 ug of encapsulated unmodified hCFTR mRNA in PEI nanoparticles via racheal administration. Intense positive intracellular staining is observed within six hours throughout both lungs within bronchial and alveolar s while substantial positive staining is still observed at 24 hours post-administration.
Figure 10. In situ hybridization of human CFTR mRNA in untreated (PBS) (top) and treated (bottom) CFTR KO mouse lungs. Mice were exposed to 15 ug of encapsulated fied hCFTR mRNA in C12-200 lipid nanoparticles via intratracheal administration.
Substantial positive staining is observed throughout both lungs at 6 hours post-administration.
Figure 11. High magnification (40x) representative lung ns demonstrating in situ hybridization of human CFTR mRNA treated CFTR KO mouse lungs. Human CFTR mRNA was detected in the apical cytoplasm of target bronchial epithelial (left) as well as intracellular alveolar regions (right) six hours post administration. Mice were exposed to 15 ug Page 9 of 121 of encapsulated unmodified hCFTR mRNA in 0 lipid nanoparticles via intratracheal administration.
Figure 12. Screening of different cell lines for hCFTR sion. Immunoblot of CH0 and COS-7 (A) and BHK and PKC (B) cells transfected with hCFTR coding constructs.
Protein s were ed 24 hrs post transfection and screened using MAl-935 as primary antibody. Arrow indicates putative CFTR. See the discussion of MAI-935 specificity in Example 6.
Figure 13. Cross reactivity of different anti-human CFTR antibodies. (A) — Mouse anti-human CFTR 5 (Chemicon): (B) — Mouse anti-human CFTR AB570 (Cystic Fibrosis Foundation): (C) — Mouse anti-human CFTR AB596 (Cystic Fibrosis Foundation): (D) Rabbit anti-human CFTR G449 (Rockefeller University). Arrow indicates CFTR.
Figure 14. Immunoprecipitation of human CFTR using three different antibodies (R29, R66/l7 and R66/l6) followed by immunodetection using AB596. Lane 1: T84 cells (positive control), Lane 2: untreated pig lung tissue (300 mg), Lane 3: treated pig lung tissue (697 mg), Lane 4: treated pig lung tissue (163 mg).
Figure 15. Immunoprecipitation and Western blotting of a mouse at 24 hrs post IT spray application of 20 ug hCFTR SNIM RNA/10 ug FFL SNIM RNA each in the HGTSOOl Formulation of Example 6. T84 cells served a positive control showing the mature ylated C-band and the mannosylated B-band of hCFTR. “supernatant” remaining cellular extract fraction without immunoprecipitated fraction. “1P” immunoprecipitated fraction.
Figure 16. Immunoprecipitation of hCFTR from T84 cells using 3l followed by detection using AB570 (A) and MAB1660 (B).
Figure 17. precipitation of CFTR from NIH3T3 cells at 72 hrs post transfection with different constructs.
Figure 18. Immunoprecipitation of CFTR from NIH3T3 cells at 72 hrs post transfection with different constructs using 500 ug protein and MAB1660 (left and center panels) and increased amount of total n (8 mg) using MAB25031 (right panel).
Figure 19. Immunoprecipitation of hCFTR using MAB2503l and subsequent immunodetection using AB570 from pig lung samples post hCFTR SNIM RNA delivery in the Page 10 of 121 PEI Formulation of Example 6. Lane 1: sample from luciferase-negative left caudal lobe of pig #2, Lane 2: sample from luciferase-positive lung regions of pig #1.
Figure 20. Nebulisation was performed on anesthetized and ventilated pigs (left).
The nebulizer was connected in-line to the ventilation system , see white arrow).
Figure 21. Luciferase expression measured in homogenates of pig tissue ens from different lung s after aerosol administration of 1 mg FFL SNIM RNA in the PEI Formulation of Example 6 with the EFlow mesh nebulizer. Lung specimens were ex vivo ed overnight before luciferase measurements (pg luciferase/mg lung tissue).
Figure 22. BLI of luciferase expression in entative pig tissue specimens from different lung regions after aerosol administration of 1 mg FFL SNIM RNA in the PEI ation of Example 6. Lung ens were ex vivo ed overnight before measurements.
Figure 23. BLI imaging of luciferase expression in representative pig tissue specimens from different lung regions after aerosol administration of 1 mg FFL SNIM RNA in the PEI Formulation of Example 6 using a PARI BOY jet nebulizer. Lung specimens were ex vivo cultured overnight before measurements.
Figure 24. BLI of luciferase expression in representative pig tissue specimens from different lung regions after l administration of each 1 mg FFL SNIM RNA and hCFTR mRNA in the PEI Formulation of Example 6 using an Aeroneb mesh nebulizer. Lung specimens were ex vivo cultured overnight before measurements.
Figure 25. BLI of luciferase expression in representative pig tissue specimens from different lung regions after aerosol stration of 1 mg FFL SNIM RNA in “SHIRE Formulation #3” (HGTSOOl :DOPE:Chol:DMGPEG2K (50:25 :20:5) (mol ratio) using an Aeroneb mesh nebulizer. Lung specimens were ex vivo cultured overnight before measurements.
Figure 26. BLI of luciferase sion in pig tissue specimens from different lung regions from one untreated control pig. The other untreated control pig showed the same result (data not shown).
Page 11 of121 Figure 27. BLI of luciferase expression in lung specimens of once-treated pigs #3 and #6. Aerosol administration of each 1 mg FFL SNIM RNA and hCFTR SNIM RNA in the PEI Formulation of Example 6 was performed using an Aeroneb mesh nebulizer. Slices of the entire pig lung are shown. Upper three rows: pig #3, lower three rows: pig #6.
Figure 28. BLI of luciferase expression in lung specimens of twice-treated pigs #4 and #8. Aerosol administration of each 1 mg FFL SNIM RNA and hCFTR SNIM RNA in the PEI Formulation of Example 6 was performed using an Aeroneb mesh nebulizer. Slices of the entire pig lung are shown. Upper three rows: pig #4, lower three rows: pig #8.
Figure 29. BLI of luciferase expression in lung specimens of three times-treated pigs #1 and #2. Aerosol administration of each 1 mg FFL SNIM RNA and hCFTR-mRNA SNIM RNA in the PEI Formulation of e 6 were med using an Aeroneb mesh nebulizer.
Slices of the entire pig lung are shown. Upper three rows: pig #1, lower three rows: pig #2.
Figure 30. Luciferase IHC on lung tissue of three times treated pig #1. Aerosol administration of each 1 mg FFL SNIM RNA and hCFTR SNIM RNA in the PEI Formulation of e 6 was med using an Aeroneb mesh nebulizer. Luciferase sion appeared in reddish-pink colour (Anti-Luciferase pAb 1:300, G74Sl, Promega, Ref1ne AP-Kit, chromogen: New fiJchsine).
Figure 31. Highly BLI-positive lung tissue of threefold treated pig #1 was subjected to hCFTR IP/WB. Lane l:T84 cells (positive control), Lane 2: untreated pig lung tissue (300 mg), Lane 3: treated pig lung tissue (697 mg), Lane 4: treated pig lung tissue (163 mg). Mature complex-glycosylated hCFTR appeared as the disperse so-called C-band. Mannose- rich hCFTR appeared as the more dense led B-band. hCFTR expression was observed in T84 cells and pig lung tissue of hCFTR SNIM RNA treated pig #1, whereas no hCFTR sion was observed in ted pigs.
Figure 32. Immunoprecipitation of hCFTR using MAB2503l and subsequent immunodetection using ABS70 from pig lung samples post hCFTR SNIM RNA delivery in the PEI Formulation of Example 6. Lane 1: sample from luciferase-negative left caudal lobe of pig #2, Lane 2: sample from rase-positive lung regions of pig #1.
Page 12 of 121 Figure 33 A&B. In vitro transfection ofHEK 293T cells with C-terminal Hislo tagged (CO-CFTR—C-Hislo) and non-tagged (CO-CFTR) codon optimized human CFTR SNIM RNA. Following transfection, whole cell lysate was collected and analyzed for human CFTR expression by Western blot using (A) anti-CFTR antibody #217 and (B) anti-His antibody 1187.
Transfected samples were compared to non-transfection HEK 293T control lysate (Lane 3).
Figure 33 C. In vitro transfection of HEK 293T cells with SNIM RNA encoding codon optimized human CFTR with a growth hormone leader sequence and a (GH-CO-CFTR) or SNIM RNA encoding a C-terminal Hislo tagged codon optimized human CFTR TR- C-Hislo). Following transfection, whole cell lysate was collected and analyzed for human CFTR expression by Western blot using anti-CFTR antibody #217. Transfected samples were ed to non-transfection HEK 293T control lysate (Lane 3).
Figure 34. In vivo transfection of CFTR knockout mice with C-terminal Hislo tagged codon zed human CFTR SNIM RNA encapsulated within either a lipid 12) or polymeric (PEI) nanoparticle formulation. Following nebulized delivery of each respective mRNA formulation, Right and Left lung tissue lysate was ted and analyzed for CFTR expression by Western blot using anti-His antibody 1187. Control CFTR knockout lung tissue and CFTR-His10 HEK293 lysate was used as a negative and positive controls respectively.
Figure 35. Bioluminescent detection of FFL expression in porcine lung samples collected ing nebulization with water for injection.
Figure 36. Bioluminescent ion of FFL expression in e lung s collected following nebulization with 1 mg FFL SNIM RNA + 1 mg CO-CFTR SNIM RNA in a branched 25 kDa PEI formulation.
Figure 37. Bioluminescent detection of FFL expression in porcine lung samples collected following nebulization with 1 mg FFL SNIM RNA + 5 mg CO-CFTR SNIM RNA in a branched 25 kDa PEI formulation.
Figure 38. Bioluminescent detection of FFL expression in porcine lung samples collected following zation with 1 mg FFL SNIM RNA + 10 mg CO-CFTR SNIM RNA in a branched 25 kDa PEI formulation.
Page 13 of 121 Figure 39. Relative quantification of CFTR expression in different chorots.
Band intensities were normalized to lSOkDa band in the protein ladder.
Figure 40. Representative example of a “CFTR-positive” bronchi with at least one lial cell detected within the epithelial cell layer and displaying a clear membrane localized CFTR signal via CFTR immunohistochemical staining using an anti-CFTR antibody.
Figure 41. Immunohistochemical staining of CFTR in e lung ing aerosol delivery of control (WFI) or 5 mg CO-CFTR SNIM RNA.
Figure 42. ents a “low” CFTR expression level, assayed in porcine lung by immunohistochemical staining with anti-CFTR following aerosol delivery of 5 mg CO-CFTR SNIM RNA.
Figure 43. Represents a “medium” CFTR sion level, assayed in porcine lung by immunohistochemical staining with anti-CFTR following aerosol delivery of 5 mg CO- CFTR SNIM RNA.
Figure 44. ents a “high” CFTR expression level, assayed in porcine lung by immunohistochemical staining with anti-CFTR following aerosol delivery of 5 mg CO-CFTR SNIM RNA.
Figure 45. Immunohistochemical staining of CFTR in porcine lung following aerosol delivery of control (WFI) or 10 mg CO-CFTR SNIM RNA.
Figure 46. Quantification of relative numbers of CFTR-positive bronchi / bronchioles per animal. Analysis of each cohort (WFI; and lmg, 5mg, 10mg human CFTR SNIM RNA) 24 hours post aerosol administration. CFTR expression normalized to signal intensity for 150 kDa protein standard. .4::5.6%, lMG=lS.2::6.6%, .4::14.1%, 0.9::3.7%; WFI vs SMG p=0.0281, WFI vs lOMG p=0.0174) Figure 47. Illustrates lex nucleic acid in situ detection of (A) ubiquitin C and (B) clap B in porcine lung, post aerosol delivery of water for injection by nebulizer.
Figure 48. Illustrates multiplex nucleic acid in situ detection of (A) ubiquitin C and (B) clap B in porcine lung, post aerosol delivery of 1 mg FFL SNIM RNA + 10 mg CO- CFTR SNIM RNA in a branched 25 kDa PEI formulation.
Page 14 of 121 2014/028849 Figure 49. Illustrates multiplex nucleic acid in situ detection of (A) right cranialis and (B) left cranialis in porcine, post aerosol delivery of water for injection by nebulizer.
Figure 50. Illustrates multiplex nucleic acid in situ detection of (A) right cranialis and (B) left cranialis in porcine, post aerosol ry of 1 mg FFL SNIM RNA + 1 mg CO-CFTR SNIM RNA in a branched 25 kDa PEI formulation.
Figure 51. Illustrates multiplex nucleic acid in situ detection of (A) right cranialis and (B) left cranialis in porcine, post aerosol delivery of 1 mg FFL SNIM RNA + 5 mg CO-CFTR SNIM RNA in a branched 25 kDa PEI formulation.
Figure 52. Illustrates multiplex nucleic acid in situ detection of (A) right cranialis and (B) left cranialis in porcine, post aerosol delivery of 1 mg FFL SNIM RNA + 10 mg CO-CFTR SNIM RNA in a ed 25 kDa PEI formulation.
Figure 53. rates positive detection of active firefly luciferase (FFL) protein in a d pig lung via luminescence upon exposure to FFL/CO-CFTR—C-Hile mRNA encapsulated cKK-El2 lipid nanoparticles. Pigs were treated with 1 mg FFL + 9 mg CO-CFTR- C-Hile mRNA encapsulated lipid rticles via nebulization using a Pari jet zer and sacrificed 24 hours post-treatment. FFL luminescence was visualized using an IVIS bioluminometer.
Figure 54. Illustrates exemplary results of hCFTR expression in HEK cells transfected using neubilized complexes given to pigs 10, ll and 12 (1 mg dose).
Figure 55. Illustrates exemplary results of hCFTR expression in HEK cells transfected using neubilized complexes given to pigs l3, l4 and 15 (5 mg dose) and in HEK cells transfected using neubilized complexes given to pigs 19, 20 and 21 (10 mg dose).
Figure 56. Illustrates exemplary results of hCFTR sion in HEK cells transfected using neubilized complexes given to pig l6 (5 mg dose), 22 (10 mg dose) and 67 (1 mg dose).
Figure 57. Illustrates ary results of hCFTR expression in HEK cells ected using neubilized complexes given to pigs l7, l8 (5 mg dose), 23, 24 (10 mg dose) and 68, 69 (1 mg dose).
Page 15 of 121 DETAILED DESCRIPTION OF THE INVENTION Definitions As used herein, the term “polynucleotide” is generally used to refer to a nucleic acid (e.g., DNA or RNA). The terms polynucleotide, nucleic acid, DNA, RNA, and mRNA include such molecules that are comprised of: rd or unmodified residues; nonstandard or modified residues; and mixtures of standard and nonstandard es.
As used herein, the term “mRNA” is used to refer to modified and unmodified RNA including both a coding region and a noncoding region.
As used herein, the phrase g region” of an mRNA generally refers to that portion that when ated results in the production of an expression product, such as a polypeptide, protein, or enzyme.
A “nonstandard nucleobase” is a base moiety other than the natural bases adenine (A), cytosine (C), guanine (G), thymine (T), or uracil (U). The nonstandard base is an analog of a specific nucleobase (A, C, G, T, or U) when its base pairing properties in a nucleic acid double helix and locus of incorporation by DNA or RNA polymerases in a nucleic acid double helix ding a local RNA-DNA helix such as that formed during transcription of a DNA template by RNA polymerase) are most similar to one of the five preViously listed nucleobases, with the exception that analogs of T will generally also be analogs ofU and Vice versa. For purposes of determining percentage identity of a first sequence ve to a second ce, an analog of a base is not a mismatch to the natural base; for example, pseudouridine matches uridine, 5-methylcytidine matches cytidine, etc.
The term andard” used in conjunction with terms including but not limited to “nucleoside”, “base , nucleotide”, or “residue” is to be interpreted in the same manner as if it were used in ction with “nucleobase.” “GC content” is the on or percentage of total nucleobase residues in a nucleic acid sequence that are guanine residues, cytosine residues, or analogs thereof. For Page 16 of 121 example, a 100 nt sequence that contains exactly 30 cytosines, exactly 30 guanines, exactly one ne analog, and exactly one guanine analog has a GC richness of 62%.
As used herein, a “disfavored codon” refers to a codon which is translated less efficiently or y by mammalian cells than another codon for the same amino acid residue.
Disfavored codons generally include codons with an A or U in the 3rd or “wobble” position of the codon. For a discussion of disfavored codons, see, e. g., US. Patent Publication 2009/0069256 A1.
A “non-naturally occurring mRNA molecule” is an mRNA that is not produced through normal ription and splicing processes of wild-type cells. An mRNA may qualify as non-naturally occurring by virtue of its sequence (e. g., a series of codons and/or one or more UTRs that do not present in any naturally-occurring CFTR mRNA) and/or e it includes nonstandard nucleotide residues. A non-naturally occurring mRNA molecule may be in vitro synthesized.
In each of Tables 1 and 2 below, the NWT column indicates the non-wild-type base at the position (Pos.) in the CFTR coding sequence (see, e. g., SEQ ID NO: 3), and the WT column indicates the wild-type base at the same position (see, e.g., SEQ ID NO: 2 or the RefSeq entry for human CFTR (accession no. NM_000492.3, Feb. 10, 2013, version, available from GenBank; note that the sequence ofNM_000492.3 contains noncoding sequence such that the coding sequence occurs at position 133 to 4575, such that, for example, position 7 in the tables below corresponds to position 139 of the 492.3 ce).
Non-naturally occurring CFTR mRNA In addition to providing methods of producing functional CFTR in viva using naturally occurring or wild-type CFTR mRNA (and compositions comprising that mRNA), the invention also provides non-naturally occurring CFTR mRNA that s CFTR protein (e.g., SEQ ID NO:l). In some embodiments, the non-naturally occurring CFTR mRNA is purified or isolated.
In other embodiments, the non-naturally ing CFTR mRNA is present in a cell. In some embodiments, the cell comprising the turally occurring CFTR mRNA did not synthesize the turally occurring CFTR mRNA and/or does not comprise DNA Page 17 of 121 complementary to the non-naturally occurring CFTR mRNA and/or a onal CFTR gene; the cell may optionally comprise an ve CFTR gene, such as a CFTR gene with a nonsense, missense, frameshift, ion, or deletion mutation that renders the expression product of the gene nonfunctional. In some ments, the cell comprising the non-naturally occurring CFTR mRNA fiarther comprises fianctional CFTR protein translated from the non-naturally occurring CFTR mRNA. The cell may be, e.g., a lung epithelial cell, a liver cell, or a kidney cell. In some embodiments, the cell is in a cell culture.
CFTR Coding Sequence In some embodiments, CFTR mRNA according to the invention ses a coding sequence with fewer complements of cryptic promoters than SEQ ID NO: 2 (i.e., the coding sequence of wild-type human CFTR), fewer direct and/or inverted repeats than SEQ ID NO: 2, fewer disfavored codons than SEQ ID NO: 2, and/or the GC content of the coding sequence is lower than the GC content of SEQ ID NO: 2.
Cryptic promoters, direct and/or ed s and/or disfavored codons of a sequence may be recgnized by one skilled in the art using routine methods. For example, the direct and/or inverted repeat content of a sequence can be determined by sequence analysis (Liu et al., Journal of Theoretical Biology (2014) 344: 19-30). The cryptic promoter content of a sequence can also be determined by sequence analysis, e.g., presence of Shine-Dalgamo ces within construct or the like.
In some embodiments, CFTR mRNA according to the invention is in vitro- transcribed, i.e., the mRNA was synthesized in an artificial setting not within a biological cell (e.g., a cell free in vitro transcription system). Generally, in vitro transcription involves providing a DNA template comprising a promoter and a sequence complementary to the desired mRNA (which may be circular or linear), an RNA polymerase, and nucleoside triphosphates in suitable reaction conditions (salts, buffers, and temperature). RNase inhibitors, ng agents, and/or pyrophosphatase may be t in the on mixture. In some embodiments, the RNA polymerase is T7 RNA polymerase.
In some embodiments, the CFTR mRNA according to the invention comprises a coding ce comprising at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, Page 18 of 121 at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of the non-Wild-type bases laHMpmMmmfimewfigammmemmmewblmMWMDmMMM- type coding sequence of SEQ ID NO: 2.
Table 1. Non-Wild-type bases that can be used in the coding sequence ofmRNA encoding CFTR.
Pos. NVVT VVT Pos. NVVT VVT Pos. NVVT VVT 7 c a 117 g a 222 a g 12 c g 123 c u 223 a c g u 126 g u 225 g a 18 c g 129 a u 228 c u u c 135 g u 231 c u 33 c u 138 g u 238 c a 36 g c 141 u c 240 g a 45 c u 144 c u 243 c u 48 c u 147 c a 252 c u 52 u a 150 g u 255 u a 53 c g 153 g a 261 c u 54 a c 156 g a 264 g a 60 u c 157 c u 268 c u 61 c a 159 c g 270 c a 63 g a 163 c a 276 g a 66 u a 165 g a 282 a c 69 c u 174 c u 291 c a 70 c u 175 c a 294 a g 72 u g 177 c a 297 c u 75 a g 180 a g 300 g c 78 g a 183 c g 303 g a 81 g a 186 g u 304 u c 84 u c 189 u a 309 u a 85 c a 198 c u 310 c a 87 g a 201 g u 312 c a 91 a c 204 g a 315 u c 93 g c 210 c u 318 c a 96 u g 213 c u 321 c u 99 g a 216 a c 324 g c 105 u a 219 g u 327 c u 111 c a 220 a c 333 c g Page 19 of 121 WO 53052 P3333333333333333333334444444444444444444 O4455556r0r07_/_/78oooooo99990001111222344567888 S2512343r092589145703692891247369547724036 NaagagCCCCgcanuUgucccauuguguaccccucccccam ngCUCUUuacaCuaCCUCUUgggcccaccuuuuaaauuugT P4444555555555555555555555555555555555566 O99OJ9000O01111222223333444444555567788801 S235ool45r07034r025r0781478034569345843958992 NananUnggUggUUCCCUguggUCCgagUUCnggCUCm WuuaggaagcuucaaaaguuaacuuagUCUCCCguauaUCUT Pr06r0r06r06r0r06r06r06r0r0666667777777777777777777 O122333344556_/_/oooooo99990002224444556666788 S54_/013925273Zoo14736792350461247692678703 NgCCUUgCUUCgaUCgauUgugaugUCgUCCCguaUCgCCCm WT CCUCC uaaaca UUgga gUUgU Page 20 of 121 WO 53052 Pos. NVVT VVT Pos. NVVT VVT Pos. NVVT VVT 786 u c 967 u c 1161 u a 789 g a 969 g u 1164 u g 798 c u 972 u c 1170 g a 804 c u 978 c a 1173 g a 810 g a 979 u c 1179 a g 813 g u 981 g a 1191 g a 816 c u 984 u c 1194 g a 819 a g 987 g a 1197 u c 822 c a 990 g a 1200 u c 825 u c 993 u c 1206 a g 840 u a 1002 c g 1212 u a 846 g a 1005 g a 1218 a g 849 g a 1008 u a 1222 c u 862 c u 1017 g c 1224 g a 864 c a 1020 u c 1239 g a 865 c a 1023 g a 1242 g a 867 c a 1035 a u 1245 u c 873 u a 1036 u c 1248 c u 876 g a 1047 a g 1254 c u 888 c u 1050 g c 1255 c a 891 c g 1053 a u 1257 c a 897 g a 1065 g c 1260 g a 900 g c 1071 c u 1263 c u 906 c g 1074 g a 1266 a u 907 c a 1077 g a 1272 g u 909 g a 1092 g u 1275 c u 912 u c 1101 g a 1278 u c 919 u a 1104 c a 1279 u a 920 c g 1113 c a 1280 c g 921 g c 1116 a g 1284 g c 927 g c 1119 c u 1287 u c 936 u c 1125 g a 1291 u a 939 c a 1137 g a 1292 c g 948 c u 1140 c u 1293 g u 951 u g 1146 c a 1296 c u 954 c g 1147 c u 1302 c a 958 c u 1152 g a 1305 g u 960 c a 1155 c u 1308 c u 963 g u 1158 u c 1311 a u 966 u g 1159 c u 1314 a u PageZlolel WO 53052 Pos. NVVT VVT Pos. NVVT VVT Pos. NVVT VVT 1317 c u 1458 g a 1632 g u 1320 g c 1459 c a 1635 u a 1321 u c 1461 u a 1638 u c 1326 g a 1464 c u 1642 u c 1329 c u 1474 a u 1645 u a 1332 c u 1475 g c 1646 c g 1344 u a 1476 c u 1647 g u 1347 g a 1485 a c 1653 g u 1350 g a 1491 c u 1656 g a 1357 c u 1497 c u 1662 g a 1359 u g 1500 a c 1663 c a 1360 c u 1512 g a 1665 g a 1362 c g 1515 c u 1668 c u 1368 a u 1521 u c 1669 a u 1371 g u 1524 c u 1670 g c 1375 a u 1527 a u 1671 c u 1376 g c 1530 a u 1672 c u 1383 u a 1542 g a 1674 c a 1386 g a 1545 c u 1677 g a 1389 a c 1546 c a 1683 g a 1392 a g 1555 u a 1698 a u 1396 a u 1556 c g 1708 c u 1397 g c 1557 g c 1710 g a 1398 c a 1563 u c 1711 c u 1401 c u 1566 g a 1713 u a 1402 u c 1569 g a 1716 u c 1404 g a 1575 g a 1719 a u 1419 g a 1576 u c 1722 g u 1422 g a 1578 g a 1734 c a 1425 u g 1590 u c 1737 c u 1431 c u 1593 u c 1740 a u 1432 a u 1599 c u 1743 g a 1433 g c 1602 c a 1758 c a 1434 c a 1608 g a 1761 c u 1440 g u 1611 u c 1764 g a 1443 g a 1614 c u 1765 u a 1449 a g 1617 c a 1766 c g 1453 u a 1620 c u 1767 g c 1454 c g 1621 u c 1770 c u 1455 c u 1623 g u 1773 g c Page 22 of 121 WO 53052 Pos. NVVT VVT Pos. NVVT VVT Pos. NVVT VVT 1782 u g 1914 g a 2049 g a 1791 u c 1920 c u 2052 g a 1794 g a 1921 u a 2055 g a 1797 g u 1922 c g 2058 g u 1800 a g 1923 a c 2064 g a 1803 c u 1924 a u 2070 a u 1804 c u 1925 g c 2076 a g 1809 g c 1926 c a 2082 u g 1812 a u 1938 g a 2085 g a 1815 a u 1944 c u 2091 a g 1827 c u 1947 a u 2097 c u 1828 c u 1956 g a 2098 a u 1830 u a 1959 c u 2099 g c 1836 g a 1962 c u 2103 c u 1839 g u 1965 g a 2104 u c 1845 g a 1969 c a 2106 g c 1848 c a 1971 g a 2112 u a 1849 c u 1972 c a 2115 u c 1851 g a 1974 g a 2121 a u 1854 c u 1977 c u 2124 u a 1855 c u 1980 g a 2127 c a 1857 c g 1984 u c 2130 g a 1860 c u 1986 g a 2133 c u 1866 a u 1989 g u 2136 a c 1867 u a 1992 a g 2139 c u 1868 c g 1995 g c 2142 c g 1869 g c 1996 c u 2145 g a 1870 u a 1998 g a 2148 a g 1871 c g 2004 a u 2154 a c 1875 c u 2010 g a 2155 c u 1881 c u 2011 c u 2157 g a 1884 c g 2013 u a 2160 g a 1887 u a 2016 g a 2169 a c 1890 c u 2019 u a 2172 u c 1896 g a 2025 c u 2184 g u 1897 u c 2028 g u 2187 c u 1899 g c 2031 a c 2190 a g 1905 c u 2034 g c 2193 c u 1906 u c 2040 c a 2194 c u 1908 g a 2043 g a 2196 g a Page 23 of 121 WO 53052 Pos. NVVT VVT Pos. NVVT VVT Pos. NVVT VVT 2200 c a 2325 u c 2484 u c 2202 c a 2328 g a 2487 g a 2208 u g 2331 a u 2490 a g 2209 a u 2337 g a 2496 u c 2210 g c 2340 g u 2499 c u 2212 c u 2343 a g 2508 c u 2214 c a 2355 c a 2514 a g 2217 g a 2358 a g 2515 u a 2220 g a 2361 g a 2516 c g 2226 a u 2364 g a 2517 a c 2232 a g 2367 c a 2520 c a 2235 g a 2370 a c 2526 g a 2241 c g 2373 g a 2532 a u 2244 u a 2374 a c 2535 g a 2247 u g 2388 u g 2548 u c 2250 c u 2391 a c 2550 g u 2253 g c 2394 c u 2553 u a 2256 u c 2400 g a 2556 c u 2257 u a 2403 u c 2559 c u 2258 c g 2415 c g 2562 g u 2259 g c 2418 c u 2565 g c 2265 u c 2421 c a 2572 u a 2266 u a 2424 c u 2573 c g 2267 c g 2425 a u 2577 g a 2268 a c 2426 g c 2583 c u 2271 c u 2427 c a 2586 c g 2274 a c 2428 c a 2589 c a 2277 u c 2430 u a 2592 c u 2280 a g 2434 c u 2598 u c 2289 g a 2436 u a 2599 c u 2290 a c 2439 g u 2601 c a 2292 g a 2448 c u 2604 g a 2293 c a 2451 a c 2607 c u 2295 a g 2452 c u 2613 c g 2301 a g 2454 u g 2616 u a 2304 c u 2457 g a 2622 c g 2307 g c 2460 c a 2625 a u 2310 c g 2463 c u 2628 g u 2316 c g 2472 c u 2631 a u 2322 g a 2475 u c 2632 c u Page 24 of 121 WO 53052 Pos. NWT WT Pos. NWT WT Pos. NWT WT 2634 u g 2805 c a 2964 c u 2637 g u 2811 c g 2967 g u 2640 c g 2814 u g 2970 g c 2643 c g 2817 c u 2973 c a 2649 g c 2820 g u 2976 c u 2655 u a 2823 u a 2994 g a 2658 u c 2829 u a 2995 c u 2661 g u 2832 c g 2997 g a 2664 c u 2835 c g 3000 c u 2665 u c 2838 g a 3009 g a 2667 g u 2842 c u 3015 u a 2679 c g 2844 c a 3021 a u 2683 u a 2850 u c 3027 u a 2684 c g 2853 g a 3030 c u 2688 a u 2857 c u 3031 c u 2691 c u 2859 u a 3033 c a 2692 u a 2863 a u 3036 g a 2693 c g 2864 g c 3039 u c 2694 a u 2865 c u 3045 u c 2700 c u 2868 a u 3051 c u 2703 u c 2871 g u 3054 g a 2704 u a 2874 g a 3057 c a 2705 c g 2877 u a 3060 u g 2712 c a 2880 c u 3063 g a 2724 u c 2886 c a 3069 c a 2725 u a 2890 u c 3075 g u 2726 c g 2892 g c 3081 c u 2727 u c 2895 u c 3085 c u 2730 a c 2899 c u 3088 c a 2733 c u 2901 c g 3090 g a 2742 c u 2904 g a 3093 c a 2754 c u 2907 g a 3100 u c 2760 a g 2910 a u 3102 g c 2766 g a 2913 u g 3105 g a 2776 c u 2917 u c 3108 g c 2781 c u 2919 g u 3117 g a 2784 g u 2923 c a 3120 u c 2790 u a 2925 c a 3123 g a 2797 c a 2931 a c 3132 g a 2802 a u 2940 u a 3141 g c Page 25 of 121 WO 53052 Pos. NWT WT Pos. NWT WT Pos. NWT WT 3145 u a 3304 c a 3477 c u 3146 c g 3306 c a 3480 u g 3147 g u 3309 u a 3481 u a 3150 u a 3312 g a 3482 c g 3153 c u 3324 g c 3483 g c 3156 u c 3333 u c 3484 a c 3159 g u 3336 c u 3486 g a 3168 g u 3339 g u 3501 c u 3171 c a 3342 g u 3510 g a 3174 u c 3345 u c 3513 g a 3177 g a 3348 u c 3516 g a 3180 g a 3351 c u 3519 a u 3184 u c 3357 c u 3522 g a 3186 g a 3360 g a 3525 c u 3192 g a 3363 c a 3528 a c 3193 u c 3366 g a 3531 a g 3195 g u 3372 g a 3532 a u 3198 c u 3375 c a 3533 g c 3204 u c 3378 g a 3534 u a 3207 c a 3382 c a 3537 g c 3208 a c 3384 g a 3543 c a 3216 c u 3387 c u 3546 u c 3228 a u 3402 a u 3555 g c 3243 g u 3403 c u 3559 u c 3250 c u 3405 c a 3561 g c 3252 c a 3414 c u 3562 a u 3258 g u 3417 u c 3563 g c 3261 a c 3423 c u 3564 u g 3264 u c 3426 u a 3567 g a 3270 u c 3438 a u 3570 a u 3276 u c 3441 g a 3576 c u 3277 u c 3445 a u 3579 c u 3280 a u 3446 g c 3585 c u 3281 g c 3448 u a 3586 a u 3282 u a 3449 c g 3587 g c 3285 c a 3450 g c 3588 u a 3288 c g 3453 u a 3600 g a 3291 a c 3466 c u 3615 u c 3297 u c 3472 a c 3616 a u 3300 g a 3474 g a 3617 g c Page 26 of 121 WO 53052 Pos. NVVT VVT Pos. NVVT VVT Pos. NVVT VVT 3618 c a 3750 a g 3901 c a 3624 u c 3751 u a 3906 g a 3627 g a 3752 c g 3909 u c 3633 c u 3753 g u 3910 c u 3636 g c 3756 g u 3912 c g 3639 g a 3760 c u 3918 u c 3642 c u 3762 g a 3931 u a 3645 g c 3765 g a 3932 c g 3648 g a 3768 c u 3933 a u 3660 c a 3771 c u 3942 g a 3663 g a 3780 u a 3945 u a 3666 a u 3786 u c 3954 c u 3669 g a 3789 a u 3957 g a 3672 c u 3792 g a 3960 c u 3675 a c 3795 u a 3969 c g 3678 c a 3798 g a 3972 u c 3679 c u 3810 c u 3973 c a 3681 u a 3813 c u 3975 g a 3684 a g 3816 u g 3976 a u 3690 c u 3819 g u 3977 g c 3693 g c 3826 a u 3981 a g 3697 a u 3827 g c 3984 c a 3698 g c 3828 c a 3987 g a 3699 c a 3831 c a 3996 g u 3702 u a 3834 c u 3999 a g 3705 c u 3840 g a 4002 a g 3708 c u 3847 c a 4005 c u 3711 u c 3855 g c 4020 a g 3715 c a 3864 a g 4029 a c 3717 u g 3867 c a 4032 c u 3723 g c 3870 c a 4038 g a 3724 u c 3873 a g 4039 u a 3726 g c 3876 g a 4040 c g 3727 c u 3879 c a 4041 g c 3729 c g 3885 c u 4047 g c 3732 g a 3889 a u 4057 c u 3735 g a 3890 g c 4059 c g 3738 c u 3891 c u 4066 c u 3741 g a 3897 c a 4071 g u 3747 a g 3900 c u 4072 c a Page 27 of 121 Pos. NWT WT Pos. NWT WT Pos. NWT WT 4077 c u 4182 c u 4324 u a 4080 c u 4188 g a 4325 c g 4084 u a 4191 g a 4326 a c 4085 c g 4203 g a 4329 a c 4089 a g 4206 u c 4335 u c 4095 a g 4207 c a 4344 a g 4098 u c 4209 u g 4347 u c 4099 c u 4212 c a 4353 a c 4101 u g 4215 g a 4357 a c 4104 c g 4218 c a 4359 a g 4105 u c 4224 c g 4362 u c 4107 g u 4233 g a 4365 g a 4116 u c 4240 c u 4366 u a 4117 u a 4242 u g 4367 c g 4118 c g 4248 c a 4368 g c 4119 g u 4257 u c 4380 c u 4122 c u 4260 g a 4383 a g 4126 c u 4263 c g 4386 g c 4131 c u 4266 c g 4392 c u 4134 g a 4275 c u 4395 g u 4140 g a 4287 g a 4398 c u 4143 u c 4293 u g 4399 u c 4146 g a 4296 u c 4407 a g 4149 c a 4302 a g 4413 u a 4152 c u 4303 u a 4422 a g 4158 g a 4304 c g 4425 u g 4161 a u 4305 a c 4431 c u 4164 u a 4306 u c 4434 g a 4167 g a 4308 g c 4435 c a 4170 g a 4317 g a 4437 u g 4173 g a 4320 g c 4443 a g 4179 c u 4323 u c In some embodiments, the CFTR mRNA according to the invention comprises a coding sequence sing at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of the non-Wild-type bases listed in Table 2 at the corresponding positions of the coding sequence listed in Table 2 relative to the Wild-type coding sequence of SEQ ID NO: 2.
Page 28 of 121 Table 2. Subset of non-Wild-type bases that can be used in the coding sequence ofmRNA encoding CFTR.
P71134566667888899111111111111111122 0 & NCgcccaUCgUUgUCggugaggucgccgccacgugcm waUgUuccaaagacaacguuuucaugaaaagguauuT P22222222223333333333333333333334444 578990011112234456777889990112 s65802502144902584732519258450699273 NagcgcucacauUCCUCgccaagCgcauuuccuuuam T WT 5835401362145736223344556677888801 aaaug 695817093557036913 wcaaauaacagcaaacaCUgggcacaCCCCUgCCCC P44444444555555555555555555666666666 023445699000112223334455678123446789 s95477228147045671484558438541253247 Ncccuccaacggguuuccuuucuuccggcuuuauaum gua gCCgU gcacg Page 29 of 121 WO 53052 Pos. NVVT VVT Pos. NVVT VVT Pos. NVVT VVT 702 a c 963 g u 1280 c g 703 u c 966 u g 1293 g u 720 u a 967 u c 1308 c u 724 c a 972 u c 1311 a u 726 g a 979 u c 1314 a u 741 u c 984 u c 1317 c u 742 c a 990 g a 1321 u c 744 c a 993 u c 1350 g a 756 g u 1002 c g 1362 c g 759 u g 1008 u a 1368 a u 762 a g 1017 g c 1371 g u 768 g u 1020 u c 1383 u a 777 c u 1023 G a 1386 g a 780 c g 1035 a u 1389 a c 786 u c 1036 u c 1392 a g 789 g a 1047 a g 1401 c u 798 c u 1053 a u 1402 u c 813 g u 1065 g c 1425 u g 816 c u 1071 c u 1440 g u 819 a g 1092 g u 1449 A g 825 u c 1101 g a 1455 C u 840 u a 1116 a g 1458 G a 864 c a 1158 u c 1459 C a 865 c a 1161 u a 1461 U a 867 c a 1164 u g 1485 A c 873 u a 1170 g a 1497 C u 891 c g 1179 a g 1500 a c 897 g a 1194 g a 1521 u c 900 g c 1197 u c 1524 c u 906 c g 1200 u c 1527 a u 907 c a 1206 a g 1530 a u 909 g a 1212 u a 1557 g c 912 u c 1218 a g 1563 u c 921 g c 1245 u c 1569 g a 927 g c 1255 c a 1576 u c 939 c a 1257 c a 1590 u c 948 c u 1266 a u 1593 u c 951 u g 1275 c u 1599 c u 954 c g 1278 u c 1602 c a 960 c a 1279 u a 1611 u c Page 30 of121 WO 53052 Pos. NVVT VVT Pos. NVVT VVT Pos. NVVT VVT 1617 c a 1897 u c 2190 a g 1620 c u 1906 u c 2200 c a 1621 u c 1914 g a 2202 c a 1635 u a 1923 a c 2208 u g 1638 u c 1938 g a 2214 c a 1642 u c 1947 a u 2220 g a 1647 g u 1962 c u 2226 a u 1653 g u 1965 g a 2232 a g 1662 g a 1969 c a 2244 u a 1674 c a 1971 g a 2247 u g 1677 g a 1972 c a 2253 g c 1683 g a 1974 g a 2256 u c 1698 a u 1980 g a 2259 g c 1713 u a 1984 u c 2265 u c 1716 u c 1989 g u 2266 u a 1719 a u 1992 a g 2267 c g 1722 g u 1995 g c 2268 a c 1734 c a 2010 g a 2271 c u 1737 c u 2013 u a 2274 a c 1740 a u 2019 u a 2277 u c 1761 c u 2028 g u 2280 a g 1765 u a 2031 a c 2289 g a 1766 c g 2034 g c 2301 a g 1767 g c 2040 c a 2304 c u 1770 c u 2058 g u 2310 c g 1782 u g 2076 a g 2316 c g 1791 u c 2082 u g 2322 g a 1797 g u 2104 u c 2325 u c 1812 a u 2112 u a 2328 g a 1815 a u 2115 u c 2331 a u 1830 u a 2121 a u 2340 g u 1839 g u 2124 u a 2343 a g 1857 c g 2127 c a 2355 c a 1860 c u 2136 a c 2358 a g 1866 a u 2139 c u 2361 g a 1869 g c 2142 c g 2364 g a 1870 u a 2154 a c 2370 a c 1871 c g 2169 a c 2373 g a 1881 c u 2184 g u 2388 u g 1887 u a 2187 c u 2391 a c Page3],of121 WO 53052 Pos. NWT WT Pos. NWT WT Pos. NWT WT 2400 g a 2661 g u 2923 c a 2403 u c 2665 u c 2925 c a 2415 c g 2683 u a 2931 a c 2428 c a 2684 c g 2970 g c 2430 u a 2688 a u 2976 c u 2436 u a 2694 a u 3000 c u 2439 g u 2703 u c 3021 a u 2448 c u 2704 u a 3030 c u 2451 a c 2705 c g 3033 c a 2454 u g 2712 c a 3039 u c 2463 c u 2724 u c 3045 u c 2484 u c 2725 u a 3051 c u 2490 a g 2726 c g 3054 g a 2514 a g 2727 u c 3060 u g 2515 u a 2730 a c 3063 g a 2516 c g 2742 c u 3069 c a 2517 a c 2760 a g 3075 g u 2526 g a 2781 c u 3088 c a 2532 a u 2784 g u 3090 g a 2535 g a 2802 a u 3108 g c 2548 u c 2805 c a 3120 u c 2553 u a 2811 c g 3141 g c 2562 g u 2814 u g 3145 u a 2572 u a 2820 g u 3146 c g 2573 c g 2823 u a 3147 g u 2583 c u 2829 u a 3150 u a 2586 c g 2832 c g 3156 u c 2589 c a 2844 c a 3159 g u 2598 u c 2850 u c 3174 u c 2601 c a 2859 u a 3184 u c 2613 c g 2865 c u 3192 g a 2622 c g 2868 a u 3193 u c 2625 a u 2877 u a 3198 c u 2628 g u 2890 u c 3228 a u 2631 a u 2895 u c 3243 g u 2634 u g 2901 c g 3252 c a 2640 c g 2907 g a 3258 g u 2643 c g 2910 a u 3261 a c 2655 u a 2913 u g 3264 u c 2658 u c 2917 u c 3270 u c Page 32 of 121 WO 53052 Pos. NWT WT Pos. NWT WT Pos. NWT WT 3276 u c 3559 u c 3864 a g 3277 u c 3564 u g 3873 a g 3282 u a 3570 a u 3879 c a 3288 c g 3579 c u 3889 a u 3297 u c 3588 u a 3890 g c 3304 c a 3615 u c 3891 c u 3306 c a 3624 u c 3901 c a 3336 c u 3633 c u 3912 c g 3339 g u 3648 g a 3918 u c 3345 u c 3660 c a 3933 a u 3348 u c 3666 a u 3945 u a 3366 g a 3669 g a 3954 c u 3375 c a 3672 c u 3957 g a 3382 c a 3675 a c 3960 c u 3387 c u 3681 u a 3972 u c 3402 a u 3684 a g 3981 a g 3405 c a 3693 g c 3984 c a 3417 u c 3702 u a 3996 g u 3426 u a 3711 u c 3999 a g 3438 a u 3717 u g 4002 a g 3448 u a 3723 g c 4005 c u 3449 c g 3724 u c 4020 a g 3450 g c 3729 c g 4029 a c 3474 g a 3732 g a 4032 c u 3477 c u 3741 g a 4039 u a 3480 u g 3747 a g 4040 c g 3481 u a 3750 a g 4041 g c 3482 c g 3751 u a 4047 g c 3483 g c 3752 c g 4059 c g 3486 g a 3753 g u 4071 g u 3501 c u 3756 g u 4072 c a 3510 g a 3765 g a 4077 c u 3513 g a 3786 u c 4080 c u 3519 a u 3795 u a 4084 u a 3528 a c 3810 c u 4085 c g 3531 a g 3813 c u 4089 a g 3534 u a 3816 u g 4095 a g 3537 g c 3819 g u 4098 u c 3546 u c 3847 c a 4104 c g 3555 g c 3855 g c 4105 u c Page 33 of121 WO 53052 Pos. NWT WT Pos. NWT WT Pos. NWT WT 4116 u c 4257 u c 4362 u c 4119 g u 4263 c g 4365 g a 4134 g a 4266 c g 4366 u a 4140 g a 4293 u g 4367 c g 4143 u c 4303 u a 4368 g c 4158 g a 4304 c g 4383 a g 4161 a u 4305 a c 4386 g c 4164 u a 4306 u c 4392 c u 4173 g a 4320 g c 4395 g u 4179 c u 4323 u c 4399 u c 4188 g a 4324 u a 4407 a g 4206 u c 4325 c g 4413 u a 4207 c a 4326 a c 4422 a g 4209 u g 4329 a c 4425 u g 4212 c a 4335 u c 4434 g a 4224 c g 4344 a g 4435 c a 4242 u g 4347 u c 4437 u g 4248 c a 4353 a c Page 34 of 121 In some ments, the present invention comprises a non-naturally occurring CFTR mRNA comprising a coding sequence of SEQ ID NO: 3. Additional exemplary non- naturally occurring CFTR mRNA coding sequences are described in the Brief Description of Sequences section, such as, for example, SEQ ID NOs:9, 10, ll, 12, l3, l4, l5, 16, or 17. In some embodiments, the present invention provides a CFTR mRNA comprising a coding sequence at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to any ofSEQ ID NO: 3, 9,10,ll,lZ,l3,l4,l5,l6, or 17. In some embodiments, a turally occurring CFTR mRNA ses a 5’UTR, 3’UTR, a signal peptide coding sequence or a cap or tail structure as described below.
The above-described CFTR mRNAs comprising coding sequence which differs from wild-type CFTR coding sequence can e advantages with respect to y and ease of preparation. For e, in vitro transcription reactions using a polynucleotide comprising te sequence complementary to the CFTR coding ce can give greater RNA yield; a polynucleotide comprising said te sequence can be more stable (i.e., less prone to mutation) during growth in a host cell, reducing the amount of purification needed to generate template usable in a reaction; and the in viva translation of an mRNA comprising the coding sequence can be higher.
Signal Peptide Sequence In some embodiments, an mRNA encoding a CFTR protein incorporates a nucleotide sequence encoding a signal peptide. As used herein, the term “signal peptide” refers to a peptide present at a newly synthesized protein that can target the protein towards the secretory pathway. In some ments, the signal peptide is cleaved after translocation into the endoplasmic reticulum following translation of the mRNA. Signal peptide is also referred to as signal sequence, leader sequence or leader peptide. Typically, a signal peptide is a short (e. g., -30, 5-25, 5-20, 5-15, or 5-10 amino acids long) peptide. A signal peptide may be present at the N—terminus of a newly synthesized protein. Without g to be bound by any particular Page 35 of 121 WO 53052 theory, the incorporation of a signal peptide encoding sequence on a CFTR encoding mRNA may facilitate the secretion and/or production of the CFTR protein in viva.
A suitable signal peptide for the present invention can be a heterogeneous sequence derived from various eukaryotic and prokaryotic proteins, in particular secreted proteins. In some embodiments, a suitable signal peptide is a leucine-rich sequence. See Yamamoto Y et al. (1989), Biochemistry, 28:2728-2732, which is incorporated herein by reference. A le signal peptide may be derived from a human growth hormone (hGH), serum albumin protein, Ig kappa light chain precursor, Azurocidin preproprotein, cystatin- S precursor, nogen 2 precursor, ium channel blocker, alpha conotoxin lpl .3, alpha conotoxin, alfa-galactosidase, cellulose, aspartic proteinase nepenthesin-l, acid chitinase, K28 -toxin, killer toxin zygocin precursor, and Cholera toxin. ary signal peptide sequences are described in Kober, et al., Biotechnol. Bioeng, 110: 1164-73, 2012, which is incorporated herein by reference.
In some embodiments, a CFTR ng mRNA may incorporate a sequence encoding a signal peptide derived from human growth hormone (hGH), or a fragment thereof A non-limiting nucleotide sequence encoding a hGH signal peptide is show below. ’ human growth hormone (hGH) ce (SEQ ID NO:l8): AUGGCCACUGGAUCAAGAACCUCACUGCUGCUCGCUUUUGGACUGCUUUGCCUGC CCUGGUUGCAAGAAGGAUCGGCUUUCCCGACCAUCCCACUCUCC Alternative 5’ human growth hormone (hGH) sequence (SEQ ID NO: 19): AUGGCAACUGGAUCAAGAACCUCCCUCCUGCUCGCAUUCGGCCUGCUCUGUCUCC CAUGGCUCCAAGAAGGAAGCGCGUUCCCCACUAUCCCCCUCUCG In some embodiments, an mRNA according to the t invention may incorporate a signal peptide encoding sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity to SEQ ID NO:18 or SEQ ID NO: 19.
Page 36 of121 2014/028849 ’-UTR, 3’-UTR, Poly-A Tail, Cap, and Nonstandard tide Residues In some ments, the mRNA comprises a sequence in its 5 ’-UTR which is identical to SEQ ID NO: 4 or is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identical to SEQ ID NO: 4.
In some embodiments, the mRNA comprises a sequence in its 3 ’-UTR which is identical to SEQ ID NO: 5 or is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identical to SEQ ID NO: 5.
In some embodiments, the mRNA comprises a poly-A tail. In some embodiments, the poly-A tail has a length of at least 70, 100, 120, 150, 200, 250, 300, 400, or 500 residues. In some embodiments, the poly-A tail has a length ranging from 70 to 100, 100 to 120, 120 to 150, 150 to 200, or 200 to 300, 300 to 400, or 400 to 500 residues. Poly A tails can be added using a variety of art-recognized techniques. For example, long poly A tails can be added to synthetic or in vitro transcribed RNA using poly A polymerase , el al. Nature Biotechnology. 1996; 14: 1252-1256). A transcription vector can also encode long poly A tails.
In addition, poly A tails can be added by transcription directly from PCR products. Poly A may also be ligated to the 3' end of a sense RNA with RNA ligase (see, e. g., Molecular Cloning A Laboratory Manual, 2nd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor tory Press: 1991 edition)). In some embodiments, a poly-U or poly-C tail may be used instead or in addition to a poly-A tail. For e, CFTR encoding mRNAs may include a 3 ’ poly(C) tail structure. A suitable poly-C tail on the 3' terminus ofmRNA typically include about to 200 cytosine nucleotides (e.g., about 10 to 150 cytosine nucleotides, about 10 to 100 cytosine nucleotides, about 20 to 70 cytosine nucleotides, about 20 to 60 cytosine nucleotides, or about 10 to 40 cytosine nucleotides). The poly-C tail may be added to the poly-A tail or may substitute the poly-A tail.
Page 37 of 121 WO 53052 In some embodiments, the mRNA comprises a 5’-cap, for example, a capl structure. For mRNA capping s and procedures, see, e.g., Fechter, P.; Brownlee, G.G.
“Recognition ofmRNA cap structures by Viral and cellular proteins” J. Gen. Virology 2005, 86, 1239-1249; European patent publication 2 010 659 A2; US. Patent No. 6,312,926. A 5’ cap is typically added as follows: first, an RNA terminal phosphatase removes one of the al phosphate groups from the 5’ nucleotide, leaVing two terminal ates; guanosine triphosphate (GTP) is then added to the al phosphates Via a guanylyl transferase, producing a 5’5’5 triphosphate linkage; and the 7-nitrogen of guanine is then ated by a methyltransferase. Examples of cap structures include, but are not limited to, m7G(5')ppp (5'(A,G(5')ppp(5')A and G(5')ppp(5')G- In some ments, the mRNA comprises one or more nonstandard nucleotide residues. The nonstandard nucleotide residues may include, e.g., 5-methyl-cytidine (“5mC”), pseudouridine (“u/U”), and/or 2-thio-uridine (“2sU”). See, e.g., US. Patent No. 8,278,036 or WO2011012316 for a discussion of such residues and their incorporation into mRNA. In some ments, mRNA may be SNIM RNA. As used herein, SNIM RNA is an acronym of Stabilized Non-Immunogenic Messenger RNA, designating messenger RNAs produced by in vitro transcription (IVT) including certain percentages of modified nucleotides in the IVT reaction as described in PCT Publication WO 12316. SNIM RNA used in the Examples disclosed herein was produced by IVT in which 25% ofU residues were 2-thio-uridine and 25% of C residues were 5-methylcytidine. The presence of nonstandard nucleotide residues may render an mRNA more stable and/or less immunogenic than a control mRNA with the same sequence but containing only standard residues. In further embodiments, the mRNA may comprise one or more nonstandard nucleotide residues chosen from osine, pseudoisocytosine, 5-bromouracil, 5-propynyluracil, 6-aminopurine, 2-aminopurine, inosine, diaminopurine and 2-chloroaminopurine cytosine, as well as combinations of these modifications and other base ations. Certain embodiments may filrther include additional modifications to the se ring or nucleobase. Additional modifications may Page 38 of121 WO 53052 include, for example, sugar modifications or substitutions (e. g., one or more of a 2’-O-alkyl modification, a locked c acid (LNA)). In some embodiments, the RNAs may be complexed or hybridized with onal polynucleotides and/or peptide polynucleotides (PNA).
In embodiments where the sugar modification is a 2’-O-alkyl modification, such modification may include, but are not limited to a 2’-deoxy-2’-fiuoro modification, a 2’-O-methyl modification, a 2’-O-methoxyethyl modification and a 2’-deoxy modification. In certain embodiments, any of these modifications may be present in 0-100% of the nucleotides—for example, more than 0%, 1%, 10%, 25%, 50%, 75%, 85%, 90%, 95%, or 100% ofthe constituent nucleotides individually or in combination.
Compositions comprising CFTR mRNA In certain embodiments, the mRNA molecules of the invention may be administered as naked or unpackaged mRNA. In some embodiments, the administration of the mRNA in the compositions of the invention may be tated by inclusion of a suitable carrier.
In certain embodiments, the r is selected based upon its ability to facilitate the transfection of a target cell with one or more mRNAs.
As used herein, the term “carrier” includes any of the rd ceutical carriers, vehicles, ts, excipients and the like which are generally intended for use in connection with the administration of biologically active agents, including mRNA.
In certain embodiments, the carriers employed in the compositions of the invention may comprise a liposomal vesicle, or other means to facilitate the er of a mRNA to target cells and/or tissues. Suitable carriers include, but are not limited to, polymer based rs, such as hyleneimine (PEI) and multi-domain-block polymers, lipid nanoparticles and liposomes, nanoliposomes, ceramide-containing nanoliposomes, proteoliposomes, both l and synthetically-derived exosomes, natural, synthetic and semi-synthetic lamellar bodies, nanoparticulates, calcium phosphor-silicate nanoparticulates, calcium phosphate Page 39 of121 nanoparticulates, silicon dioxide nanoparticulates, nanocrystalline particulates, semiconductor nanoparticulates, dry powders, poly(D-arginine), nanodendrimers, starch-based delivery systems, micelles, emulsions, ls, niosomes, plasmids, s, calcium phosphate nucleotides, aptamers, peptides, peptide conjugates, small-molecule targeted ates, and other vectorial tags. Also contemplated is the use of bionanocapsules and other viral capsid proteins assemblies as a suitable carrier. (Hum. Gene Ther. 2008 Sep;l9(9):887-95).
In some embodiments, the carrier comprises an organic cation, such as a cationic lipid or a cationic organic polymer. If present, the ic lipid may be a component of mal vesicles encapsulating the mRNA.
In certain embodiments of the ion, the carrier is formulated using a polymer as a carrier, alone or in combination with other carriers. Suitable polymers may include, for example, polyacrylates, polyalkycyanoacrylates, polylactide, polylactide-polyglycolide mers, polycaprolactones, dextran, albumin, gelatin, te, collagen, chitosan, cyclodextrins, protamine, PEGylated protamine, PLL, PEGylated PLL and polyethylenimine (PEI). When PEI is present, it may be branched PEI of a molecular weight ranging from 10 to 40 kDa, e. g., 25 kDa ed PEI (Sigma #408727). Additional exemplary polymers suitable for the present invention include those described in PCT Publication WO20l3 182683, the contents of which is hereby incorporated by reference.
The use of mal carriers to facilitate the delivery of cleotides to target cells is contemplated by the present invention. Liposomes (e.g., mal lipid nanoparticles) are generally useful in a variety of applications in research, ry, and medicine, particularly for their use as carriers of diagnostic or therapeutic compounds in viva (Lasic, Trends Biotechnol., 16: 307-321, 1998; Drummond et al., Pharmacol. Rev., 51: 691-743, 1999) and are usually characterized as microscopic vesicles having an interior aqua space sequestered from an outer medium by a membrane of one or more rs. Bilayer membranes of liposomes are typically formed by hilic molecules, such as lipids of synthetic or natural origin that comprise spatially separated hydrophilic and hydrophobic domains (Lasic, Trends Biotechnol, Page 40 of 121 16: 1, 1998). Bilayer membranes of the liposomes can also be formed by amphiphilic polymers and surfactants (e. g., polymerosomes, niosomes, etc.).
In certain embodiments, the mRNA is complexed with lipid nanoparticles to facilitate ry to the target cell. In certain embodiments, the compositions of the invention may be combined with a multi-component lipid e employing one or more cationic lipids, additional lipids such as non-cationic lipids (also referred to as helper lipids), cholesterol-based lipids, and/or PEGylated lipids for mRNA encapsulation.
Cationic Lipids In some embodiments, a suitable lipid nanoparticle contains a cationic lipid. As used herein, the phrase nic lipid" refers to any of a number of lipid species that have a net positive charge at a selected pH, such as physiological pH. Some cationic , in particular, those known as titratable or pH-titratable cationic lipids are ularly effective in delivering mRNA. Several cationic (e.g., titratable) lipids have been described in the literature, many of which are commercially ble. Particularly suitable cationic lipids for use in the itions and methods of the invention include those bed in international patent publications WO 53572 (and particularly, C12-200 described at paragraph [00225]) and WC 2012/170930, both ofwhich are incorporated herein by reference. In some emodiments, the cationic lipid cKK-E12 is used (disclosed in ), the teachings of which are incorporated herein by reference in their entirety. In some embodiments, the cationic lipid N—[l- (2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride or "DOTMA" is used. (Feigner et al. (Proc. Nat'lAcad. Sci. 84, 7413 (1987); US. Pat. No. 4,897,355). DOTMA can be formulated alone or can be combined with the neutral lipid, dioleoylphosphatidyl-ethanolamine or "DOPE" or other cationic or non-cationic lipids into a liposomal transfer vehicle or a lipid nanoparticle, and such liposomes can be used to enhance the delivery of nucleic acids into target cells. Other suitable ic lipids e, for example, 5- carboxyspermylglycinedioctadecylamide or "DOGS," 2,3-dioleyloxy-N—[2(spermine- Page 41 of 121 carboxamido)ethyl]-N,N—dimethyl-l-propanaminium or "DOSPA" (Behr et al. Proc. Nat. 'l Acad.
Sci. 86, 6982 (1989); US. Pat. No. 678; US. Pat. No. 5,334,761), l,2-Dioleoyl Dimethylammonium-Propane or "DODAP", l,2-DioleoylTrimethylammonium-Propane or ". Contemplated cationic lipids also include l,2-distearyloxy-N,N—dimethyl aminopropane or "DSDMA", oleyloxy-N,N—dimethylaminopropane or "DODMA", 1 ,2- dilinoleyloxy-N,N—dimethylaminopropane or "DLinDMA", l,2-dilinolenyloxy-N,N-dimethyl- 3-aminopropane or "DLenDMA", N—dioleyl-N,N—dimethylammonium chloride or "DODAC", N,N—distearyl-N,N—dimethylammonium bromide or "DDAB", N—(l,2-dimyristyloxypropyl)- N,N-dimethyl-N-hydroxyethyl ammonium bromide or "DMRIE", 3-dimethylamino(cholest enbeta-oxybutanoxy)-l-(ci s,cis-9,12-octadecadienoxy)propane or "CLinDMA", 2-[5'- (cholestenbeta-oxy)—3'-oxapentoxy)—3-dimethy is,cis-9', l-2'-octadecadienoxy)propane or "CpLinDMA", N,N-dimethyl-3,4-dioleyloxybenzylamine or ", 1 ,2-N,N'- dioleylcarbamyldimethylaminopropane or bDAP", 2,3-Dilinoleoyloxy-N,N— ylpropylamine or "DLinDAP", l,2-N,N'-Dilinoleylcarbamyldimethylaminopropane or "DLincarbDAP", l ,2-Dilinoleoylcarbamyldimethylaminopropane or "DLinCDAP", 2,2- dilinoleyldimethylaminomethyl-[1,3]-dioxolane or "DLin- -DMA", 2,2-dilinoleyl dimethylaminoethyl-[l,3]-dioxolane or K-XTC2-DMA", and 2-(2,2-di((9Z,12Z)- octadeca-9,l 2-dien- 1-yl)-l ,3-dioxolanyl)-N,N—dimethylethanamine (DLin-KC2-DMA)) (See, ; Semple et al., Nature Biotech. 28: 172-176 (2010)), or mixtures thereof.
(Heyes, J., et al., J Controlled e 107: 276-287 (2005); Morrissey, DV., et al., Nat. hnol. 23(8): 1003-1007 (2005); PCT Publication WO2005/121348A1).
In certain embodiments, the compositions and methods of the invention employ a lipid nanoparticles comprising an ionizable cationic lipid described in US. provisional patent application 61/617,468, filed March 29, 2013 (incorporated herein by nce), such as, e.g, (15Z, 18Z)—N,N—dimethyl(9Z, 12Z)-octadeca-9, 12-dien-l -yl)tetracosa- 15,18-dienamine (HGT5000), ( 15Z, 18Z)-N,N—dimethyl((9Z, 12Z)—octadeca-9, 12-dienyl)tetracosa- 4,15,18-trien-l -amine (HGT5001), and (15Z,18Z)-N,N—dimethyl((9Z, 12Z)-octadeca-9, 12- dienyl)tetracosa-5, 15 18-trienamine (HGT5002).
Page 42 of 121 In some embodiments, one or more of the cationic lipids present in such a composition se at least one of an imidazole, dialkylamino, or inium moiety. In a preferred embodiment, one or more of the cationic lipids does not se a quaternary amine.
Non-cationic/Help_er Lipids In some embodiments, a suitable lipid nanoparticle contains one or more non- cationic (“helper”) lipids. As used herein, the phrase "non-cationic lipid" refers to any neutral, rionic or anionic lipid. As used , the phrase "anionic lipid" refers to any of a number of lipid s that carry a net negative charge at a selected pH, such as logical pH. In some embodiments, a non-cationic lipid is a neutral lipid, i.e., a lipid that does not carry a net charge in the conditions under which the composition is formulated and/or administered. Non- cationic lipids include, but are not limited to, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), ylphosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine 4-(N- maleimidomethyl)-cyclohexane-l-carboxylate (DOPE-mal), dipalmitoyl phosphatidyl lamine , dimyristoylphosphoethanolamine (DMPE), distearoyl-phosphatidyl- ethanolamine (DSPE), l6-O-monomethyl PE, l6-O-dimethyl PE, 18-l-trans PE, l-stearoyl oleoyl-phosphatidyethanolamine (SOPE), or a mixture thereof.
Cholesterol-based Lipids In some embodiments, a suitable lipid nanoparticle comprises one or more cholesterol-based lipids. For example, suitable cholesterol-based cationic lipids include, for example, cholesterol, PEGylated cholesterol, DC-Choi (N,N—dimethyl-N— ethylcarboxamidocholesterol), l,4-bis(3-N-oleylamino-propyl)piperazine (Gao, et al. Biochem.
Page 43 of 121 Biophys. Res. Comm. 179, 280 ; Wolf et al. BioTechm'ques 23, 139 (1997); US. Pat. No. ,744,335), or ICE.
PEGylated Lipids In some embodiments, a suitable lipid nanoparticle comprises one or more ted lipids. For example, the use of polyethylene glycol (PEG)—modifled phospholipids and derivatized lipids such as derivatized des ER), including N—Octanoyl- Sphingosine-l-[Succinyl(Methoxy Polyethylene Glycol)—2000] (C8 PEG-2000 ceramide) is contemplated by the present invention in combination with one or more of the cationic and, in some embodiments, other lipids. In some embodiments, suitable PEGylated lipids comprise PEG-ceramides having shorter acyl chains (e. g., C14 or C18). In some embodiments, the ted lipid DSPE-PEG-Maleimide-Lectin may be used. Other contemplated PEG-modified lipids include, but are not limited to, a polyethylene glycol chain of up to 5 kDa in length covalently attached to a lipid with alkyl chain(s) of C6-C20 length. Without wishing to be bound by a particular theory, it is contemplated that the addition of PEGylated lipids may prevent complex ation and increase circulation lifetime to facilitate the delivery of the lipsome encapsulated mRNA to the target cell.
In certain embodiments, the composition ses one of the following combinations of lipids: C12-200, DOPE, cholesterol, DMG-PEGZK; DODAP, DOPE, cholesterol, DMG-PEGZK; HGTSOOO, DOPE, cholesterol, GZK; l, DOPE, cholesterol, DMG-PEGZK; XTC, DSPC, cholesterol, PEG-DMG; MC3, DSPC, cholesterol, PEG-DMG; Page 44 of 121 WO 53052 ALNY-100, DSPC, cholesterol, PEG-DSG; cKK-E 12, DOPE, Chol, PEGDMGZK.
In some embodiments, lipid:mRNA ratios can be 5:1 (mg:mg), 6:1, 7:1, 8:1, 9:1, :1 and greater up to 30:1 (mg:mg) or more. N/P ratios can be in the range of 1.1:1 up to 10:1 or higher. Example lipid ratios are 40:30:20:10, 55:20:20:5, 50:25:20:5 (cationic lipid:helper lipid:chol:PEG lipid).
In some ments, the pharmaceutical compositions according to the invention do not comprise a mucolytic agent (e.g., N—acetylcysteine, erdosteine, bromheksin, carbocysteine, guiafenesin, or iodinated ol).
Apparatuses loaded with a pharmaceutical composition In some embodiments, a pharmaceutical composition according to the invention, such as a cationic lipid-based or PEI-based composition comprising a turally occurring CFTR mRNA, is provided Within an apparatus for administration to the respiratory system of a subject. The apparatus can be, e. g., an instillation, aerosolization, or nebulization apparatus. le apparatuses include, for e, a PARI Boy jet nebulizer, Aeroneb® Lab zer, MicroSprayer®, or EFlow mesh nebulizer. Alternatively, dry powder inhalers or aerosolization apparatuses such as portable inhalers may be used.
Uses and s mRNAfor Uses and s According to the Invention Among other things, the present invention provides methods for in vivo production of a CFTR protein, in particular, in a lung of a mammal. In some embodiments, the invention provides methods of inducing CFTR expression in epithelial cells in a lung of a Page 45 of 121 mammal, comprising contacting the epithelial cells with a ceutical composition comprising an in vitro transcribed mRNA, wherein the in vitro transcribed mRNA comprises a coding ce encoding SEQ ID NO: 1 (the amino acid sequence of wild-type human CFTR).
The ion also provides uses of ceutical compositions comprising an in vitro transcribed mRNA, wherein the in vitro transcribed mRNA comprises a coding sequence encoding SEQ ID NO: 1, for the induction of CFTR sion in epithelial cells in a lung of a mammal.
The invention fiarther provides methods of ng CFTR expression in a mammalian target cell, the method comprising ting the ian target cell with a composition, the composition comprising an in vitro transcribed mRNA encoding the amino acid sequence of SEQ ID NO: 1. The invention further provides a use of composition, the composition comprising an in vitro transcribed mRNA encoding the amino acid sequence of SEQ ID NO: 1, for the induction of CFTR expression in a ian target cell.
In some embodiments of such uses and methods of treatment, the in vitro transcribed mRNA is a naturally occurring or wild-type mRNA encoding human CFTR (SEQ ID NO: 2). In other embodiments, the in vitro transcribed mRNA is a non-naturally ing mRNA as described above.
In certain embodiments, the in vitro transcribed mRNA comprises a coding sequence encoding SEQ ID NO: 1 which is at least 65%, 70%, 75%, 80%, 85%, 88%, 90%, 92% 95%, or 100% identical to SEQ ID NO: 2 (wild-type human CFTR mRNA coding sequence). mRNA comprising a coding sequence encoding SEQ ID NO: I which is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identical to SEQ ID NO: 2 may have greater cryptic promoter, direct and inverted repeat, and/or GC content than the mRNA discussed above. It was observed that vectors comprising SEQ ID NO: 2 frequently underwent insertion/deletion/rearrangement mutations in host cells under l growth conditions, resulting in a heterogeneous population of vectors that could not be used directly for in vitro transcription. It was found that growing host cells under conditions such as lower temperature, Page 46 of 121 subdued light and/or low copy cells such as CopyCutter® d, but did not ate, the occurrence of mutation. Accordingly, it can be advisable for in vitro transcription reactions of mRNA comprising a coding ce at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identical to SEQ ID NO: 2 to use a template obtained by growing the vector as described above, harvesting and linearizing the vector, and purifying the desired species for use in the transcription on. The purification step can be, e.g., size exclusion chromatography or weak anion exchange.
The in vitro transcribed mRNA for uses and methods according to the ion can comprise a 5’-UTR, 3’UTR, poly-A, poly-U and/or poly-C tail, cap, and/or nonstandard tide residues, as discussed in the section above concerning such features.
Pharmaceutical Compositionsfor Uses and s Pharmaceutical compositions for use according to the invention may comprise mRNA for uses and methods according to the invention as discussed in the preceding section and additional ingredients as discussed in the section above regarding compositions sing CFTR mRNA. Thus, use and/or administration of pharmaceutical compositions comprising any of the carriers discussed above is contemplated.
In some preferred embodiments, pharmaceutical compositions comprise PEI, such as branched PEI having a molecular weight ranging from 10-40 kDa, for example, 25 kDa.
In other preferred ments, pharmaceutical compositions comprise a cationic lipid, a pegylated lipid, and an additional lipid (such as a neutral lipid). The cationic lipid, pegylated lipid, and/or additional lipid may be chosen from those listed in the section above regarding compositions comprising CFTR mRNA.
Page 47 of 121 2014/028849 Routes ofadministrationfor induction ofexpression in lung In some embodiments of methods and uses for induction of CFTR expression in a lung of a mammal, a ceutical composition as described above is administered by a route chosen from intratracheal instillation, nebulization, and aerosolization. The apparatus for administering the composition can be chosen from the apparatuses listed in the section above regarding apparatuses loaded with a pharmaceutical composition.
In preferred embodiments, the composition is administered via zation or aerosolization. Some lipid formulations may have a tendency to aggregate when nebulization is attempted but it is generally possible to solve aggregation issues by adjusting the formulation, e. g., by substituting the cationic lipid.
Treatment ofcysticfibrosis Among other things, the present invention can be used for treating cystic fibrosis.
In some embodiments, the t invention provides a method of treating cystic fibrosis by administering to a subject in need of treatment an mRNA ng a CFTR protein as described herein or a ceutical composition ning the mRNA. The mRNA or a pharmaceutical composition containing the mRNA may be stered directly to the lung of the subject.
Various administration routes for pulmonary delivery may be used. In some embodiments, an mRNA or a composition containing an mRNA bed herein is administered by inhalation, nebulization or aerosolization. In various embodiments, administration of the mRNA results in expression of CFTR in the lung of the subject (e. g., epithelial cells of the lung).
In a particular embodiment, the present invention provides a method of treating cystic fibrosis by administering to the lung of a subject in need of treatment an mRNA comprising a coding sequence which s SEQ ID NO: 1. In certain embodiments, the present invention provides a method of treating cystic fibrosis by administering to the lung of a subject in need of ent an mRNA comprising a coding sequence which encodes an amino Page 48 of 121 acid sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1. In another particular embodiment, the present invention provides a method of treating cystic fibrosis by administering to the lung of a subject in need of treatment an mRNA comprising a coding sequence of SEQ ID NO: 3. In other embodiments, the present invention provides a method of treating cystic fibrosis by administering to the lung of a subject in need of treatment an mRNA comprising a coding sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical to SEQ ID NO: 3. Additional exemplary non-naturally occurring CFTR mRNAs that can be used for treating cystic s are described in the Brief Description of ces section, such as, for example, SEQ ID NOs:9, 10, 11, 12, 13, 14, 15, 16, or 17. In some embodiments, non-naturally occurring CFTR mRNAs that can be used for treating cystic fibrosis comprises a coding sequence at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NO: 3, 9, 10, 11, 12, 13, 14, 15, 16, or 17.
EXAMPLES The following specific examples are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. Without further elaboration, it is believed that one d in the art can, based on the description herein, utilize the present invention to its t extent.
Unless otherwise ted, CFTR mRNA and SNIM RNA used in the es disclosed herein comprised a 5’ UTR with the sequence of SEQ ID NO: 4, a coding ce (CDS) with the ce of SEQ ID NO: 3, and a 3’ UTR with the sequence of SEQ ID NO: 5.
FFL mRNA and SNIM RNA used in the Examples disclosed herein comprised a 5’ UTR, CDS, and 3’ UTR with the sequences of SEQ ID NOS: 6, 7, and 8, respectively.
Page 49 of 121 Example 1: In Vitro Synthesized mRNA Encoding CFTR Messenger RNA Synthesis. Human cystic fibrosis transmembrane conductance regulator (CFTR) mRNA and firefly luciferase (FFL) mRNA were synthesized by in vitro transcription from a d DNA template encoding the gene, which was ed by the addition of a 5’ cap structure (Cap 1) (Fechter, P.; Brownlee, G.G. “Recognition ofmRNA cap structures by viral and ar proteins” J. Gen. Virology 2005, 86, 249) and a 3’ poly(A) tail of approximately 200 nucleotides in length as determined by gel electrophoresis. 5’ and 3’ untranslated regions were present in each mRNA product.
Exemplary non-naturally occurring CFTR mRNAs include SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ UD NO:15, SEQ ID NO: 16, or SEQ ID NO:17described in the Brief Description of Sequences section.
Example 2: CFTR Expression and Activity in HEK cells This example demonstrates that fully functional CFTR protein is expressed from tic human CFTR mRNA delivered to cells.
Cells and CFTR ection. Human embryonic kidney HEK293T cells were grown in DMEM (Invitrogen Cat # 11965-092) mented with 10% fetal bovine serum, 2 mM L-Glutamine, 100 U/ml penicillin and 100 ug/ml streptomycin. The day before transfection, cells were plated on 6-well plates at 50-60% nce and incubated under normal tissue culture conditions (36°C in a humidified atmosphere of 5% C02, 95% air). 60 ul Lipofectamine 2000 (Invitrogen Cat # 11668019) was diluted in 900 ul OptiMem reduced serum media (Invitrogen Cat # 31985-062) and gently vortexed. 24 ug CFTR mRNA (4 ug per plate) was diluted in 900 ul OptiMem media. The mRNA was immediately added to the diluted Lipofectamine and incubated at room temperature for 30 minutes. The g media was gently aspirated from the HEK293T cells and replaced with 1 ml OptiMem Reduced Serum Medium. 300 ul of mRNA/Lipofectamine complex was added to each well and the cells allowed to rest Page 50 of 121 under normal tissue culture conditions for 24 hrs before being re-plated by mechanical detachment on poly-L-Lysine coated glass cover slips (BD Biosciences, BD Biocoat) so that the cells could be easily transferred to a recording chamber for electrophysiological recording. Cells were incubated under standard tissue e conditions for a minimum of a fithher 24 hours and were used within 48 hours of final plating.
Electrophysz’ologz’cal Recording. Whole-cell patch-clamp recordings were conducted at room temperature using an Axopatch 200B amplifier with 5-8 M9 electrodes. Data were digitized (50 kHz) and d (5 kHz) appropriately. Series resistance was compensated (70-80%) to minimize voltage errors. Voltage-clamp recordings were performed with pipette solution of the following composition: 140 mM NMDG-Cl; 5 mM EGTA; 1 mM MgCl2; 10 mM HEPES; pH 7.2; 310 mOsm/l. The bathing solution ned: 140 mM NaCl, 3 mM KCl, 2 mM MgCl2, 2 mM CaCl2, and 10 mM HEPES; pH 7.3, adjusted to 315 mOsm/l with D-glucose.
Voltage clamp recordings ced 3-5 s after establishing cell ration.
Cells were voltage-clamped at a holding potential of either -60 mV or 0 mV and a series of positive and negative voltage steps (either -80 mV to +80 mV or -100 to +100 mV in 20 mV increments) injected into the recorded T cells to evoke CFTR-induced whole-cell chloride (Cl-) ts. The membrane permeable analogue of cAMP, 8-Br-cAMP (500 uM, Sigma Aldrich) was applied for 4 mins to recorded cells to tate CFTR currents. The ‘gold- standard’ CFTR blocker, CFTRinh-172 (10 uM, Sigma) was applied at the end of each recording to block the CFTR induced Cl- current. Control recordings were performed in non-transfected HEK293T cells.
Test Compounds. Test compounds were applied using a DAD-16VC fast perfusion system (ALA Scientific Instruments, USA) with the ejection pipette placed approximately 200 um fiom the recorded cell. 8-Br-cAMP was made as a 500 mM stock concentration in ddH20. CFTRinh-172 was made as a 10 mM stock in DMSO. All compounds were stored at -20°C and were rapidly defrosted and diluted to the desired final tration immediately prior to use.
Page 51 of 121 Analysis. All analysis was conducted using Clampf1t (MDS Analytical Technologies) and Excel (Microsoft) software. All values are maximum evoked-peak current amplitude. Statistical differences in the data were ted by Student’s , paired or un- paired as appropriate and ered significant at P < 0.05.
In Vitro Human CFTR Protein Production. The production of human CFTR protein Via hCFTR mRNA was accomplished Via transfection of human CFTR mRNA in HEK293T cells described herein. Treated and untreated cells were harvested and subjected to immunoprecipitation methods 24 hours ransfection. Detection of human CFTR protein via Western blot analysis demonstrates that the fillly complex glycosylated CFTR protein (designated as “C” band) was produced from the synthetic messenger RNA (Figure 1A).
In Vitro Human CFTR n Activity. To ine the activity of the synthetic human CFTR erived CFTR protein produced after transfection, whole cell patch clamp assays were performed in both HEK 293 and HEK 293T cells. Treated cells as well as l cells (untreated and mock transfected) were subjected to tor (8-Br-cAMP, forskolin) and inhibitor (CFTRinh-l72, GlyH-lOl) substrates to help ine changes in current flow ide ion transport).
HEK293T cells were transfected with 4 ug of hCFTR mRNA and analyzed 24 hours post transfection. Whole cell clamp assays were conducted to measure current flow, as represented by chloride ion transport upon ation of a set voltage. A plot of current vs voltage as a result of a voltage ramp of -80 mV to +80 mV (depicted in Figure 2) demonstrates substantial differences in current when comparing untreated versus hCFTR mRNA-treated cells.
This increase in current after exposure to 8-Br-cAMP, a known activator of CFTR protein, is suggestive that human CFTR protein is present in these cells. Upon treatment of these previously transfected cells with a known specific CFTR inhibitor, CFTRinh-l72, the respective current drops back down to near control levels (~89% decrease). Such a decrease after exposure of this inhibitor strongly supports the presence of human CFTR protein. These results in sum demonstrate that synthetic hCFTR mRNA can produce active human CFTR protein.
Page 52 of 121 Separately, CFTR whole cell activity assays were performed using an automated system rks) within HEK293 cells. As described above, treated cells as well as control cells (untreated and mock transfected) were subjected to activator and inhibitor substrates to help determine changes in current flow (chloride ion transport). In these studies, forskolin was employed as the CFTR protein activator and a n of the hCFTR mRNA-transfected cells were filrther exposed to a different specific CFTR inhibitor, GlyH-lOl. GlyH-lOl is believed to act as a CFTR pore blocker which acts upon the extracellular membrane side of the protein.
Notably, this action of mechanism is different from that of h-172, which is ed to fianction from the intracellular side of the CFTR n.
Figure 4 represents a current-voltage plot of the parental HEK293 cell line d with forskolin as well as GlyH-101. No significant change in current was observed, suggesting that these specific CFTR activators/inhibitors have no effect on the endogenous proteins present in the cell line.
A plot of current vs. voltage as a result of a voltage ramp of -100 mV to +100 mV ted in Figure 5) demonstrates substantial ences in t when comparing ted HEK293 cells versus hCFTR mRNA-treated cells. This increase in current after exposure to forskolin a known activator of CFTR protein, is indicative that human CFTR protein is present in these cells. Upon treatment of these previously transfected cells with a different known specific CFTR inhibitor, GlyH-101, the respective current drops back down to near control levels (~95% decrease). Such a decrease after exposure of this inhibitor strongly supports the presence of human CFTR protein.
In total, these inhibition data which are a result of two distinct mechanisms ly support the identity of a fully fianctional CFTR protein derived from the synthetic human CFTR messenger RNA.
Page 53 of 121 Example 3: In Vivo Expression of CFTR This example demonstrates that CFTR protein is effectively sed in vivo from a CFTR encoding mRNA delivered through pulmonary stration.
Formulation Protocol 1. Aliquots of 50 mg/mL ethanolic ons of Cl2-200, DOPE, Chol and DMG-PEG2K were mixed and diluted with ethanol to 3 mL final volume.
Separately, an aqueous buffered solution (10 mM citrate/150 mM NaCl, pH 4.5) of CFTR mRNA was prepared from a 1 mg/mL stock. The lipid solution was injected y into the aqueous mRNA on and shaken to yield a final sion in 20% ethanol. The resulting nanoparticle suspension was filtered, diafiltrated with lx PBS (pH 7.4), followed by water, concentrated and stored at 2-8°C. Final concentration = 1.09 mg/mL CFTR mRNA sulated). Zawe = 80.2 nm (Dv(50) = 55.5 nm; Dv(90) = 99.6 nm).
Formulation Protocol 2. Aliquots of a 2.0 mg/mL aqueous solution PEI (branched, 25 kDa) were mixed with aqueous solution of CFTR mRNA (1 .0 mg/mL). The resulting complexed mixture was pipetted up and down several times and put aside for 20 minutes prior to injection. Final concentration = 0.60 mg/mL CFTR mRNA (encapsulated).
Zawe = 75.9 nm (Dv(50) = 57.3 nm; Dv(90) = 92.1 nm).
Analysis ofFFL and CFTR protein produced via intratracheal administered mRNA-loaded nanoparticles. All studies were performed using either female BALB/C mice or CFTR KO mice.
FFL s were introduced via either direct instillation (MicroSprayer®) or nebulization (PARI Boy or Aeroneb) respective dose of encapsulated FFL mRNA. CFTR mRNA was introduced using a PARI Boy jet nebulizer. Mice were sacrificed and perfilsed with saline after allowing time for expression.
Intratracheal stration ofFFL mRNA. FFL test materials were administered by a single intratracheal aerosol administration via a MicrosprayerTM (50 uL/animal) while Page 54 of 121 s are anesthetized with intraperitoneal injection of a e of ketamine 50-100 mg/kg and xylazine 5-15 mg/kg. zation ol) Administration ofFFL mRNA. FFL test materials were administered by a single l inhalation via Aeroneb® Lab nebulizer al dose volume of up to 8 mL/group). The test material was delivered to a box containing the whole group of s (n=4) and connected to oxygen flow and scavenger system.
Administration ofCFTR mRNA. CFTR mRNA was prepared in the manner described in e 6 below. Four CFTR knockout mice were placed in an aerosol chamber box and exposed to 2 mg total codon optimized unmodified human CFTR mRNA (comprising the coding sequence of SEQ ID NO: 3) via nebulization (Pari Boy jet nebulizer) over the course of approximately one hour. Mice were sacrificed 24 hours post-exposure.
Euthanasia. Animals were euthanized by C02 asphyxiation at representative times post-dose administration (:: 5%) followed by otomy and exsanguinations. Whole blood (maximal obtainable volume) was collected via cardiac puncture and discarded.
Perfusion. Following exsanguination, all animals underwent cardiac perfusion with saline. In brief, whole body intracardiac perfusion was med by inserting 23/21 gauge needle attached to 10 mL syringe containing saline set into the lumen of the left ventricle for perfusion. The right atrium was incised to provide a drainage outlet for perfusate. Gentle and steady pressure was applied to the r to perfuse the animal after the needle had been positioned in the heart. Adequate flow of the flushing solution was ensured when the exiting perfiJsate flows clear (free of Visible blood) indicating that the flushing solution has saturated the body and the procedure was complete.
Tissue Collection. Following perfilsion, all animals had the liver and lungs (right and left) harvested. Select groups were subjected to approximately one half of the liver and both (right and left) lungs snap frozen in liquid nitrogen and stored separately at nominally -70°C.
Select groups were subjected to approximately half of the liver placed in one histology cassette Page 55 of 121 per animal. Additionally, the lungs were inflated with 10% NBF h a cannula that was inserted into the trachea. The trachea was tied off with a ligature and the lungs (right and left) and trachea were placed intact in one histology cassette per animal. All histology tes were stored ambient in 10% NBF for 24 hours and transferred to 70% ethanol.
Expression ofFFL in FFL-treated mice. Upon analysis of the tissue samples, FFL expression was detected in FFL-treated mice (data not shown). sion ofCFTR in CFTR knockout mice. CFTR expression was detected by immunoprecipitation-Westem blot analysis of CFTR mRNA-treated mouse lungs. Mature “C” band was detected in left and right lungs of all treated mice while unobserved in control mice e 1B). Antibodies used were MAB25031 (R&D Systems) for immunoprecipitation and SAB4501942 (Sigma) for detection via Western blot analysis.
The results shown here indicate that a CFTR protein can be successfully expressed in vivo based on lung delivery . Furthermore, the fact that CFTR mRNA has been successfully delivered to the lung of CFTR knock out mice and resulted in effective protein production in the lung tes that CFTR mRNA based in vivo protein production may be used to treat the CFTR protein deficiency.
Example 4: Lung Delivery of CFTR mRNA Using Polymeric Nanoparticles The delivery of human CFTR messenger RNA to the lungs of a mouse can be lished via either direct ation as well as nebulization. Using in situ hybridization methods, one can successful detect human CFTR mRNA after intratracheal administration of human CFTR mRNA-loaded nanoparticles to mice. Administration may be accomplished employing based nanoparticles (eg. C12-200) as well as polymeric rticles (eg.
Polyethyleneimine, PEI).
Administration ofCFTR mRNA Using Polymeric Nanocarriers. CFTR KO mice were treated with polyethyleneimine (PEI)-based CFTR mRNA loaded nanoparticles via Page 56 of 121 intratracheal administration (30 ug encapsulated mRNA). The treated mice were sacrificed six hours and -four hours post-administration and the lungs were harvested and fixed in 10% neutral buffered formalin (NBF). In situ hybridization was employed for detection of the exogenous human CFTR mRNA (Figure 6). ntial staining was observed 24 hours post- administration with widespread bution in both mouse lungs of the treated CFTR KO mice while no staining was observed for PBS-treated control mice. is of the treated lungs at higher magnifications (up to 20x magnification) revealed extensive positive intracellular staining throughout the bronchial and alveolar s of both lungs (Figure 7). Upon further cation (40x), positive staining within the cytoplasm of target apical bronchial epithelial cells was observed (Figure 8). Thus, one can conclude that the messenger RNA API was successfully delivered to the target apical bronchial epithelial cells.
Further, while ntial staining can be observed at 6 hours post-administration, significant ve detection of hCFTR mRNA was still observed after 24 hours (Figure 9).
Substantial positive intracellular staining was observed throughout both lungs within bronchial and alveolar s at 24 hours post-administration.
Example 5: Lung ry of CFTR mRNA Using Lipid-Based Nanoparticles Administration ofCFTR mRNA Using Lipid-Based Nanocarriers. As mentioned above, successful lung delivery of human CFTR mRNA can be accomplished via lipid nanoparticle based delivery vehicles. Disclosed here are examples of hCFTR mRNA-loaded ic lipid nanoparticles utilizing C 12-200 as the cationic lipid component.
Successful detection of human CFTR mRNA within the lungs of CFTR KO mice was achieved via in situ hybridization. Knockout mice were treated with 15 ug of hCFTR mRNA encapsulated in Cl2based lipid nanoparticles and sacrificed 6 hours post- administration. Positive detection of hCFTR mRNA was observed throughout the bronchial and ar regions of both lungs when compared to PBS-treated control mice (Figure 10).
Page 57 of 121 Upon filrther magnification (40x), positive detection of human CFTR mRNA was observed within the apical asm of bronchial lial cells and well as intracellular terminal alveolar s (Figure 11).
In total, successful delivery of synthetic human CFTR messenger RNA can be achieved utilizing both ric (PEI) and lipid nanoparticle-based (C12-200) delivery systems. These systems afforded intracellular accumulation of the drug substance within the target cells of the mice. Further, substantial amounts of hCFTR mRNA were present in these target cells 24 hours post-administration. e 6: tion of Human CFTR Expression Using Specific Antibody Antibody validationfor human CFTR protein detection in mouse, pig, and cultured cells. Experiments were performed to identify an dy which is specific for the hCFTR protein, which does not cross-react with the mouse and swine analogue and which is ble in sufficient supply for future experiments. Briefly, g of various anti-hCFTR antibodies from academic and commercial sources led to identification of a combination of anti- hCFTR antibodies which were e of detecting human CFTR protein after immunoprecipitation and Western blotting (IP/WB) without cross-reactivity for either murine or porcine CFTR. Thus, suitable anti-hCFTR antibodies for detection of hCFTR protein without cross-reactivity for either murine or porcine CFTR were identified based on IP/WB results.
Cells were transfected with hCFTR mRNA and protein lysates were ed using ProteoExtract Transmembrane Kit (Merck) at 24 hrs post transfection and transmembrane fraction was screened by Western blotting for hCFTR using mouse anti-human CFTR antibody (MAI-935). Lysates from l6HBE cells were used as positive control. Figure 12A presents the data from CH0 and COS-7 cells.
Baby Hamster Kidney cells (BHK), described as CFTR-negative in the literature, were transfected similar to CH0 and COS-7 cells and protein lysates screened by Western blot.
Page 58 of 121 In contrast to the previously published reports, a clear ve signal for CFTR could be observed using the mouse monoclonal FTR antibody (Figure 12B). To test the specificity of antibody used in Western blot analysis, Pig Kidney Cells from CFTR-knockout pig (PKC), kindly provided by Prof Eckhardt Wolf (Ludwig Maximilians University, Munich), were used in transfection experiments and protein lysates screened for CFTR expression. As was evident in Figure 12B, no signal for CFTR could be detected in PKC cells. However, transfection did not result in any detectable hCFTR expression either. Using luciferase as a control for transfection, PKC cells were found to express luciferase several fold less efficient when compared to CH0 or COS-7 cells. As no significant difference in the intensity of hCFTR band could be detected in any of the screened cell lines post ection, extensive screening for other hCFTR antibodies with higher sensitivities and specificity towards hCFTR was performed.
Antibody Screening via Western Blots. Protein lysates were prepared from human bronchial lial cell line (BEAS-2B), human embryonic kidney cell line (HEK), mouse lungs and pig lungs using ProteoExtract Transmembrane Kit (Merck) and transmembrane fraction used for immunoblotting using ent primary antibodies (MAl-935 from Thermo Scientific Pierce Antibodies, Rockford, IL, USA, AB596 from the Cystic Fibrosis Consortium, University of Pennsylvania, PA, USA, and AB570 from the Cystic Fibrosis Consortium, sity of Pennsylvania, PA, USA). The data are summarized as Figure 13. s 5 detected CFTR in all the three species, AB596 detects human and murine CFTR but not porcine and dy G449 detects only human CFTR specifically.
With AB570, it was not clear if the slightly low molecular weight bands observed with murine and porcine samples are indeed CFTR or non-specific products. In subsequent experiments (data not shown), it was found that 5 recognizes a band which is not CFTR. Therefore, in general, MAl-935 results were considered as confirming results generated using other antibodies, but experiments in which the only anti-CFTR antibody used was MAl-935 were not considered conclusive.
Page 59 of 121 Immunoprecipitation ofhCFTR (IP-hCFTR) from Tissue samples. Given that all the screened antibodies produced several non-specific bands and none of them produced the characteristic banding pattern of hCFTR (C-band representing the fully glycosylated protein and B-band representing the core ylated form), immunoprecipitation (IP) of hCFTR and subsequent detection by Western blot was established to increase the sensitivity and specificity of detection thereby increasing the signal to noise ratio. l IP experiments were performed in oration with Prof. Burkhard Tummler (Medizinsche hule Hannover) using ols and antibodies published by van ld et al. 2012, Immunochemical analysis of Mutant CFTR in Lung explants, Cell Physiol. Biochem. 30, 587-595 (2012)). Human colon oma cells (T84) which overexpress hCFTR were used as positive controls for IP experiments.
Immunoprecipitation of hCFTR using three different antibodies (R29, R66/17 and R66/16) followed by immunodetection with ABS96 resulted in specific detection of hCFTR in protein s from lungs of pigs treated with an aerosol of hCFTR SNIM RNA as described in Example 8 below (Figure 14).
HGT5001 Formulation. Aerosol experiments using hCFTR SNIM RNA in a formulation of HGT5001 :DOPE;Chol;PEGDMG2K (relative amounts 50:25:20:5 (mg:mg:mg:mg)) (“HGTSOOl Formulation”) were performed in mice and protein lysates from the isolated lungs at 24 hrs post mRNA delivery were also analysed by IP using the same antibodies and conditions as for the pig lysates. However, no characteristic mature CFTR banding n could be detected for mouse samples e 15).
Immunoprecipitation ofhCFTR (IP-hCFTR) from in transfected cells. Initial IP results using tissue material from pigs provided the evidence for the technical feasibility of hCFTR detection post transcript delivery in vivo. However, as none of the antibodies used in immunoprecipitating CFTR (R29, R66/17 and R66/16) are commercially available, other commercially ble antibodies were screened for their efficacy in IP reactions. Two antibodies from R&D systems (MAB25031 and MAB1660) were tested.
Page 60 of 121 Protein lysates were prepared from T84 cells and 500 ug of total protein was used in the IP reaction using different concentrations of MAB25031 antibody. The amount of hCFTR protein immunoprecipitated was then detected by immunobloting using AB570 (Cystic Fibrosis Foundation). ABS96 under these conditions resulted in much higher background and so was not tested further. As ed in Figure 16A, there was no further increase in the amount of CFTR protein precipitated when the tration of IP antibody was increased from 2 ug/ml to 4 ug/ml. Both the fillly glycosylated and only core glycosylated forms (C- and B-band, respectively) were detected. The same immunoprecipitates were also screened using MABl660 as primary antibody in western blot. With this antibody however, only band-C was visible (Figure 16B).
After the successful detection of endogenous hCFTR from T84 immunoprecipitates using MAB25031 antibody, experiments were performed in NIH3T3 cells with the aim to detect hCFTR protein post transfection. NIH3T3 cells were transfected with hCFTR SNIM RNA. n lysates were prepared at 72 hrs post transfection and protein amounts quantified using BCA method. Human CFTR protein was immunoprecipitated from 500 ug of total n lysate using MAB25031 dy at 2 ug/ml followed by immunoblotting using AB570 (Figure 17). However, no CFTR could be detected. Cells ected with LacZ encoding mRNA were analysed as control samples for the effect of transfection per se on amount of CFTR protein.
Increasing the amount of total protein used in immunoprecipitation from 500 ug to 8 mg did not result in any detectable hCFTR protein post immunodetection with AB570.
Another hCFTR specific antibody, MABl660 (R&D Systems), was also ed for immunoprecipitation (Figure 18). However, this antibody does not itate CFTR as effectively as MAB2503 1. Therefore all future precipitations were performed with MAB2503 l.
Lack of hCFTR detection in mRNA transfected samples may not necessarily mean lack of functionality of the tested mRNAs as kinetic ments using luciferase as Page 6lof121 marker gene have shown that maximum expression with mRNA is observed at 24 hrs post transfection. Lack of hCFTR detection is rather due to insufficient hCFTR concentration in the tested samples or lack of city of the d antibodies.
PEI ation. The established conditions were tested for their feasibility to detect hCFTR after hCFTR SNIM RNA in delivery to pigs (see Example 7) of a nanoparticle formulation with 25 kDa branched PEI (“PEI Formulation”) prepared as follows.. The required amount of SNIM RNA was diluted just before application in water for injection (Braun, gen) to a total volume of 4 ml and added quickly to 4 ml of an aqueous solution of branched PEI 25 kDa using a pipette at an N/P ratio of 10. The solution was mixed by pipetting up and down ten times and nebulized as two te 4.0 ml fractions one after another to the pig lungs using the indicated nebulizer. One sample from the rase expressing lung areas from pig #1 and another from the caudal lobe of pig #2, where no luciferase activity could be detected, thus indicating lack ofmRNA delivery and/or expression, were selected as positive and negative controls. Protein lysates prepared from these samples were immunoprecipitated using MAB25031 (R&D Systems) and hCFTR protein detected using ABS70. As shown in Figure 19, luciferase expression correlated with the expression of hCFTR mRNA. Sample from the left caudal lobe from pig #2 where no luciferase activity was detectable, was also negative for hCFTR (lane 1) s hCFTR could be detected in s from pig #1 which were positive for luciferase (lane 2). e 7: Aerosol Delivery of mRNA Establishment ofencapsulated mRNA aerosol delivery to the lungs ofpigs.
Aerosol administration of firefly luciferase (FFL) SNIM RNA to the pig lungs was established by a stepwise experimental procedure. In a first step FFL SNIM RNA formulations were nebulized to anaesthetized pigs during controlled ventilation. In a second step lungs were excised immediately after aerosol stration was completed and lung specimens were Page 62 of 121 ted in cell culture medium overnight before ex vivo luciferase measurement was performed on lung specimens by BLI.
Pigs of the German Landrace were ed from Technical University Munich, Weihenstephan, Germany. The pigs had a body weight ranging from 35-90 kg. Each treatment was performed on one pig. In total five pigs were treated. The first pig (90 kg weight) was treated with FFL SNIM RNA in the PEI ation of Example 6 using an EFlow mesh nebulizer and measurement of luciferase activity in lung homogenates. The second pig (60 kg weight) was d with FFL SNIM RNA in the PEI Formulation of e 6 using an EFlow mesh nebulizer and measurement of luciferase activity in lung specimens by BLI. The third pig (80 kg weight) was treated with FFL SNIM RNA in the PEI ation of Example 6 using a PARI BOY jet nebulizer and measurement of luciferase activity in lung specimens by BLI. The fourth pig (60 kg weight) was treated with FFL SNIM RNA/hCFTR mRNA in the PEI Formulation of Example 6 using an Aeroneb mesh nebulizer and measurement of luciferase activity in lung specimens by BLI. The fifth pig (35 kg weight) was d with FFL SNIM RNA in the HGTS001 Formulation of Example 6 using an Aeroneb mesh nebulizer and measurement of luciferase activity in lung specimens by BLI.
Sedation in pigs was initiated by premedication with azaperone 2 mg/kg body weight, ketamine 15 mg/kg body weight, atropine 0.1 mg/kg body weight and followed by insertion of an intravenous line to the lateral auricular vein. Pigs were anesthetized by intravenous injection of propofol 3-5 mg/kg body weight as required. Anesthesia was maintained by ane (2-3%) with 1% propofol bolus injection at 4 to 8 mg/kg body weight to enhance anesthesia as required. Duration of the anesthesia was approximately 1-3 hrs. Pigs were killed with bolus injection of arbital (100 mg/kg body weight) and potassium chloride via the lateral ear vein. Lungs were d and tissue specimens were collected from various lung regions followed by incubation in cell culture medium overnight. For measurement of rase activity tissue specimens were either homogenized and analyzed in a tube Page 63 of 121 luminometer or incubated in a medium bath comprising D-Luciferin substrate and subjected to ex vivo luciferase BLI.
Details and Resultsfor Pig #1 . The experimental set up is illustrated in Figure 20.
For aerosol administration an EFlow mesh nebulizer was connected in-line to the ation tubing of the ator. Aerosol administration took approximately 60 min and was longer than expected from control experiments with an open system. This was apparently caused by increased back pressure during nebulisation as ced by aerosol outflow at the reservoir of the mesh nebulizer. Eight milliliters of the PEI Formulation of Example 6 comprising 1 mg FFL SNIM RNA in water for injection were prepared as described in WPS and were nebulized in two separate 4 ml portions one after another. Luciferase measurement was med in tissue homogenates of excised lung specimens of various lung regions after overnight incubation in cell culture medium. Expression values were mapped according to the origin of the lung specimens (Figure 21).
The results showed successful luciferase expression in pig lung tissue. Luciferase expression was highest in central parts of the lung and declined s more distal regions of the lung. The sion pattern correlated with the ed tion pattern of the inhaled FFL SNIM RNA-PEI nanoparticles according to the chosen ventilation parameters. Levels of luciferase expression were in the same range as observed in mouse ments in WPS using the same the PEI Formulation of Example 6.
Details and Resultsfor Pig #2. Aerosol administration of FFL SNIM RNA in the PEI Formulation of Example 6 in pig #2 was med as in pig #1 but luciferase activity was measured on lung specimens by bioluminescent imaging (BLI). This experiment was performed to ish ex vivo luciferase measurement of organ cultured lung specimens by BLI.
Luciferase measurement was clearly observed in individual tissue ens of different lung regions of the treated pig (Figure 22). The experiment confirmed results obtained from pig #1.
Details and Resultsfor Pig #3. Aerosol administration in pig #1 and #2 using the EFlow mesh nebulizer revealed some technical difficulties and inadequate nebulisation time.
Page 64 of 121 WO 53052 Therefore, pig #3 was treated using the PARI BOY jet nebulizer which was connected to the ventilation tubing Via a T-connector. Aerosol administration lasted longer (approximately 80 min) than with the EFlow mesh nebulizer and aerosol administration was non-satisfying. Very low luciferase actiVity was detected in sliced lung samples from ent lung regions of the treated pig (Figure 23).
Details and Resultsfor Pig #4. The results of the previous experiments demonstrated that a mesh nebulizer is more le for aerosol administration to the lungs of pigs in the chosen set up than a jet nebulizer. For this reason, another mesh nebulizer was tested for this purpose which satisfactorily nebulized the PEI Formulation of Example 6 when tested in an open system. Pig #4 was treated using the Aeroneb mesh nebulizer which was connected in- line to the tubing of the ator. In this experiment, 1 mg of hCFTR mRNA was ivered together with 1 mg of FFL SNIM RNA in the PEI Formulation of Example 6. This was done to test formulation stability and nebulisability of mulated FFL SNIM RNA/hCFTR mRNA- PEI rticles with respect to repeated dosing in to be performed in Example 8. The formulation was stable and did not reveal incompatibility with nebulisation. rase actiVity was clearly observed in individual tissue specimens of different lung regions of the treated pig (Figure 24).
The experiment confirmed results obtained from pig #1 and pig #2, although higher expression levels were obtained. The experiment showed that the Aeroneb mesh nebulizer was best suited for ry of the the PEI Formulation of Example 6 to the lungs of pigs. Moreover, the experiment demonstrated FFL SNIM RNA was still active when co- delivered together with hCFTR mRNA. s and Resultsfor Pig #5. Pig #5 was treated with 1 mg of FFL SNIM RNA in the HGT5001 Formulation of Example 6 aerosolized with the Aeroneb mesh nebulizer. The formulation could be aerosolized without technical difficulties. Luciferase actiVity was clearly observed in individual tissue specimens of different lung regions of the d pig (Figure 25).
Page 65 of 121 The experiment showed that aerosolized FFL SNIM RNA in the HGTSOOl Formulation of Example 6 is active in pig lung tissue, although expression levels were approximately lSfold lower than in pigs treated with the the PEI Formulation of Example 6.
Conclusion. sful s were obtained using the Aeroneb mesh nebulizer with the PEI Formulation of Example 6. Four pigs were treated with the PEI ation of Example 6 to identify the optimal experimental setup for aerosol delivery. The results demonstrated that luciferase sion could be detected in pig lung homogenates and by BLI.
Luciferase expression was highest in central parts of the lungs and hardly seen in the distal areas of the lungs. The b mesh nebulizer was found to give the best s together with the shortest delivery time. According to these experiments another pig was treated with FFL SNIM RNA encapsulated in the HGTSOOl Formulation of Example 6. Although luciferase expression was clearly observed in some parts of the pig lungs, expression levels were lower than for FFL SNIM RNA in the PEI Formulation of Example 6. The results from this work package clearly demonstrated that SNIM RNA delivery to the lungs of pigs as a large preclinical animal model was feasible using various formulations such as r (e.g., PEI) based Formulation and lipid (e.. g, l) based formulations. The results of this example ed proof of concept for successful SNIM RNA ry to the lungs of a large animal which closely mimics the situation in human patients by nebulizer used in clinical practice.
Example 8: In Vivo mRNA Delivery (Weekly Dose) A trial was performed to evaluate practicability of an aerosol application once a week in pigs. cability was defined as performing three l applications of modified mRNA in intervals of one week without induction of lung disease (absence of adverse events higher than grade 2). Additional objectives were to evaluate i) grade of distress of the animals, ii) adverse events occurring during laboratory or clinical assessment of the pigs, and iii) measurement of the induced proteins (luciferase and hCFTR).
Page 66 of 121 Repeated aerosol administration of SNIM RNA in the PEI Formulation to the lungs of pigs was established. Groups of two pigs were treated one, two, or three times at weakly intervals with FFL SNIM FTR SNIM RNA in the PEI Formulation of Example 6. Two untreated pigs served as ls. Lungs were excised 24 hrs after treatment and ex vivo luciferase activity was measured in isolated lung specimens by BLI. Expression of hCFTR protein was analysed using IP/WB. Immunohistochemistry (IHC) was performed for ion of luciferase expression on the cellular level. Toxicology was investigated by measurement of inflammatory cytokines in serum and blood chemistry. Histopathology was performed on lung s. The study protocol “Pilot project: Repeated ation of modified mRNA to establish an animal model for aerosol therapy of cystic fibrosis in pigs” was approved by the local authorities before the start of the experiments (Animal experiments license Nr.: 012).
Experimental Design. Pigs, German Landrace, female approximately 6 weeks old (~25 kg body mass in average) at nebulisation, were purchased from Technical University Munich, Weihenstephan, Germany. Pigs were ized and treated according to the scheme below (Table 3). Treatment groups of each two pigs were as follows: Group 0 - Control group without treatment Group I - Aerosol administration of 1 mg FFL SNIM RNA and 1 mg hCFTR SNIM RNA in the PEI Formulation of Example 6 on day 1.
Group II - Aerosol administration of 2 mg hCFTR SNIM RNA in the PEI Formulation of Example 6 on day l and 1 mg FFL SNIM RNA and 1 mg hCFTR SNIM RNA in the PEI Formulation of Example 6 on day 8.
Group III - l stration of 2 mg hCFTR SNIM RNA (6379-186) in the PEI Formulation of Example 6 on day l and day 8, l administration of 1 mg FFL SNIM RNA and 1 mg hCFTR SNIM RNA in the PEI Formulation of Example 6 on day 15.
Page 67 of 121 The scheme for treatment and evaluation of each group is shown in Table 3. In addition to the illustrated interventions, physical examination of the pigs was done on a daily basis.
Table 3. Time-line m of different treatment groups.
(Abbreviations used: 0 AA Aerosol application 0 Bw Blood work D day 0 Euth. Euthanasia of the animal) Group 0 (untreated animals): 1 St Euth.
Grou I (I aerosol a lication; survival Id .‘ 1 SI 1 SI Bw Bw AA Euth. i i d1,d2 Grou 2 (2 aerosol a lications; al 8d .‘ ‘ 15‘ 2nd 2nd Bw Bw Bw Bw AA AA Euth i i i i (11, d2, d3, d4, d5, d6, d7, d8, d9 Grou 3 (3 aerosol a ons; survival 15d .‘ 181 181 2nd 2nd 3rd 3rd Bw Bw Bw Bw Bw Bw AA AA AA Euth iii iii (11, d2, d3, d4, d5, d6, d7, d8, d9, d10, dll, d12, d13, d14, d15, d16 Experimentalprocedure. Sedation in pigs was initiated by premedication with azaperone 2 mg/kg body weight, ketamine 15 mg/kg body weight, atropine 0.1 mg/kg body Page 68 of 121 weight and followed by insertion of an intravenous line to the lateral auricular vein. Pigs were anesthetized by intravenous injection of propofol 3-5 mg/kg body weight as ed. esia was maintained with continuous intravenous infusion of 1% propofol as required.
Ventilation parameters were matched with endexpiratory carbon dioxide and adjusted if necessary. Anesthesia, respiratory and cardiovascular parameters were monitored continuously using pulse oximetry, capnography, rectal temperature probe and reflex status. Animals received infusion of balanced electrolyte solution at 10 ml/kg/h. Duration of the anesthesia was approximately 80-120 min. Pigs were extubated after onset of sufficient spontaneous breathing.
Pigs were killed with bolus injection of pentobarbital 100 mg/kg of body weight via the l ear vein after sedation. Lungs were d and sliced approximately 1 cm thick tissue specimens were collected from various lung regions followed by incubation in cell culture. For measurement of luciferase ty tissue specimens were incubated in a medium bath comprising D-Luciferin substrate and subjected to ex vivo luciferase BLI.
Luciferase expression in treatment groups by BLI.
For Group 0 ol group without treatment), no luciferase activity was observed in lung slices (Figure 26).
For Group I (Aerosol administration of 1 mg FFL SNIM RNA and 1 mg hCFTR SNIM RNA in the PEI Formulation of Example 6), Luciferase activity was clearly detected in lung specimens of one time treated pigs #3 and #6 (Figure 27). rase expression was highest in l parts of the lungs.
For Group II (Aerosol administration of 2 mg hCFTR SNIM RNA in the PEI ation of Example 6 on day l and 1 mg FFL SNIM RNA and 1 mg hCFTR SNIM RNA in the PEI Formulation of Example 6 on day 8), rase activity was clearly detected in lung specimens of twice-treated pigs #4 and #8 (Figure 28). rase expression was highest in central parts of the lungs. It has to be considered that samples were stored for additional 10 hours in cell culture medium before measurement because of a power blackout on the day of the measurements and resulting technical problems with the BLI system.
Page 69 of 121 For Group III (Aerosol administration of 2 mg hCFTR SNIM RNA in the PEI ation of Example 6 on day l and day 8, l administration of 1 mg FFL SNIM RNA and 1 mg hCFTR SNIM RNA in the PEI Formulation of Example 6 on day 15), Luciferase activity was clearly detected in lung specimens of thrice-treated pigs #1 and #2 (Figure 29).
Luciferase expression was highest in central parts of the lungs.
Properties ofSNIMRNA-PEI nanoparticles. Particle size and zeta potential was measured for SNIM RNA-PEI ations before nebulisation (Table X1). The SNIM RNA- PEI nanoparticles could be reproducibly formed with a size ranging from 25-37 nm and zeta potentials ranging from 30-49 mV.
Table X1. Particle size and Zeta Potential measurements Pig # Treatment # 132311;: Zeta potential d: S.D.(mV) l l 26.7:0.3 9 2 3:53:06 42.5:5.5 3 3 l .6::0.4 41 3:34 2 l 24.7::0.5 3,3 2 2 41.5::1.4 3 32.5::0.4 29.l::l.l 3 l 35.2::0.8 42.9::l.9 4 l 36.9::1.1 45.4:0.6 6 l 27.5:Z0.l 30.5:6.6 2 33.0::0.8 3.0 8 l 25.5::0.l 2.l 2 3:53:03 45.9:9.5 Luczferase expression in treatment groups by IHC. IHC for FFL was performed on tissue specimens of lung slices (Sophistolab AG, Eglisau, Switzerland) which were positive by BLI and compared with lung tissue of an ted pig and luciferase-positive mouse tumor tissue as positive control. As expected a strong signal was seen in the luciferase-positive mouse tumor tissue, whereas lung tissue of the untreated pig did not show specific staining. A clearly detectable staining pattern could be observed in the lung tissue of pig #1 which received three Page 70 of 121 treatments. FFL expression was most prominent in the bronchial epithelium of large and small airways (Figure 30).
Detection ofhCFTR protein in lung tissue oftreatedpig by IP/WB. Highly BLI- positive lung tissue of three times d pig #1 was subjected to hCFTR IP/WB ing to the protocol described by van Bameveld A et al., Cell Physiol Biochem. 30, 587-95 (2012) (Figure 31). Mature complex-glycosylated hCFTR appears as the disperse so-called C-band.
Mannose-rich hCFTR appears as the more dense so-called B-band. y hCFTR expression is observed in T84 positive control cells and lung tissue of pig #1 treated with hCFTR SNIM RNA in the PEI Formulation of Example 6. Expression of hCFTR protein was not observed in untreated pigs. A ison of hCFTR protein expression in human lung tissue from a published study using the identical protocol (van Bameveld A et al., supra) suggested that expression of hCFTR in pig lung tissue after hCFTR SNIM aerosol treatment was similar to hCFTR expression in healthy human lung.
This finding was filrther confirmed by using a different set of antibodies for ion of hCFTR protein by IP/WB in treated pig lung (see Example 6). One sample from the luciferase expressing lung areas from pig #1 and another from the caudal lobe of pig #2, where no luciferase activity could be detected, thus indicating lack ofmRNA delivery and/or expression were selected as positive and negative controls. Protein lysates prepared from these samples were immunoprecipitated using 31 (R&D s) and hCFTR protein detected using AB570. As shown in Figure 32, luciferase expression correlated with the expression of hCFTR mRNA. Sample from the left caudal lobe from pig #2 where no luciferase activity was detectable, was also negative for hCFTR (lane 1), whereas hCFTR could be detected in samples from pig #1 which were positive for luciferase (lane 2). logy: Preliminary histological ment oflung samples. A histological assessment of samples of the lungs taken after the euthanasia of three animals was performed.
After embedding in paraffin sections lung s were stained with Hematoxiline-Eosine for morphological tion. The findings were consistent across the samples from the three pigs, Page 71 of 121 two of which (pig #1 and pig #2) received three aerosol applications and the third (pig #7) was an untreated control with no aerosol application. logy: Distress. Only pig #2 and pig #1 showed mild signs of distress on day 2-4 after the first treatment. Thus, three aerosol applications within three weeks caused only mild distress Toxicology: Adverse events. Kind and frequency of adverse events (AE) were analyzed by laboratory parameters (blood, MBS and BAL) and by physical examination of the pigs (defined as a secondary objective in this .
Serum and whole blood samples were taken at the time points defined by the study protocol. Twelve entative parameters (haemoglobin, hematocrit, AP, ALT, AST, CK, bilirubin, creatinine, glucose, potassium, thrombocytes, and white blood cells) being indicative to show organ specific pathology (blood, bone marrow, liver, muscle, and kidney) were selected and the test results obtained from the VetMedLab, Ludwigsburg, Germany classified according to VCOG, n 2011.
The results showed that no severe adverse events (AE) were observed in the pigs (an AE of grade 3, 4, or 5 would have qualified as severe). There was no impairment of laboratory parameters after aerosol application of SNIM RNA in the PEI ation of Example 6. For the slight s in some parameters (e.g. CK or liver enzymes) it is more likely that these changes were caused by the experimental procedure per se (e.g. i.m. injections and anaesthesia). Also no negative effect from repeated application could be ed -even after the third ation, the pigs of group 3 show no AE higher than AE grade 2. Even AE grade 1 or 2 were rare and showed no correlation to the l application of SNIM RNA in the PEI Formulation of Example 6.
Besides the repeated blood samples two other parameters were assessed to evaluate pathological processes in the lung: i) -Alveolar—Lavage fluid (BALF) - taken after euthanasia, and ii) microbiology samples (MB S) (smear form the trachea - taken during the Page 72 of 121 anaesthesia). BALF was taken from each pig during y and was stored at -80°C for filrther examination. Tracheal smears were taken prior to each aerosol ation and microbiologically examined. These examinations ed a broad spectrum of pathogens including Bordetella bronchiospectica (a common en of the respiratory tract of the pig) and Escherichia coli. Pigs were once d with tulathromycin i.m.-inj ection (1 ml Draxxin® %).
Physical examination. In addition to the laboratory parameters, physical examinations of the pigs were performed in the ation periods between the aerosol applications (for s see 1.1.2 of annex 1 and annex 4 of the study protocol). As no system for documenting, grading and assigning the attribution of the AE, either to the intervention or something else is defined for pigs, the common toxicology criteria (CTC)—system established for dogs and cats was used (published by VOCG in 2011). To grade the laboratory parameters, species specific ULN (upper limits of normal) and LLN (lower limits of normal) were used.
Clinical assessments were made within the following six AE categories: (1) allergic/immunologic events; (2) pulmonary/respiratory; (3) constitutional clinical signs; (4) dermatologic/skin; (5) gastrointestinal; and (6) pulmonary/respiratory.
The results showed that no severe AE (no grade 3, 4, or 5) were observed in the pigs. There was no impairment of parameters assessed by al examination after the aerosol application of SNIM RNA in the PEI Formulation. The two pigs of group 3 showed grade 1 and 2 AB in three of the respiratory parameters (bronchospasm/wheezing, larynx oedema, and ea) but these mild or moderate findings were restricted to one or two days. As these observations only occurred after the first anaesthesia/intubation/aerosol application in these two pigs but not after the second or third aerosol application in these two pigs or in any other pig, it is unlikely that these findings are caused by the substance under investigation.
Conclusion. The results of this example demonstrated that the PEI Formulation encoding FFL and hCFTR SNIM RNA could be successfully lized repeatedly to the lungs Page 73 of 121 of pigs without loss of activity after each ent cycle and without adverse events. Luciferase expression was found in central parts of the lung tissue but hardly detected in distal lung areas.
The al pattern of luciferase expression correlated with the expected deposition pattern of the the PEI Formulation of Example 6 according to settings used for controlled ventilation.
Immunohistochemistry on selected lung samples form d pigs showed luciferase sion predominantly in the bronchial epithelium of large and small s. IP/WB clearly demonstrated expression of complex-glycosylated C-band of mature human CFTR in treated pig lung which was absent in ted pig lung and luciferase-negative lung specimens. Expression of hCFTR in pig lung tissue after hCFTR SNIM RNA aerosol treatment was comparable to the hCFTR expression in healthy human lung when compared to published reports using the identical ol for hCFTR protein detection. Adverse events grade 1 or 2 were very rare and showed no correlation to the aerosol application of SNIM RNA in the PEI Formulation. Thus, expression of hCFTR protein was successfully demonstrated in lungs of pigs treated with SNIM hCFTR mRNA.
Example 9: CFTR ng mRNA Containing Signal Peptide This example demonstrates that a CFTR protein may be ivey expressed from a CFTR encoding mRNA with a signal peptide encoding sequence.
Messenger RNA Synthesis. For the experiment, C-terminal Hislo tagged codon optimized human cystic fibrosis transmembrane conductance regulator TR—CHis10 )(SEQ ID NO: 15), a codon zed human CFTR with a growth hormone signal sequence leader (GH-CO-CFTR)(SEQ ID NO: 16) and codon optimized human CFTR (CO-CFTR)(SEQ ID NO: 17) SNIM RNA were synthesized by in vitro transcription from a plasmid DNA template using standard methods. Cells and CFTR transfectz'on. Human embryonic kidney HEK293T cells were grown in DMEM (Invitrogen Cat # 11965-092) supplemented with 10% fetal bovine serum, 2 mM L-Glutamine, 100 U/ml penicillin and 100 ug/ml streptomycin. The day before Page 74 of 121 transfection, cells were plated on 6-well plates at 50-60% confluence and incubated under normal tissue culture conditions (36°C in a humidified atmosphere of 5% C02, 95% air). In preparation for ection, 60 ul Lipofectamine 2000 (Invitrogen Cat # 11668019) was d in OptiMem reduced serum media (Invitrogen Cat # 31985-062) and gently vortexed. For the experiment 4 ug of either CO-CFTR, GH-CO-CFTR or CO-CFTR—C-His10 SNIM RNA was diluted in 900 ul OptiMem media. The mRNA was immediately added to the diluted Lipofectamine® and incubated at room temperature for 30 minutes. The plating media was gently aspirated and replaced with 1 ml m Reduced Serum Medium and 300 ul of each respective mRNA/Lipofectamine® x. Cells were incubated under standard tissue culture conditions.
Western Analysis. imately 48 post ection, cells were removed from their respective plates and lysed. Whole cell lysate was subjected to separation by GE and probed by Western blot. As shown in Figure 33, robust expression of human CFTR protein was detected following CO-CFTR, GH-CO-CFTR and human CO-CFTR-C-His10 mRNA transfection, by FTR (A&B) or anti-His (C) antibodies (Figure 33).
Example 10: In Vivo CO-CFTR—C-His10 mRNA Delivery to CFTR Knockout Mice Analysis ofhuman CFTR protein produced via intratracheal administered mRNA- loaded nanoparticles. All studies were performed using CFTR KO mice. CFTR mRNA formulation or vehicle control was introduced using a PARI Boy jet nebulizer. Mice were sacrificed and perfused with saline, after a predetermined period of time, to allow for protein expression from the mRNA.
Messenger RNA sis. In the example, C-terminal Hislo tagged codon optimized human cystic fibrosis transmembrane conductance regulator (CO-CFTR—C-Hislo) SNIM RNA and codon-optimized FFL SNIM RNA were synthesized by in vitro transcription from plasmid DNA templates.
Page 75 of 121 2014/028849 PEI Formulation. For the approach, delivery and sion of CO-CFTR-C- Hislo mRNA in the lungs of CFTR knockout mice was evaluated using both polymeric and lipid- based nanoparticle forluations. Polymeric nanoparticle formulations with 25 kDa branched PEI prepared as follows. The required amount of SNIM RNA was diluted just before application in water for injection (Braun, gen) to a total volume of 4 ml and added quickly to 4 ml of an aqueous solution of branched PEI 25 kDa using a pipette at an N/P ratio of 10. The solution was mixed by pipetting up and down ten times and nebulized as two te 4.0 ml fractions one after another to the mouse lungs using the indicated nebulizer. cKK-EI2 Formulation. For the lipid-based nanoparticle experiment, a lipid formulation was created using CO-CFTR-C-Hile SNIM RNA in a formulation of CK- E12:DOPE:Chol:PEGDMG2K (relative amounts 50:25:20:5 (mg:mg:mg:mg). The solution was nebulized to the mouse lungs using the indicated nebulizer.
Nebulization (Aerosol) Administration ofHuman CO-CFTR-C—Hisl 0 mRNA.
CFTR test materials were administered by a single aerosol inhalation via PARI Boy jet zer (nominal dose volume of up to 8 mL/group). The test material was delivered to a box containing the whole group of animals (n=4) and connected to oxygen flow and scavenger .
Administration ofHuman CO-CFTR-C—His10 mRNA. CFTR mRNA was prepared in the manner described above. Four CFTR knockout mice were placed in an aerosol chamber box and exposed to 2 mg total codon optimized unmodified human CFTR mRNA ising the coding ce of SEQ ID NO: 3) via nebulization (Pari Boy jet nebulizer) over the course of approximately one hour. Mice were sacrificed 24 hours xposure.
Euthanasia. Animals were euthanized by C02 asphyxiation at representative times post-dose stration (:: 5%) followed by thoracotomy and exsanguinations. Whole blood (maximal obtainable volume) was collected via c puncture and discarded.
Perfusion. Following exsanguination, all s underwent cardiac perfusion with saline. In brief, whole body intracardiac perfusion was performed by inserting 23/21 gauge Page 76 of 121 needle attached to 10 mL syringe ning saline set into the lumen of the left ventricle for perfusion. The right atrium was d to provide a drainage outlet for perfusate. Gentle and steady pressure was applied to the plunger to perfuse the animal after the needle had been positioned in the heart. Adequate flow of the flushing on was ensured when the exiting perfiasate flows clear (free of visible blood) indicating that the g solution has saturated the body and the procedure was complete.
Tissue tion. Following perfilsion, all animals had their lungs (right and left) harvested. Both (right and left) lungs were snap frozen in liquid nitrogen and stored separately at nominally -70°C.
Expression ofhuman CFTRfrom C0-CFTR-C—His10 mRNA in CFTR knockout mice. CFTR expression was detected by Western blot analysis of tissue lysate collected from CFTR mRNA-treated mouse lungs. Mature “C” band was detected in left and right lungs of all treated mice, for both the lipid-based and polymeric-based formulations (Figure 34). Expression of the mature “C” band was d by comparison with lysate collected from HEK 293T human CO-CFTR—C-His10 positive cells as described in Example 9. In contrast, no detectable signal was observed in lysate collected from wild type untreated control mice (Figure 34). Taken together, these data suggest that both polymeric and lipid based formulations (such as the cKK- E12 formulation listed above) are effective for lung delivery of CFTR mRNA, e.g., Via tion, and that once delivered, the codon optimized CFTR mRNA can effectively express human CFTR n.
Example 11: In Vivo Dose Escalation Study Dose Escalation ofPEI encapsulated mRNA aerosol delivery to the lungs ofpigs.
Aerosol stration of a combination of firefly luciferase (FFL) SNIM RNA and codon optimized human CFTR (CO-CFTR) SNIM RNA at varying concentrations to pig lungs was established by a stepwise mental procedure. In a first step the FFL/CO-CFTR SNIM RNA Page 77 of 121 formulation was nebulized to anaesthetized pigs during controlled ventilation. In a second step, the animals were sacrificed by bolus injection of pentobarbital (100 mg/kg of body weight) and potassium chloride via the lateral ear vein after sedation 24 hours after aerosol administration was completed. Lungs were excised and sliced to approximately 1 cm thick tissue specimens.
For measurement of luciferase activity, tissue specimens were incubated in a medium bath comprising D-Luciferin substrate and subjected to ex vivo rase BLI. After BLI, samples from luciferase-positive and luciferase-negative regions were taken for histopathology, immunohistochemistry and in situ hybridization. The al specimens were shock-frozen in liquid nitrogen and subsequently stored at -80°C until analysis by IP/WB and Elisa.
Messenger RNA Synthesis. In the example, codon zed human cystic fibrosis transmembrane conductance regulator (CO-CFTR) SNIM RNA, codon-optimized FFL mRNA SNIM RNA were synthesized by in vitro transcription from plasmid DNA templates using standard methods.
Experimental Design. Pigs of the German Landrace were obtained from Technical University Munich, Weihenstephan, Germany. The pigs had a body weight ranging from 35-90 kg. The study was ed using both age and weight-matched pigs to control for ility.
A single cohort of 6 pigs (3 male and 3 female) was ished for each experimental group of the 4-arm study. The first cohort was treated with water for injection (WFI) alone, which was stered using a Aeroneb mesh zer. The second cohort was treated with a solution of 1 mg FFL SNIM RNA and 1 mg of codon optimized human CFTR (CO-CFTR) SNIM RNA in the PEI Formulation described below, using an Aeroneb mesh nebulizer. The third cohort received 1 mg of FFL SNIM RNA and 5 mg of codon optimized human CFTR (CO-CFTR) SNIM RNA in the PEI Formulation described below. The fourth cohort was treated with 1 mg of FFL SNIM RNA and 10 mg of codon optimized human CFTR TR) SNIM RNA in the PEI Formulation described below. The scheme for treatment and evaluation of each group is shown in Table 4 below.
Page 78 of 121 Table 4. Experimental Design for Dose Escalation Study Pis No.andSeX 1 6 (3 male + 3 female) N/A WFI 2 6 3 male + 3 female 1 m FFL + 1 m R Branched 25 kDa PEI + WFI 6 3 male +3 female 1 m FFL + 5 m CO-CFTR Branched 25 kDa PEI + WFI 4 6 (3 male + 3 female) 1 mg FFL + 10 mg CO-CFTR Branched 25 kDa PEI + WFI mRNA - PEIformulation. An exemplary standardized formulation procedure described below was performed just before treatment of the animals. als: Syringe pump (Mixing device): Manufacturer: KD Scientific Type: KDSCE Syringe: Manufacturer: B.Braun Type: x, 20mL or 30 mL / Luer Lock Solo Ref: 4617207V Tubing: cturer: B.Braun Type: Safeflow Extension Set Ref: 4097154 Needle: Manufacturer: B.Braun Type: Sterican, 20G x l 1/2 " Ref: 46575 19 Mixing valve: Manufacturer: B.Braun Type: Discofix C 3SC Ref: l6494C Water for ion: Manufacturer: B.Braun Page 79 of 121 Type: Aqua Ref: 82423E Examplary method for the preparation of polyplexes containing lmg hCFTR SNIM RNA and 1 mg FFL SNIM RNA N/P 10 in a volume of 8mL: 3mL water for injection and 3mL RNA stock solution (c: lmg/mL in water; l.5mL FFL mRNA + l.5mL CFTR mRNA) were filled into a lSmL falcon tube. In a second falcon tube 5.6lmL water for injection were mixed with 0.39mL brPEI stock on (c: lOmg/mL in water). Two 20mL syringes were fixed in the mixing device. Each of them was connected to a needle via a tubing. One syringe was filled with the RNA- and the other with the PEI-solution using the awal filnction of the syringe pump. (Settings: Diameter: , Flow: SmL/min, Volume: 5.9mL). The s were removed and the tubes connected to the mixing valve. It was important to connect the syringe ning the RNA-solution to the angled position of the valve. To control the outlet diameter, a needle was connected. The mixing was performed using the infusion function of the syringe pump (Settings: Diameter: 20.1mm, Flow: 40mL/min, Volume: 5.8mL). To achieve a reproducible polydispersity index, the samples were fractionated manually during mixing. The first few uL until the flow was stable (100-200uL) and the last few uL sometimes containing air s were collected in a separate tube. The mixture was incubated for 30min at room temperature for polyplex formation and ards stored on ice. For different doses, the parameters were modified and adapted as shown in Table 5.
Page 80 of 121 WO 53052 2014/028849 Table 5: Exemplary volumes and settings for different mixing volumes mRNA component PEI component V (FFL V (hCFTR Water V (brPEI Aerosolized SNIM RNA stock; 10 volume 1 mg/mL) mg/mL) (ml) C0110“ V(withdrawal) V(infusion) (ml) (ml) V(withdrawal) and V(infusion) designate the setting on the syringe pump for tion and dispension, respectively, of the mRNA and PEI components.
Transfectz'on ofHEK cells to check thefunctionality 0fthe nebulized complexes.
Post nebulization, an aliquot of complexes (80ul) was used to transfect HEK cells. One day prior to transfection, lxlO6 cells were plated in 6 well plates. At the day of transfection, medium was removed from the cells, cells were washed with PBS once following which 80ul of complexes together with 920ul of serum free MEM medium was added per well. For each complex, three replicate wells were prepared. The cells were incubated with the complexes for 4 hours under standard cell culture conditions. At the end of incubation, complex containing medium was removed and serum containing MEM medium (lml) was added per well. Plates were incubated under standard cell culture conditions. At 24 hours post transfection, protein s were prepared using the same protocol and buffers used for animal tissues with exclusion of homogenization step. Cells from three wells were pooled for analysis. Expression of human CFTR was detected using immunoprecipitation with R24.l antibody (R&D Systems) and Page 81 of 121 Western Blot with a combination of 217, 432 and 596 antibodies (all from Cystic Fibrosis Consortium, University of Pennsylvania, PA, USA). hCFTR could be detected for all of complexes nebulized in pigs (see Figures 54-57).
Aerosol Application. The aerosol (WFI alone 44 ml; d mRNA PEI formulation in WFI: 8, 24 and 44 ml) was nebulized and d into the anaesthetized pig Via an Aeroneb® mesh nebulizer. Sedation in pigs was initiated by premedication with azaperone 2 mg/kg body weight, ketamine 15 mg/kg body weight, atropine 0.1 mg/kg body weight and followed by insertion of an intravenous line to the lateral lar vein. Pigs were anesthetized by intravenous injection of propofol 3-5 mg/kg body weight as required. Anesthesia was maintained by isoflurane (2-3%) with 1% propofol bolus injection at 4 to 8 mg/kg body weight to enhance anesthesia as required. Duration of the anesthesia was approximately 1-3 hrs. Pigs were ced with bolus injection of pentobarbital (100 mg/kg body ) and potassium chloride via the lateral ear vein 24 hours after completion of aerosolization. Lungs were excised and tissue specimens were collected from various lung regions. The stored samples were subjected to different assessment methods such as bioluminescence, histopathology, IP/Westem Blot and Elisa. inescence Analysis. For measurement of luciferase activity tissue specimens were either homogenized and analyzed in a tube luminometer or incubated in a medium bath comprising D-Luciferin substrate and subjected to ex vivo luciferase BLI. The data illustrates that a strong bioluminescence signal was observed for each of cohorts 2-4 (1 mg, 5, mg and 10 mgs respectively), when compared to control lung tissue samples from cohort l (WFI e l) (Figures 35-3 8).
CFTR Expression Analysis by Western Blot and Immanohistochemistry. FFL positive tissues samples were excised (minimum of 10 s for each pig within a cohort) and ed by immuneprecipitation / Western blot (IP-WB) and immunohistochemistry for human CFTR. Briefly, protein lysates were prepared from pig lungs as follows: Between 300-400mg of lung tissue was used for analysis. The tissue was homogenized in basis buffer (20mM Tris, 150 Page 82 of 121 mM NaCl, pH 8.0) containing protease inhibitors using LysingMatrixA (MPBiomedicals, Ref:6910-500) and niser “FastPrep24” (MP Biomedicals). The whole tissue mix was transferred to a new 2ml safe lock pre-cooled Eppendorf tube and 25 ul iodoacetamide : 16125) and 1 ul Omni cleave (1 :5 diluted in Omni cleave buffer) nter: OC7810K) was added. The samples were then incubated on ice for 5 minutes, followined by addition of 26ul of %SDS solution. Samples were further incubated at 4°C for 60 min on a shaker. Post incubation, 260ul of lysis buffer (850ul basis buffer + 10% TritonX-100 + 5% Sodium deoxcholate) was added to the samples and they were incubated at 4°C on a shaker for 90 s. Finally, protein s were centrifuged at 13,000 rpm at 4°C for 10-20 min and the supernatant was transferred into a new orf tube. Protein concentration was quantified using the BCA Protein Assay e). Samples were aliquoted containing 10mg of total protein and end volumes were adjusted with basis buffer to 1 ml per sample. Based on the data presented in Example 6, immunoprecipitation of CFTR was carried out using antibody R241 and was followed by Western blot immunodetection of CFTR using a triple combination of three different dies obtained from Cystic Fibrosis Consortium, University of Pennsylvania, PA, USA (antibodies 217, 432, 596). To control for intra-group variability among different animals and variability in CFTR expression, the markers band in protein size standard corresponding to 150 kDa was set as reference and the band instensities of ent groups were normalized to this value. As demonstrated in Figure 39, only 16% of the tissues sample analysed form the control pigs of cohort 1 resulted in a CFTR expression level greater than baseline. In contrast, cohorts 3 and 4, which represent the 5 mg and 10 mg ent groups respectively, each resulted in greater than 30 % of their lung tissue samples testing positive for a CFTR expression level higher than baseline (Figure 39). Furthermore, the se in CFTR expression observed within cohorts 3 and 4, was almost two fold greater than that of control.
Analysis of CFTR immunohistochemistry was performed by quantification of CFTR-positive bronchi and ioles. A bronchus / bronchiole was regarded as positive if at least one epithelial cell was detected within the epithelial cell layer displaying a clear membrane- Page 83 of 121 localizaed CFTR signal. A entative image of a “positive” sample is depicted in Figure 40.
Coditions for CFTR immunohistochemistry were optimized by assessing specificity of ble antibodies against CFTR utilizing single antibody or ations of up to three antibodies respectively. Clear CFTR-specific signals were observed after incubation of antibody 596. The data demonstrates, that CFTR-positive epithelial cells were detected in lung tissue sections of all four cohorts, demonstrating detection of human and porcine CFTR by the immunohistochemistry procedure (Figure 41 and 45). While low e 42), medium (Figure 43) and high (Figure 44) CFTR expression levels were observed for cohort 3, the overall finding demonstrates that the 5 mg treatment of codon optimized human CFTR SNIM RNA resulted in a greater number of CFTR positive cells and overall CFTR signal intensity compared to vehicle control. The data also illustrates a yet further enhancement of CFTR expression following 10 mg ent, thus demonstrating a clear dose response effect (Figure 45). Quantification of absolute and relative numbers of CFTR-positive bronchi / bronchioles further support these findings, revealing a significant higher numbers in animals which were treated with 5 or 10 mg of human CFTR SNIM RNA compared to vehicle control (Figure 46). ting an overall elevation in CFTR expression levels following treatment with human CFTR SNIM RNA.
CFTR Expression is by In Situ Hybridization (ISH). FFL positive tissues samples were excised (minimum of 10 samples for each pig within a cohort) and ted to manual in situ hybridization analysis using the RNAscope® (Advanced Cell Diagnostic) “ZZ” probe technology. Probes were generated based on the codon-optimized sequence of codon optimized human CFTR SNIM RNA (SEQ ID NO: 17). Briefly, the RNAscope® assay is an in situ hybridication assay designed to Visualize single RNA molecules per cell in formalin-fixed, paraffin-embedded (FFPE) tissue mounted on slides. Each embedded tissue sample was pretreated ing to the manufacturers protocol and incubated with a target specific human CFTR specif1c RNA probe. The hCFTR probe was shown bind CFTR, with cross reactivity to human, mouse, rat, pig and monkey. Once bound, the probe is hybridized to a e of signal amplification les, through a series of 6 utive rounds of amplification. The sample was then treated with an HRP-labeled probe specific to the signal amplification cassette and Page 84 of 121 assayed by tic visualization using 3,3’-diaminobenzidine (DAB). A probe specific for Ubiquitin C was used as the positive control (Figures 47A and 48A), while dapB was used as the negative l (Figures 47B and 48B). Positive CFTR signal was compared to that of untreated and vehicle control treated porcine lung tissue (Figure 49 A and B). Stained s were visualized under a standard bright field microscope. The data demonstrates that treatment with 1 mg of codon optimized human CFTR SNIM RNA resulted in a dramatic increase in CFTR expression in both the right (A) and left (B) lung tissue of corhort 2, when compared to vehicle control (Figure 49 and 50 A &B) Furthermore, a r increase in CFTR expression was ed for the 5 mg and 10 mg treatment groups, as demonstrated by a ic increase staining ed within the right (A) and left (B) lung samples analyzed for cohorts 3 and 4 (Figures 51 and 52 A&B). Taken together, these data strongly supports the effective delivery of mRNA via inhalation and expression of human CFTR within both lobes of the lung and their various tissues. sion. The results demonstrated that both luciferase and CFTR mRNA can be effectively delivered in vivo to lung tissues. Luciferase expression was observed throughout various tissue samples collected from ent regions within both the right and left lobs of the lungs. Thus suggestions, that nebulization is an effective approach for administering mRNA and results in fairly uniform distribution. Furthermore, in addition to rase, CFTR mRNA was also efficiently delivered to the lungs, resulting in enhanced protein expression. Expression and protein activity was verified by IP-WB, immunohistochemistry and in situ ization. Each approach clearly demonstrated a dose dependent increase in mRNA ry and CFTR expression and/or activity, within the tissues of the lung. Taken together, the experiments highlight the overall practicality and feasibility for delivering CFTR mRNA to the lung of a human subject and demonstrate the effectiveness of in vivo CFTR protein production for therapeutic use.
Example 12: In Vivo Expression in the Lung Page 85 of 121 2014/028849 This example desmonstrates successful in vivo expression in the lung following aerosol delivery of mRNA-loaded nanoparticles. All studies were performed using pigs of the German Landrace, obtained from Technical University Munich, Weihenstephan, Germany. The pigs had a body weight ranging from 35-90 kg. FFL/CO-CFTR-C-Hile mRNA ation or vehicle control was introduced using a Pari jet nebulizer. Pigs were sacrificed and perfused with saline, after a predetermined period of time, to allow for protein expression from the mRNA.
Messenger RNA Synthesis. In the example, codon zed fire fly rase (CO-FFL) mRNA was synthesized by in vitro transcription from plasmid DNA templates. cKK-EI2 Formulation. For the lipid-based nanoparticle experiment, a lipid formulation was created using 1 mg FFL + 9 mg of CO-CFTR-C-Hile mRNA encapsulated in a formulation of cKK-E12:DOPE:Chol:PEGDMG2K (relative amounts 40:30:25:5 (mol ratio).
The solution was nebulized to the Pig lungs using the indicated nebulizer.
Aerosol Application. The aerosol (Saline or CO-FFL cKK-E12 formulation) was nebulized and inhaled into the anaesthetized pig. Sedation in pigs was initiated by premedication with azaperone 2 mg/kg body weight, ketamine 15 mg/kg body weight, atropine 0.1 mg/kg body weight and followed by insertion of an intravenous line to the lateral auricular vein. Pigs were anesthetized by intravenous ion of ol 3-5 mg/kg body weight as required.
Anesthesia was maintained by isoflurane (2-3%) with 1% propofol bolus injection at 4 to 8 mg/kg body weight to enhance anesthesia as required. Duration of the esia was imately l-3 hrs. Pigs were killed with bolus injection of pentobarbital (100 mg/kg body weight) and potassium chloride via the lateral ear vein. Lungs were d and tissue specimens were collected from various lung regions followed by incubation in cell culture medium overnight. The stored samples were subjected to bioluminescence detection.
Bioluminescence Analysis. For measurement of luciferase activity tissue specimens were either homogenized and analyzed in a tube meter or incubated in a medium bath comprising ferin substrate and subjected to ex vivo luciferase BLI. A strong inescence signal was observed for each of the (A) FFL/CO-CFTR—C-Hile mRNA Page 86 of 121 treated pigs, when compared to (B) control lung tissue samples from control pigs (Saline vehicle control) (Figure 53 A&B).
These data illustrate that FFL/CFTR mRNA were successfully delivered to and expressed in the lung by aerosol administration.
BRIEF DESCRIPTION OF SEQUENCES SEQ ID NO 1. ype CFTR amino acid sequence.
SEQ ID NO 2. Wild-type CFTR mRNA coding sequence.
SEQ ID NO 3. Non-naturally occurring CFTR mRNA coding sequence #1.
SEQ ID NO 4. CFTR mRNA .
SEQ ID NO 5. CFTR mRNA 3’—UTR #1.
SEQ ID NO 6. FFL 5’ UTR.
SEQ ID NO 7. FFL coding sequence.
SEQ ID NO 8. FFL 3’ UTR.
SEQ ID NO 9. Non-naturally occurring CFTR mRNA coding sequence SEQ ID NO 10. Non—naturally occurring CFTR mRNA coding sequence SEQ ID NO 11. Non—naturally occurring CFTR mRNA coding sequence SEQ ID NO 12. Non—naturally ing CFTR mRNA coding sequence SEQ ID NO 13. Non—naturally ing CFTR mRNA coding sequence SEQ ID NO 14. Non-naturally occurring CFTR mRNA coding sequence mRNA coding SEQ ID NO 15. Codon Optimized Human CFTR inal Hislo fusion sequence.
Page 87 of 121 RECTIFIED SHEET (RULE 91) ISAIEP SEQ ID NO 16. Codon Optimized Human CFTR mRNA coding sequence with a Growth Hormone Leader Sequence.
SEQ ID NO 17. Codon Optimized Human CFTR mRNA SEQ ID NO 18. mRNA Leader Sequence #1 SEQ ID NO 19. mRNA Leader Sequence #2 SEQ ID NO 20. CFTR mRNA 3’—UTR #2.
SEQ ID NO:1 MQRSPLEKASVVSKLFFSWTRPILRKGYRQRLELSDIYQIPSVD SADNLSEKLEREWDRELASKKNPKLINALRRCFFWRFMFYGIFLYLGEVTKAVQPLLL GR].IASYDPDNKEERSIAIYLGIGLCLLFIVRTLLLHPAIFGLHHIGMQMRIAMFSLI YKKTLKLSSRVLDKISIGQLVSLLSNNLNKFDEGLALAHFVWIAPLQVALLMGLIWEL CGLGFLIVLALFQAGLGRMMMKYRDQRAGKISERLVITS'EIVIIENIQSVKAYC WEEAMEKMIENLRQTELKLTRKAAYVRYFNSSAFFFSGFFVVFLSVLPYALIKGIILR LTTTEV KIFTTISFCIVLRMAVTRQFPWAVQTWYDSLGAINKIQDFLQKQEYKTLEYN VMENVTAFWEEGFGELFEKAKQNNNNRKTSNGDDSLFFSNFSLLGTPVLKDINFKIER GQLLAVAGSTGAGKTSLLMVIMGELEPSEGKIKHSGRISFCSQFSWIMPGTIKENIIF GVSYDEYRYRSVIKACQLEEDISKFAEKDNIVLGEGGITLSGGQRARISLARAVYKDA DKILILHEGSS SPFGYLDVLTEKEIFESCVCKLMANKTRILVTSKMEHLKKA YFYGTFSELQNLQPDFSSKLMGCDSFDQFSAERRNSILTETLHRFSLEGDAPVSWTET KKQSFKQTGEFGEKRKNSILNPINSIRKFSIVQKTPLQMNGIEEDSDEPLERRLSLVP DSEQGEAILPRISVISTGPTLQARRRQSVLNLMTHSVNQGQNIHRKTTASTRKVSLAP QANLTELDIYSRRLSQETGLEISEEINEEDLKECFFDDMESIPAVTTWNTYLRYITVH KSLIFVLIWCLVIFLAEVAASLVVLWLLGNTPLQDKGNSTHS—RNNSYAVI[TSTS GVADTLLAMGFFRGLPLVHTLITVSKILHHKMLHSVLQAPMSTLNTLKAGGI IVAFIIMLR LNRFSKDIAILDDLLPLTIFDFIQLLLIVIGAIAVVAVLQPYIFVATVPV AYFLQTSQQLKQLESEGRSPIFTHLVTSLKGLWTLRAFGRQPYFETLFHKALNLHTAN WFLYLSTLRWFQMRIEMIFVIFFIAVTFISILTTGEGEGRVGIILTLAMNIMSTLQWA VNSS[DVDSLMRSVSRVFKFIDMPTEGKPTKSTKPYKNGQLSKVMIIENSHVKKDDIW PSGGQMTVKDLTAKYTEGGNAILENISFSISPGQRVGLLGRTGSGKSTLLSAFLRLLN TEGEIQIDGVSWDSITLQQWRKAFGVIPQKVF[FSGTFRKNLDPYEQWSDQEIWKVAD EVGLRSVIEQFPGKLDFVLVDGGCVLSHGHKQLMCLARSVLSKAKILLLDEPSAHLDP VTYQIIRRTLKQAFADCTVILCEl-IRIEAMLECQQFLVIEENKVRQYDSIQKLLNERSL FRQAISPSDRVKLFPHRNSSKCKSKPQIAALKEETEEEVQDTRL (SEQ ID NO:1) SEQ ID NO: 2 Page 88 of 121 RECTIFIED SHEET (RULE 91) ISAIEP AUGCAGAGGUCGCCUCUGGAAAAGGCCAGCGUUGUCUCCAAACUUUUUUUCAGCUGGACC AGACCAAUUUUGAGGAAAGGAUACAGACAGCGCCUGGAAUUGUCAGACAUAUACCAAAU CCCUUCUGUUGAUUCUGCUGACAAUCUAUCUGAAAAAUUGGAAAGAGAAUGGGAUAGAG AGCUGGCUUCAAAGAAAAAUCCUAAACUCAUUAAUGCCCUUCGGCGAUGUUUUUUCUGG AGAUUUAUGUUCUAUGGAAUCUUUUUAUAUUUAGGGGAAGUCACCAAAGCAGUACAGCC UCUCUUACUGGGAAGAAUCAUAGCUUCCUAUGACCCGGAUAACAAGGAGGAACGCUCUA UCGCGAUUUAUCUAGGCAUAGGCUUAUGCCUUCUCUUUAUUGUGAGGACACUGCUCCUAC ACCCAGCCAUUUUUGGCCUUCAUCACAUUGGAAUGCAGAUGAGAAUAGCUAUGUUUAGU UUGAUUUAUAAGAAGACUUUAAAGCUGUCAAGCCGUGUUCUAGAUAAAAUAAGUAUUGG ACAACUUGUUAGUCUCCUUUCCAACAACCUGAACAAAUUUGAUGAAGGACUUGCAUUGG UCGUGUGGAUCGCUCCUUUGCAAGUGGCACUCCUCAUGGGGCUAAUCUGGGAGU UGUUACAGGCGUCUGCCUUCUGUGGACUUGGUUUCCUGAUAGUCCUUGCCCUUUUUCAGG CUGGGCUAGGGAGAAUGAUGAUGAAGUACAGAGAUCAGAGAGCUGGGAAGAUCAGUGAA AGACUUGUGAUUACCUCAGAAAUGAUUGAAAAUAUCCAAUCUGUUAAGGCAUACUGCUG GGAAGAAGCAAUGGAAAAAAUGAUUGAAAACUUAAGACAAACAGAACUGAAACUGACUC GGAAGGCAGCCUAUGUGAGAUACUUCAAUAGCUCAGCCUUCUUCUUCUCAGGGUUCUUU GUGGUGUUUUUAUCUGUGCUUCCCUAUGCACUAAUCAAAGGAAUCAUCCUCCGGAAAAU AUUCACCACCAUCUCAUUCUGCAUUGUUCUGCGCAUGGCGGUCACUCGGCAAUUUCCCUG GGCUGUACAAACAUGGUAUGACUCUCUUGGAGCAAUAAACAAAAUACAGGAUUUCUUAC AAAAGCAAGAAUAUAAGACAUUGGAAUAUAACUUAACGACUACAGAAGUAGUGAUGGAG AAUGUAACAGCCUUCUGGGAGGAGGGAUUUGGGGAAUUAUUUGAGAAAGCAAAACAAAA CAAUAACAAUAGAAAAACUUCUAAUGGUGAUGACAGCCUCUUCUUCAGUAAUUUCUCAC UUCUUGGUACUCCUGUCCUGAAAGAUAUUAAUUUCAAGAUAGAAAGAGGACAGUUGUUG GCGGUUGCUGGAUCCACUGGAGCAGGCAAGACUUCACUUCUAAUGAUGAUUAUGGGAGA ACUGGAGCCUUCAGAGGGUAAAAUUAAGCACAGUGGAAGAAUUUCAUUCUGUUCUCAGU UUUCCUGGAUUAUGCCUGGCACCAUUAAAGAAAAUAUCAUCUUUGGUGUUUCCUAUGAU GAAUAUAGAUACAGAAGCGUCAUCAAAGCAUGCCAACUAGAAGAGGACAUCUCCAAGUU UGCAGAGAAAGACAAUAUAGUUCUUGGAGAAGGUGGAAUCACACUGAGUGGAGGUCAAC GAGCAAGAAUUUCUUUAGCAAGAGCAGUAUACAAAGAUGCUGAUUUGUAUUUAUUAGAC UCUCCUUUUGGAUACCUAGAUGUUUUAACAGAAAAAGAAAUAUUUGAAAGCUGUGUCUG GAUGGCUAACAAAACUAGGAUUUUGGUCACUUCUAAAAUGGAACAUUUAAAGA AAGCUGACAAAAUAUUAAUUUUGAAUGAAGGUAGCAGCUAUUUUUAUGGGACAUUUUCA GAACUCCAAAAUCUACAGCCAGACUUUAGCUCAAAACUCAUGGGAUGUGAUUCUUUCGAC AGUGCAGAAAGAAGAAAUUCAAUCCUAACUGAGACCUUACACCGUUUCUCAUU AGAAGGAGAUGCUCCUGUCUCCUGGACAGAAACAAAAAAACAAUCUUUUAAACAGACUG GAGAGUUUGGGGAAAAAAGGAAGAAUUCUAUUCUCAAUCCAAUCAACUCUAUACGAAAA UUUUCCAUUGUGCAAAAGACUCCCUUACAAAUGAAUGGCAUCGAAGAGGAUUCUGAUGA GCCUUUAGAGAGAAGGCUGUCCUUAGUACCAGAUUCUGAGCAGGGAGAGGCGAUACUGC CUCGCAUCAGCGUGAUCAGCACUGGCCCCACGCUUCAGGCACGAAGGAGGCAGUCUGUCC UGAACCUGAUGACACACUCAGUUAACCAAGGUCAGAACAUUCACCGAAAGACAACAGCAU CCACACGAAAAGUGUCACUGGCCCCUCAGGCAAACUUGACUGAACUGGAUAUAUAUUCAA GAAGGUUAUCUCAAGAAACUGGCUUGGAAAUAAGUGAAGAAAUUAACGAAGAAGACUUA AAGGAGUGCCUUUUUGAUGAUAUGGAGAGCAUACCAGCAGUGACUACAUGGAACACAUA CCUUCGAUAUAUUACUGUCCACAAGAGCUUAAUUUUUGUGCUAAUUUGGUGCUUAGUAA UGGCAGAGGUGGCUGCUUCUUUGGUUGUGCUGUGGCUCCUUGGAAACACUCCU Pag689of121 RECTIFIED SHEET (RULE 91) ISAIEP CUUCAAGACAAAGGGAAUAGUACUCAUAGUAGAAAUAACAGCUAUGCAGUGAUUAUCAC CAGCACCAGUUCGUAUUAUGUGUUUUACAUUUACGUGGGAGUAGCCGACACUUUGCUUG CUAUGGGAUUCUUCAGAGGUCUACCACUGGUGCAUACUCUAAUCACAGUGUCGAAAAUU UUACACCACAAAAUGUUACAUUCUGUUCUUCAAGCACCUAUGUCAACCCUCAACACGUUG AAAGCAGGUGGGAUUCUUAAUAGAUUCUCCAAAGAUAUAGCAAUUUUGGAUGACCUUCU GCCUCUUACCAUAUUUGACUUCAUCCAGUUGUUAUUAAUUGUGAUUGGAGCUAUAGCAG UUGUCGCAGUUUUACAACCCUACAUCUUUGUUGCAACAGUGCCAGUGAUAGUGGCUUUU AUUAUGUUGAGAGCAUAUUUCCUCCAAACCUCACAGCAACUCAAACAACUGGAAUCUGAA GGCAGGAGUCCAAUUUUCACUCAUCUUGUUACAAGCUUAAAAGGACUAUGGACACUUCG UGCCUUCGGACGGCAGCCUUACUUUGAAACUCUGUUCCACAAAGCUCUGAAUUUACAUAC CUGGUUCUUGUACCUGUCAACACUGCGCUGGUUCCAAAUGAGAAUAGAAAUGA UUUUUGUCAUCUUCUUCAUUGCUGUUACCUUCAUUUCCAUUUUAACAACAGGAGAAGGA GAAGGAAGAGUUGGUAUUAUCCUGACUUUAGCCAUGAAUAUCAUGAGUACAUUGCAGUG GGCUGUAAACUCCAGCAUAGAUGUGGAUAGCUUGAUGCGAUCUGUGAGCCGAGUCUUUA AGUUCAUUGACAUGCCAACAGAAGGUAAACCUACCAAGUCAACCAAACCAUACAAGAAUG GCCAACUCUCGAAAGUUAUGAUUAUUGAGAAUUCACACGUGAAGAAAGAUGACAUCUGG CCCUCAGGGGGCCAAAUGACUGUCAAAGAUCUCACAGCAAAAUACACAGAAGGUGGAAA UGCCAUAUUAGAGAACAUUUCCUUCUCAAUAAGUCCUGGCCAGAGGGUGGGCCUCUUGG CUGGAUCAGGGAAGAGUACUUUGUUAUCAGCUUUUUUGAGACUACUGAACACU GAAGGAGAAAUCCAGAUCGAUGGUGUGUCUUGGGAUUCAAUAACUUUGCAACAGUGGAG GAAAGCCUUUGGAGUGAUACCACAGAAAGUAUUUAUUUUUUCUGGAACAUUUAGAAAAA ACUUGGAUCCCUAUGAACAGUGGAGUGAUCAAGAAAUAUGGAAAGUUGCAGAUGAGGUU AGAUCUGUGAUAGAACAGUUUCCUGGGAAGCUUGACUUUGUCCUUGUGGAUGG GGGCUGUGUCCUAAGCCAUGGCCACAAGCAGUUGAUGUGCUUGGCUAGAUCUGUUCUCA GUAAGGCGAAGAUCUUGCUGCUUGAUGAACCCAGUGCUCAUUUGGAUCCAGUAACAUAC CAAAUAAUUAGAAGAACUCUAAAACAAGCAUUUGCUGAUUGCACAGUAAUUCUCUGUGA ACACAGGALAGAAGCAAUGCUGGAAUGCCAACAAUUUUUGGUCAUAGAAGAGAACAAAG UGCGGCAGLACGAUUCCAUCCAGAAACUGCUGAACGAGAGGAGCCUCUUCCGGCAAGCCAr UCAGCCCCUCCGACAGGGUGAAGCUCUUUCCCCACCGGAACUCAAGCAAGUGCAAGUCUA AGCCCCAGAUUGCUGCUCUGAAAGAGGAGACAGAAGAAGAGGUGCAAGAUACAAGGCUU UAG (SEQ ID N02) SEQIDNOfi AUGCAGCGGUCCCCGCUCGAAAAGGCCAGUGUCGUGUCCAAACUCUUCUUCUCAUGGACU CGGCCUAUCCUUAGAAAGGGGUAUCGGCAGAGGCUUGAGUUGUCUGACAUCUACCAGAU CCCCUCGGUAGAUUCGGCGGAUAACCUCUCGGAGAAGCUCGAACGGGAAUGGGACCGCGA ACUCGCGUCUAAGAAAAACCCGAAGCUCAUCAACGCACUGAGAAGGUGCUUCUUCUGGCG GUUCAUGUUCUACGGUAUCUUCUUGUAUCUCGGGGAGGUCACAAAAGCAGUCCAACCCCU GUUGUUGGGUCGCAUUAUCGCCUCGUACGACCCCGAUAACAAAGAAGAACGGAGCAUCGC GAUCUACCUCGGGAUCGGACUGUGUUUGCUUUUCAUCGUCAGAACACUUUUGUUGCAUCC AGCAAUCUUCGGCCUCCAUCACAUCGGUAUGCAGAUGCGAAUCGCUAUGUUUAGCUUGAU CUACAAAAAGACACUGAAACUCUCGUCGCGGGUGUUGGAUAAGAUUUCCAUCGGUCAGU CCCUGCUUAGUAAUAACCUCAACAAAUUCGAUGAGGGACUGGCGCUGGCACAU UUCGUGUGGAUUGCCCCGUUGCAAGUCGCCCUUUUGAUGGGCCUUAUUUGGGAGCUGUU Page 90 of 121 RECTIFIED SHEET (RULE 91) ISAIEP .-.,--_-_.,-_--.- __ -_ _)15 GCAGGCAUCUGCCUUUUGUGGCCUGGGAUUUCUGAUUGUGUUGGCAUUGUUUCAGGCUG GGCUUGGGCGGAUGAUGAUGAAGUAUCGCGACCAGAGAGCGGGUAAAAUCUCGGAAAGA CUCGUCAUCACUUCGGAAAUGAUCGAAAACAUCCAGUCGGUCAAAGCCUAUUGCUGGGAA GAAGCUAUGGAGAAGAUGAUUGAAAACCUCCGCCAAACUGAGCUGAAACUGACCCGCAA GGCGGCGUAUGUCCGGUAUUUCAAUUCGUCAGCGUUCUUCUUUUCCGGGUUCUUCGUUG UCUUUCUCUCGGUUUUGCCUUAUGCCUUGAUUAAGGGGAUUAUCCUCCGCAAGAUUUUC ACCACGAUUUCGUUCUGCAUUGUAUUGCGCAUGGCAGUGACACGGCAAUUUCCGUGGGCC GUGCAGACAUGGUAUGACUCGCUUGGAGCGAUCAACAAAAUCCAAGACUUCUUGCAAAA GCAAGAGUACAAGACCCUGGAGUACAAUCUUACUACUACGGAGGUAGUAAUGGAGAAUG UGACGGCUUUUUGGGAAGAGGGUUUUGGAGAACUGUUUGAGAAAGCAAAGCAGAAUAAC AACAACCGCAAGACCUCAAAUGGGGACGAUUCCCUGUUUUUCUCGAACUUCUCCCUGCUC CCCGUGUUGAAGGACAUCAAUUUCAAGAUUGAGAGGGGACAGCUUCUCGCGGU AGCGGGAAGCACUGGUGCGGGAAAAACUAGCCUCUUGAUGGUGAUUAUGGGGGAGCUUG AGCCCAGCGAGGGGAAGAUUAAACACUCCGGGCGUAUCUCAUUCUGUAGCCAGUUUUCAU GGAUCAUGCCCGGAACCAUUAAAGAGAACAUCAUUUUCGGAGUAUCCUAUGAUGAGUAC CGAUACAGAUCGGUCAUUAAGGCGUGCCAGUUGGAAGAGGACAUUUCUAAGUUCGCCGA GAAGGAUAACAUCGUCUUGGGAGAAGGGGGUAUUACAUUGUCGGGAGGGCAGCGAGCGC GGAUCAGCCUCGCGAGAGCGGUAUACAAAGAUGCAGAUUUGUAUCUGCUUGAUUCACCG UUUGGAUACCUCGACGUAUUGACAGAAAAAGAAAUCUUCGAGUCGUGCGUGUGUAAACU UAUGGCUAAUAAGACGAGAAUCCUGGUGACAUCAAAAAUGGAACACCUUAAGAAGGCGG ACAAGAUCCUGAUCCUCCACGAAGGAUCGUCCUACUUUUACGGCACUUUCUCAGAGUUGC AAAACUUGCAGCCGGACUUCUCAAGCAAACUCAUGGGGUGUGACUCAUUCGACCAGUUCA GCGCGGAACGGCGGAACUCGAUCUUGACGGAAACGCUGCACCGAUUCUCGCUUGAGGGUG CGGUAUCGUGGACCGAGACAAAGAAGCAGUCGUUUAAGCAGACAGGAGAAUUU GGUGAGAAAAGAAAGAACAGUAUCUUGAAUCCUAUUAACUCAAUUCGCAAGUUCUCAAU CGUCCAGAAAACUCCACUGCAGAUGAAUGGAAUUGAAGAGGAUUCGGACGAACCCCUGG AGCGCAGGCUUAGCCUCGUGCCGGAUUCAGAGCAAGGGGAGGCCAUUCUUCCCCGGAUUU CGGUGAUUUCAACCGGACCUACACUUCAGGCGAGGCGAAGGCAAUCCGUGCUCAACCUCA UGACGCAUUCGGUAAACCAGGGGCAAAACAUUCACCGCAAAACGACGGCCUCAACGAGAA AAGUGUCACUUGCACCCCAGGCGAAUUUGACUGAACUCGACAUCUACAGCCGUAGGCUUU CGCAAGAAACCGGACUUGAGAUCAGCGAAGAAAUCAAUGAAGAAGAUUUGAAAGAGUGU UUCUUUGAUGACAUGGAAUCAAUCCCAGCGGUGACAACGUGGAACACAUACUUGCGUUA CAUCACGGUGCACAAGUCCUUGAUUUUCGUCCUCAUCUGGUGUCUCGUGAUCUUUCUCGC UGAGGUCGCAGCGUCACUUGUGGUCCUCUGGCUGCUUGGUAAUACGCCCUUGCAAGACAA AGGCAAUUCUACACACUCAAGAAACAAUUCCUAUGCCGUGAUUAUCACUUCUACAAGCUC GUAUUACGUGUUUUACAUCUACGUAGGAGUGGCCGACACUCUGCUCGCGAUGGGUUUCU GACUCCCACUCGUUCACACGCUUAUCACUGUCUCCAAGAUUCUCCACCAUAAGA UGCUUCAUAGCGUACUGCAGGCUCCCAUGUCCACCUUGAAUACGCUCAAGGCGGGAGGUA UUUUGAAUCGCUUCUCAAAAGAUAUUGCAAUUUUGGAUGACCUUCUGCCCCUGACGAUC UUCAUCCAGUUGUUGCUGAUCGUGAUUGGGGCUAUUGCAGUAGUCGCUGUCCU CCAGCCUUACAUUUUUGUCGCGACCGUUCCGGUGAUCGUGGCGUUUAUCAUGCUGCGGGC CUAUUUCUUGCAGACGUCACAGCAGCUUAAGCAACUGGAGUCUGAAGGGAGGUCGCCUA UCUUUACGCAUCUUGUGACCAGUUUGAAGGGAUUGUGGACGUUGCGCGCCUUUGGCAGG CAGCCCUACUUUGAAACACUGUUCCACAAAGCGCUGAAUCUCCAUACGGCAAAUUGGUUU UUGUAUUUGAGUACCCUCCGAUGGUUUCAGAUGCGCAUUGAGAUGAUUUUUGUGAUCUU Page 91 of 121 RECTIFIED SHEET (RULE 91) ISAIEP CUUUAUCGCGGUGACUUUUAUCUCCAUCUUGACCACGGGAGAGGGCGAGGGACGGGUCG GUAUUAUCCUGACACUCGCCAUGAACAUUAUGAGCACUUUGCAGUGGGCAGUGAACAGC UCGAUUGAUGUGGAUAGCCUGAUGAGGUCCGUUUCGAGGGUCUUUAAGUUCAUCGACAU GCCGACGGAGGGAAAGCCCACAAAAAGUACGAAACCCUAUAAGAAUGGGCAAUUGAGUA AGGUAAUGAUCAUCGAGAACAGUCACGUGAAGAAGGAUGACAUCUGGCCUAGCGGGGGU CAGAUGACCGUGAAGGACCUGACGGCAAAAUACACCGAGGGAGGGAACGCAAUCCUUGA AAACAUCUCGUUCAGCAUUAGCCCCGGUCAGCGUGUGGGGUUGCUCGGGAGGACCGGGUC AUCGACGUUGCUGUCGGCCUUCUUGAGACUUCUGAAUACAGAGGGUGAGAUCC AGAUCGACGGCGUUUCGUGGGAUAGCAUCACCUUGCAGCAGUGGCGGAAAGCGUUUGGA GUAAUCCCCCAAAAGGUCUUUAUCUUUAGCGGAACCUUCCGAAAGAAUCUCGAUCCUUAU GAACAGUGGUCAGAUCAAGAGAUUUGGAAAGUCGCGGACGAGGUUGGCCUUCGGAGUGU AAUCGAGCAGUUUCCGGGAAAACUCGACUUUGUCCUUGUAGAUGGGGGAUGCGUCCUGU CGCAUGGGCACAAGCAGCUCAUGUGCCUGGCGCGAUCCGUCCUCUCUAAAGCGAAAAUUC UUCUCUUGGAUGAACCUUCGGCCCAUCUGGACCCGGUAACGUAUCAGAUCAUCAGAAGGA CACUUAAGCAGGCGUUUGCCGACUGCACGGUGAUUCUCUGUGAGCAUCGUAUCGAGGCCA UGCUCGAAUGCCAGCAAUUUCUUGUCAUCGAAGAGAAUAAGGUCCGCCAGUACGACUCCA UCCAGAAGCUGCUUAAUGAGAGAUCAUUGUUCCGGCAGGCGAUUUCACCAUCCGAUAGG GUGAAACUUUUUCCACACAGAAAUUCGUCGAAGUGCAAGUCCAAACCGCAGAUCGCGGCC UUGAAAGAAGAGACUGAAGAAGAAGUUCAAGACACGCGUCUUUAA(SBQHDNOB) SEQIDNO:4 GGACAGAUCGCCUGGAGACGCCAUCCACGCUGUUUUGACCUCCAUAGAAGACACCGGGAC CGAUCCAGCCUCCGCGGCCGGGAACGGUGCAUUGGAACGCGGAUUCCCCGUGCCAAGAGU CCGUCCUUGACACG(SHQH)NO%) SEQIDNO:5 CGGGUGGCAUCCCUGUGACCCCUCCCCAGUGCCUCUCCUGGCCCUGGAAGUUGCCACUCC AGUGCCCACCAGCCUUGUCCUAAUAAAAUUAAGUUGCAUC($32H3N05) SEQIDNO:6 GGGAUCCUACC(SEQID}K)® SEQIDNO:7 AUGGAAGAUGCCAAAAACAUUAAGAAGGGCCCAGCGCCAUUCUACCCACUCGAAGACGGG GGCGAGCAGCUGCACAAAGCCAUGAAGCGCUACGCCCUGGUGCCCGGCACCAUC GCCUUUACCGACGCACAUAUCGAGGUGGACAUUACCUACGCCGAGUACUUCGAGAUGAGC GUUCGGCUGGCAGAAGCUAUGAAGCGCUAUGGGCUGAAUACAAACCAUCGGAUCGUGGU CGAGAAUAGCUUGCAGUUCUUCAUGCCCGUGUUGGGUGCCCUGUUCAUCGGUG UGGCUGUGGCCCCAGCUAACGACAUCUACAACGAGCGCGAGCUGCUGAACAGCAUGGGCA UCAGCCAGCCCACCGUCGUAUUCGUGAGCAAGAAAGGGCUGCAAAAGAUCCUCAACGUGC AAAAGAAGCUACCGAUCAUACAAAAGAUCAUCAUCAUGGAUAGCAAGACCGACUACCAG Page920f121 RECTIFIED SHEET (RULE 91) ISAIEP GGCUUCCAAAGCAUGUACACCUUCGUGACUUCCCAUUUGCCACCCGGCUUCAACGAGUAC GACUUCGUGCCCGAGAGCUUCGACCGGGACAAAACCAUCGCCCUGAUCAUGAACAGUAGU GGCAGUACCGGAUUGCCCAAGGGCGUAGCCCUACCGCACCGCACCGCUUGUGUCCGAUUC AGUCAUGCCCGCGACCCCAUCUUCGGCAACCAGAUCAUCCCCGACACCGCUAUCCUCAGC GUGGUGCCAUUUCACCACGGCUUCGGCAUGUUCACCACGCUGGGCUACUUGAUCUGCGGC UUUCGGGUCGUGCUCAUGUACCGCUUCGAGGAGGAGCUAUUCUUGCGCAGCUUGCAAGAC UAUAAGAUUCAAUCUGCCCUGCUGGUGCCCACACUAUUUAGCUUCUUCGCUAAGAGCACU CUCAUCGACAAGUACGACCUAAGCAACUUGCACGAGAUCGCCAGCGGCGGGGCGCCGCUC AGCAAGGAGGUAGGUGAGGCCGUGGCCAAACGCUUCCACCUACCAGGCAUCCGCCAGGGC UACGGCCUGACAGAAACAACCAGCGCCAUUCUGAUCACCCCCGAAGGGGACGACAAGCCU GGCGCAGUAGGCAAGGUGGUGCCCUUCUUCGAGGCUAAGGUGGUGGACUUGGACACCGG UAAGACACUGGGUGUGAACCAGCGCGGCGAGCUGUGCGUCCGUGGCCCCAUGAUCAUGAG CGGCUACGUUAACAACCCCGAGGCUACAAACGCUCUCAUCGACAAGGACGGCUGGCUGCA CAGCGGCGACAUCGCCUACUGGGACGAGGACGAGCACUUCUUCAUCGUGGACCGGCUGAA GAGCCUGAUCAAAUACAAGGGCUACCAGGUAGCCCCAGCCGAACUGGAGAGCAUCCUGCU GCAACACCCCAACAUCUUCGACGCCGGGGUCGCCGGCCUGCCCGACGACGAUGCCGGCGA GCUGCCCGCCGCAGUCGUCGUGCUGGAACACGGUAAAACCAUGACCGAGAAGGAGAUCGU GGACUAUGUGGCCAGCCAGGUUACAACCGCCAAGAAGCUGCGCGGUGGUGUUGUGUUCG UGGACGAGGUGCCUAAAGGACUGACCGGCAAGUUGGACGCCCGCAAGAUCCGCGAGAUUC UCAUUAAGGCCAAGAAGGGCGGCAAGAUCGCCGUGUA(SBQHDNOfl) SEQ ID NO: 8 UU (SEQ ID NO:8) SEQ ID NO: 9 AUGCAGAGAAGCCCCCUGGAAAAGGCCAGCGUGGUGUCCAAGCUGUUCUUCAGCUGGACC AGACCCAUCCUGAGAAAGGGCUACAGACAGAGACUGGAACUGAGCGACAUCUACCAGAUC GUGGACAGCGCCGACAACCUGAGCGAGAAGCUGGAAAGAGAGUGGGACAGAGA GCUGGCUAGCAAGAAGAACCCCAAGCUGAUCAACGCCCUGAGGCGGUGCUUCUUCUGGCG GUUUAUGUUCUACGGCAUCUUCCUGUACCUGGGCGAAGUGACAAAGGCCGUGCAGCCCCU GCUCCUGGGCAGAAUCAUUGCCAGCUACGACCCCGACAACAAAGAGGAAAGAUCUAUCGC CAUCUACCUGGGCAUCGGCCUGUGCCUGCUGUUCAUCGUGCGGACACUGCUGCUGCACCC CGCCAUCUUCGGCCUGCACCACAUCGGCAUGCAGAUGAGAAUCGCCAUGUUCAGCCUGAU GAAAACCCUGAAGCUGAGCAGCAGGGUGCUGGACAAGAUCAGCAUCGGACAGCU CCUGCUGAGCAACAACCUGAACAAGUUCGACGAGGGACUGGCCCUGGCUCACUU CGUGUGGAUCGCUCCACUGCAGGUCGCCCUGCUGAUGGGCCUGAUCUGGGAGCUGCUGCA GGCCAGCGCUUUCUGCGGCCUGGGCUUUCUGAUUGUGCUGGCCCUGUUUCAGGCUGGCCU GGGCAGGAUGAUGAUGAAGUACAGGGACCAGAGAGCCGGCAAGAUCAGCGAGAGACUGG UCAUCACCAGCGAGAUGAUCGAGAACAUCCAGAGCGUGAAGGCCUACUGCUGGGAAGAG GCCAUGGAAAAGAUGAUCGAAAACCUGAGACAGACCGAGCUGAAGCUGACCAGAAAGGC CGCCUACGUGCGGUACUUCAACAGCAGCGCCUUCUUCUUCUCCGGCUUCUUCGUGGUGUU CCUGUCCGUGCUGCCCUACGCCCUGAUCAAGGGCAUCAUCCUGAGGAAGAUCUUCACCAC Page 93 of 121 RECTIFIED SHEET (RULE 91) ISAIEP CAUUUCUUUCUGCAUCGUGCUGAGAAUGGCCGUGACCAGACAGUUCCCCUGGGCCGUGCA GACUUGGUACGACAGCCUGGGCGCCAUCAACAAGAUCCAGGACUUCCUGCAGAAGCAGGA GUACAAGACCCUCGAGUACAACCUGACCACCACCGAGGUGGUCAUGGAAAACGUGACCGC GGAGGAAGGCUUCGGCGAGCUGUUCGAGAAGGCCAAGCAGAACAACAACAACA GAAAGACCAGCAACGGCGACGACUCCCUGUUCUUCUCCAACUUCUCCCUGCUGGGCACCC CCGUGCUGAAGGACAUCAACUUCAAGAUCGAGAGAGGCCAGCUGCUCGCCGUGGCCGGCU GCGCUGGCAAGACCUCUCUGCUGAUGGUCAUCAUGGGCGAGCUGGAACCCAGCG AGGGCAAGAUCAAGCACAGCGGCAGAAUCAGCUUCUGCAGCCAGUUCAGCUGGAUCAUGC CCGGCACCAUCAAAGAGAACAUCAUCUUCGGCGUGUCCUACGACGAGUACAGAUACAGAA GCGUGAUCAAGGCCUGCCAGCUGGAAGAGGACAUCAGCAAGUUCGCCGAGAAGGACAACA UCGUGCUGGGCGAGGGCGGCAUCACCCUGUCUGGCGGCCAGAGAGCCAGAAUCAGCCUGG CCAGAGCCGUGUACAAGGACGCCGACCUGUACCUGCUGGACAGCCCCUUCGGCUACCUGG ACGUGCUGACCGAGAAAGAGAUCUUCGAGAGCUGCGUGUGCAAGCUGAUGGCCAACAAG ACCAGAAUCCUGGUCACCAGCAAGAUGGAACACCUGAAGAAGGCCGACAAGAUCCUGAUC CUGCACGAGGGCAGCAGCUACUUCUACGGCACAUUCAGCGAGCUGCAGAACCUGCAGCCC GACUUCAGCAGCAAACUGAUGGGCUGCGACAGCUUCGACCAGUUCAGCGCCGAGAGAAGA AUCCUGACCGAGACACUGCACAGAUUCAGCCUGGAAGGCGACGCCCCCGUGUCU UGGACCGAGACAAAGAAGCAGAGCUUCAAGCAGACCGGCGAGUUCGGCGAGAAGAGAAA GAACUCCAUCCUGAACCCCAUCAACAGCAUCCGGAAGUUCAGCAUCGUGCAGAAAACCCC CCUGCAGAUGAACGGCAUCGAAGAGGACAGCGACGAGCCCCUGGAAAGACGGCUGAGCCU GGUGCCUGACAGCGAGCAGGGCGAGGCCAUCCUGCCUAGAAUCAGCGUGAUCAGCACCGG CCCCACCCUGCAGGCUAGAAGGCGGCAGAGCGUGCUGAACCUGAUGACCCACAGCGUGAA CCAGGGCCAGAACAUCCACCGCAAGACCACCGCCAGCACCAGAAAGGUGUCCCUGGCUCC UCAGGCCAACCUGACCGAGCUGGACAUCUACAGCAGAAGGCUGAGCCAGGAAACCGGCCU GGAAAUCAGCGAGGAAAUCAACGAAGAGGACCUGAAAGAGUGCUUCUUCGACGACAUGG AAUCCAUCCCCGCCGUGACCACCUGGAACACCUACCUGCGGUACAUCACCGUGCACAAGA GCCUGAUCUUCGUGCUGAUCUGGUGCCUGGUCAUCUUCCUGGCCGAGGUGGCCGCCAGCC UGGUGGUGCUGUGGCUCCUGGGAAACACCCCUCUGCAGGACAAGGGCAACAGCACCCACA GCAGAAACAACAGCUACGCCGUGAUCAUCACCUCCACCAGCUCCUACUACGUGUUCUACA UCUACGUGGGCGUGGCCGACACCCUGCUGGCUAUGGGCUUCUUCAGAGGCCUGCCCCUGG UGCACACCCUGAUCACCGUGUCCAAGAUCCUGCACCAUAAGAUGCUGCACAGCGUGCUGC AGGCUCCCAUGAGCACCCUGAACACACUGAAGGCUGGCGGCAUCCUGAACAGGUUCAGCA AGGAUAUCGCCAUCCUGGACGACCUGCUGCCUCUGACCAUCUUCGACUUCAUCCAGCUGC UGCUGAUCGUGAUCGGCGCUAUCGCCGUGGUGGCCGUGCUGCAGCCCUACAUCUUCGUGG CCACCGUGCCCGUGAUCGUGGCCUUCAUUAUGCUGAGAGCCUACUUUCUGCAGACCAGCC UGAAGCAGCUGGAAAGCGAGGGCAGAAGCCCCAUCUUCACCCACCUCGUGACCA GCCUGAAGGGCCUGUGGACCCUGAGAGCCUUCGGCAGACAGCCCUACUUCGAGACACUGU UCCACAAGGCCCUGAACCUGCACACCGCCAACUGGUUUCUGUACCUGUCCACCCUGAGAU GGUUCCAGAUGAGGAUCGAGAUGAUCUUCGUCAUCUUCUUUAUCGCCGUGACCUUCAUCU CUAUCCUGACCACCGGCGAGGGCGAGGGAAGAGUGGGAAUCAUCCUGACCCUGGCCAUGA ACAUCAUGAGCACACUGCAGUGGGCCGUGAACAGCAGCAUCGACGUGGACAGCCUGAUGA GAAGCGUGUCCAGAGUGUUCAAGUUCAUCGACAUGCCUACCGAGGGCAAGCCCACCAAGA GCACCAAGCCCUACAAGAACGGCCAGCUGAGCAAAGUGAUGAUCAUCGAGAACAGCCACG UCAAGAAGGACGACAUCUGGCCCAGCGGCGGACAGAUGACCGUGAAGGACCUGACCGCCA AGUACACAGAGGGCGGCAACGCUAUCCUGGAAAACAUCAGCUUCAGCAUCAGCCCAGGCC Page 94 of 121 RECTIFIED SHEET (RULE 91) ISAIEP AGAGAGUGGGCCUGCUGGGGAGAACAGGCAGCGGCAAGUCUACCCUGCUGUCCGCCUUCC UGAGACUGCUGAACACCGAGGGCGAGAUCCAGAUCGAUGGCGUGUCCUGGGACUCCAUCA CCCUGCAGCAGUGGCGCAAGGCCUUCGGCGUGAUCCCCCAGAAGGUGUUCAUCUUCAGCG GCACCUUCAGAAAGAACCUGGACCCCUACGAGCAGUGGUCCGACCAGGAAAUCUGGAAGG UCGCCGAUGAAGUGGGCCUGAGAUCCGUGAUCGAGCAGUUCCCCGGCAAGCUGGACUUCG UGCUGGUGGACGGCGGCUGCGUGCUGAGCCACGGCCACAAGCAGCUGAUGUGUCUGGCCC GCUCCGUGCUGAGCAAGGCUAAGAUUCUGCUGCUGGACGAGCCUAGCGCCCACCUGGACC CUGUGACCUACCAGAUCAUCAGAAGGACCCUGAAGCAGGCCUUCGCCGACUGCACCGUGA UCCUGUGCGAGCACAGAAUCGAGGCCAUGCUGGAAUGCCAGCAGUUCCUGGUCAUCGAAG AGAACAAAGUGCGGCAGUACGACAGCAUCCAGAAGCUGCUGAACGAGAGAAGCCUGUUC GCCAUCAGCCCCAGCGACAGAGUGAAGCUGUUCCCCCACCGCAACAGCAGCAAG UGCAAGAGCAAGCCCCAGAUCGCCGCCCUGAAAGAAGAGACUGAGGAAGAGGUGCAGGAC ACCAGACUGUGA($flQfl)NOfl) SEQIDNO:10 AUGCAGCGGUCCCCGCUCGAAAAGGCCAGUGUCGUGUCCAAACUCUUCUUCUCAUGGACU CGGCCUAUCCUUAGAAAGGGGUAUCGGCAGAGGCUUGAGUUGUCUGACAUCUACCAGAU CCCCUCGGUAGAUUCGGCGGAUAACCUCUCGGAGAAGCUCGAACGGGAAUGGGACCGCGA ACUCGCGUCUAAGAAAAACCCGAAGCUCAUCAACGCACUGAGAAGGUGCUUCUUCUGGCG GUUCAUGUUCUACGGUAUCUUCUUGUAUCUCGGGGAGGUCACAAAAGCAGUCCAACCCCU GUUGUUGGGUCGCAUUAUCGCCUCGUACGACCCCGAUAACAAAGAAGAACGGAGCAUCGC GAUCUACCUCGGGAUCGGACUGUGUUUGCUUUUCAUCGUCAGAACACUUUUGUUGCAUCC AGCAAUCUUCGGCCUCCAUCACAUCGGUAUGCAGAUGCGAAUCGCUAUGUUUAGCUUGAU CUACAAAAAGACACUGAAACUCUCGUCGCGGGUGUUGGAUAAGAUUUCCAUCGGUCAGU UGGUGUCCCUGCUUAGUAAUAACCUCAACAAAUUCGAUGAGGGACUGGCGCUGGCACAU UUCGUGUGGAUUGCCCCGCUGCAAGUCGCACUGCUUAUGGGACUGAUUUGGGAACUGUU GCAGGCCAGCGCCUUUUGCGGCCUGGGAUUUCUCAUUGUGCUUGCACUUUUCCAAGCAGG GCUCGGCAGAAUGAUGAUGAAGUACAGGGACCAGAGAGCCGGAAAGAUCUCAGAACGGC UUACUUCAGAAAUGAUCGAGAACAUUCAAUCGGUGAAAGCGUACUGCUGGGAA GAGGCGAUGGAAAAGAUGAUCGAAAACCUCAGACAGACCGAGUUGAAGCUGACCCGGAA GGCCGCGUACGUCAGAUACUUCAACAGCAGCGCUUUCUUCUUCUCGGGCUUCUUCGUCGU GUUCCUGUCGGUGCUGCCGUAUGCCCUCAUUAAGGGAAUUAUCUUGCGGAAGAUCUUUA CUACUAUCUCAUUUUGCAUCGUCCUUCGGAUGGCGGUCACUCGGCAGUUCCCGUGGGCCG UGCAGACCUGGUACGACAGCCUCGGGGCCAUCAACAAGAUCCAAGACUUUCUCCAAAAGC ACAAAACCCUCGAAUACAACCUCACCACUACUGAAGUGGUCAUGGAAAACGUGA CCGCCUUUUGGGAAGAAGGCUUCGGAGAACUGUUCGAGAAGGCGAAGCAAAACAACAAU AAUCGCAAGACUAGCAACGGGGAUGACUCACUGUUCUUCAGCAAUUUCUCACUGCUCGGC ACCCCGGUGCUUAAGGACAUCAACUUCAAGAUUGAACGCGGACAGCUCUUGGCGGUGGCC GGAUCCACCGGAGCAGGAAAGACUAGCCUGCUGAUGGUGAUCAUGGGUGAGCUGGAACC GUCCGAAGGCAAAAUCAAGCACUCCGGCAGAAUCAGCUUCUGCUCGCAGUUUUCGUGGAU CAUGCCAGGAACCAUCAAAGAGAACAUCAUCUUUGGAGUCUCAUACGAUGAGUACCGCUA CGUGAUUAAGGCCUGCCAGCUUGAAGAGGACAUCUCCAAGUUCGCGGAAAAGG ACAACAUCGUGCUGGGUGAGGGAGGGAUCACGUUGUCGGGCGGUCAGAGAGCCCGCAUU UCGCUGGCACGGGCUGUGUACAAGGAUGCGGAUCUUUACCUUCUGGACUCGCCAUUCGGU Page 95 of 121 RECTIFIED SHEET (RULE 91) ISAIEP UACCUCGACGUGCUGACCGAAAAAGAAAUCUUCGAGAGCUGCGUGUGUAAGCUGAUGGC UAAUAAGACUAGAAUCCUCGUGACGUCCAAAAUGGAACAUCUUAAGAAGGCGGAUAAGA UUCUCAUUCUUCACGAGGGGUCGAGCUACUUCUACGGGACUUUUAGCGAGCUGCAGAAU UUGCAGCCGGACUUCAGCUCAAAGCUCAUGGGCUGCGACUCGUUCGAUCAGUUCAGCGCC GAACGGCGCAAUUCGAUCUUGACGGAAACCCUGCACAGAUUCUCGCUGGAGGGAGAUGCA CCUGUCUCGUGGACCGAAACCAAGAAGCAGUCCUUCAAGCAGACGGGAGAGUUCGGAGAA AAGCGGAAGAACUCAAUCCUCAACCCAAUCAACUCCAUUCGCAAAUUCUCAAUCGUGCAG AAAACUCCACUGCAGAUGAACGGUAUCGAAGAGGAUUCGGACGAGCCACUUGAGCGGAG ACUGUCGCUGGUGCCAGAUUCAGAACAGGGGGAGGCAAUCCUGCCGCGCAUUUCCGUGAU CAGCACUGGGCCGACCCUCCAAGCUAGACGCAGGCAAUCAGUGCUGAAUCUCAUGACCCA CUCCGUCAACCAGGGACAGAAUAUCCACCGCAAGACCACCGCGUCGACUAGAAAGGUGUC AUUGGCACCGCAAGCAAAUUUGACUGAACUUGACAUCUACUCACGGCGCCUCUCCCAAGA AACCGGAUUGGAAAUCUCCGAAGAGAUUAACGAAGAAGAUUUGAAAGAGUGUUUCUUCG ACGAUAUGGAGUCGAUCCCCGCAGUGACCACUUGGAAUACGUAUCUUCGGUACAUCACCG UGCACAAGAGCCUGAUCUUCGUCCUCAUCUGGUGCCUGGUGAUCUUUCUGGCCGAAGUCG CCGCUUCGCUGGUCGUGCUGUGGCUGCUCGGUAAUACCCCGCUCCAAGACAAAGGCAAUU CCACUCACUCGCGCAACAACAGCUACGCUGUGAUUAUCACGUCAACCUCGUCGUACUAUG UGUUCUACAUCUACGUGGGAGUCGCGGACACUCUGCUCGCUAUGGGCUUCUUUCGCGGAC UGCCCCUGGUCCACACUCUCAUCACGGUGAGCAAGAUCCUCCAUCAUAAGAUGCUCCAUU CCGUGCUGCAGGCCCCGAUGAGCACUCUCAACACUCUGAAGGCGGGUGGAAUCUUGAACA GAUUUUCCAAAGACAUCGCGAUUCUGGACGAUCUGCUCCCACUCACUAUCUUCGACUUCA UGCUGCUGAUCGUCAUCGGAGCUAUCGCCGUGGUGGCUGUCCUCCAGCCGUAUA UCUUCGUGGCCACUGUGCCGGUGAUUGUCGCUUUCAUCAUGUUGCGCGCGUACUUCUUGC AAACCUCGCAGCAACUCAAGCAACUGGAGUCCGAGGGCCGGAGCCCAAUCUUUACCCAUC UGGUGACUUCACUGAAAGGUCUGUGGACCCUCCGCGCCUUUGGUCGCCAGCCUUACUUCG AAACUCUCUUUCACAAAGCACUGAAUCUCCACACUGCAAACUGGUUCUUGUACCUGUCCA CCCUGCGGUGGUUCCAAAUGCGGAUCGAGAUGAUCUUUGUCAUCUUCUUCAUCGCCGUGA CUUUUAUCUCCAUCCUCACCACCGGCGAGGGAGAGGGGAGAGUGGGAAUCAUCCUGACGC UGAAUAUCAUGUCCACUUUGCAGUGGGCCGUCAAUUCGAGCAUCGACGUGGAU UCGCUGAUGCGCAGCGUGUCGCGCGUGUUCAAGUUCAUCGAUAUGCCCACCGAAGGUAAA CCCACCAAGAGCACGAAGCCUUACAAGAACGGGCAGCUCUCAAAGGUGAUGAUUAUCGAG AACUCCCAUGUGAAGAAGGACGACAUCUGGCCAUCCGGAGGACAGAUGACCGUGAAGGAC CUGACCGCCAAAUACACGGAGGGCGGAAAUGCAAUCCUCGAAAACAUCUCGUUCUCCAUC UCGCCUGGCCAAAGGGUGGGACUUUUGGGACGCACUGGAUCCGGAAAGAGCACCCUGCUU AGCGCCUUCUUGAGGCUCUUGAACACCGAGGGCGAAAUCCAGAUCGAUGGCGUGUCGUGG GAUUCGAUCACCCUGCAGCAGUGGAGAAAGGCCUUCGGGGUGAUCCCGCAAAAAGUGUUC AUCUUCUCCGGAACGUUUCGGAAAAACCUUGACCCAUACGAACAAUGGUCGGAUCAAGAG AUUUGGAAGGUCGCCGACGAAGUGGGGCUGCGCUCCGUGAUCGAGCAGUUUCCGGGAAA ACUGGACUUCGUCUUGGUCGACGGCGGAUGCGUCCUGUCCCACGGACAUAAGCAGCUGAU GUGCCUGGCCCGCAGCGUCCUUUCAAAAGCUAAGAUCCUGCUGCUGGAUGAACCUUCAGC CGACCCGGUCACCUACCAGAUCAUCAGACGGACCCUGAAACAGGCCUUUGCGGA UUGUACUGUGAUCUUGUGUGAACACCGCAUUGAAGCCAUGCUGGAGUGCCAGCAGUUCC UCGAAGAGAACAAAGUGCGGCAGUACGAUUCCAUCCAAAAACUGCUCAAUGAG CGGUCCCUGUUCAGACAGGCAAUUAGCCCGAGCGACAGGGUCAAAUUGUUCCCCCAUAGA Page 96 of 121 RECTIFIED SHEET (RULE 91) ISAIEP AAUUCGUCGAAAUGUAAGUCAAAGCCUCAGAUCGCGGCACUGAAAGAAGAAACUGAAGA AGAGGUGCAAGACACCAGACUGUGA(SHQHDNOAO) SEQ ID NO:11 AGAAGCCCACUGGAAAAGGCGUCGGUGGUGUCAAAGCUGUUCUUUAGCUGGAC UAUCUUGCGGAAGGGAUACCGCCAACGCCUGGAGCUGUCGGACAUCUACCAGAU UCCGUCAGUGGAUUCAGCAGACAAUCUCUCCGAAAAGCUGGAACGCGAAUGGGACAGAG AGUUGGCGUCAAAGAAGAACCCAAAGUUGAUCAAUGCCCUGCGCCGCUGCUUCUUCUGGC GGUUCAUGUUCUACGGAAUCUUUCUGUACCUCGGCGAAGUCACCAAGGCUGUGCAACCGC UUCUGCUGGGACGCAUCAUCGCCUCAUACGACCCGGACAACAAGGAAGAACGCUCCAUCG CAAUCUACCUCGGGAUCGGCCUCUGCCUGCUGUUUAUCGUGCGGACGCUGCUGCUCCAUC CAGCCAUUUUCGGACUGCACCACAUUGGCAUGCAAAUGCGGAUCGCCAUGUUCAGCCUGA UCUACAAAAAGACCCUGAAGUUGAGCUCACGGGUGUUGGAUAAGAUUUCGAUCGGACAG CUGGUGUCGCUGCUCUCCAACAACCUCAACAAGUUUGACGAAGGCCUGGCACUGGCCCAC UUCGUGUGGAUUGCCCCGUUGCAAGUCGCCCUUUUGAUGGGCCUUAUUUGGGAGCUGUU GCAGGCAUCUGCCUUUUGUGGCCUGGGAUUUCUGAUUGUGUUGGCAUUGUUUCAGGCUG GGCUUGGGCGGAUGAUGAUGAAGUAUCGCGACCAGAGAGCGGGUAAAAUCUCGGAAAGA CUCGUCAUCACUUCGGAAAUGAUCGAAAACAUCCAGUCGGUCAAAGCCUAUUGCUGGGAA GAAGCUAUGGAGAAGAUGAUUGAAAACCUCCGCCAAACUGAGCUGAAACUGACCCGCAA GGCGGCGUAUGUCCGGUAUUUCAAUUCGUCAGCGUUCUUCUUUUCCGGGUUCUUCGUUG UCUUUCUCUCGGUUUUGCCUUAUGCCUUGAUUAAGGGGAUUAUCCUCCGCAAGAUUUUC ACCACGAUUUCGUUCUGCAUUGUAUUGCGCAUGGCAGUGACACGGCAAUUUCCGUGGGCC GUGCAGACAUGGUAUGACUCGCUUGGAGCGAUCAACAAAAUCCAAGACUUCUUGCAAAA GCAAGAGUACAAGACCCUGGAGUACAAUCUUACUACUACGGAGGUAGUAAUGGAGAAUG UGACGGCUUUUUGGGAGGAAGGAUUCGGCGAAUUGUUCGAAAAGGCUAAGCAGAACAAC CGGAAAACCUCCAAUGGGGACGAUUCGCUGUUCUUCUCGAAUUUCUCCCUGCUG GGAACGCCCGUGCUUAAAGACAUCAACUUCAAGAUCGAACGGGGCCAGCUGCUCGCGGUC GCGGGCAGCACUGGAGCGGGAAAGACUUCCCUGCUCAUGGUCAUCAUGGGAGAGCUGGA GCCCUCGGAGGGCAAAAUCAAGCACUCGGGGAGGAUCUCAUUUUGCAGCCAGUUCUCGUG GAUCAUGCCCGGUACUAUCAAAGAAAACAUCAUCUUUGGAGUCAGCUAUGACGAGUACC GCUACCGGUCGGUGAUCAAGGCCUGCCAGCUGGAAGAAGAUAUCUCCAAGUUCGCCGAAA AGGACAACAUUGUGCUGGGAGAAGGUGGAAUCACUCUCUCGGGAGGCCAGCGCGCACGG AUCUCACUCGCAAGGGCCGUGUACAAGGAUGCCGAUUUGUACCUGUUGGAUUCGCCGUUC GGUUAUCUUGAUGUCCUCACUGAGAAAGAGAUUUUUGAGUCGUGCGUCUGUAAGCUGAU GGCCAACAAAACCCGCAUCCUGGUGACCUCGAAGAUGGAGCACUUGAAGAAGGCCGACAA AAUCCUUAUCCUCCAUGAGGGUAGCUCAUACUUCUACGGCACCUUUUCGGAACUGCAGAA UCUGCAGCCCGACUUCUCAUCAAAACUGAUGGGAUGUGACUCGUUCGAUCAGUUCUCGGC GGAGCGGCGGAACUCGAUCCUCACCGAAACUCUCCACCGGUUCAGCCUCGAGGGAGAUGC CCCAGUCAGCUGGACCGAAACUAAGAAGCAGUCCUUCAAACAGACCGGAGAGUUCGGAGA AAAACGCAAGAACUCCAUCCUCAAUCCAAUCAACAGCAUCCGCAAGUUCAGCAUCGUGCA GAAAACUCCACUUCAGAUGAACGGAAUCGAAGAGGAUAGCGACGAGCCGCUUGAGCGGA GAUUGUCACUGGUGCCGGACAGCGAGCAAGGGGAAGCGAUUCUGCCGCGGAUCUCCGUGA UCUCGACUGGCCCUACCCUCCAAGCUCGCAGACGCCAGAGCGUGCUGAAUCUCAUGACCC UCAACCAGGGACAAAACAUCCAUAGAAAGACCACCGCUUCAACCCGGAAAGUGU Page 97 of 121 RECTIFIED SHEET (RULE 91) ISAIEP CACUUGCACCGCAGGCAAACCUGACCGAACUCGACAUCUACAGCAGACGGCUCUCACAAG AAACUGGAUUGGAGAUCAGCGAAGAGAUCAACGAAGAAGAUCUCAAAGAAUGCUUCUUC GACGAUAUGGAGUCCAUCCCAGCAGUCACUACGUGGAAUACCUACCUCCGCUACAUCACU GUGCACAAGAGCCUGAUUUUCGUGUUGAUCUGGUGCCUGGUCAUCUUCUUGGCCGAGGU GGCCGCGAGCCUCGUGGUCCUCUGGCUGCUCGGCAAUACGCCGCUGCAAGAUAAGGGAAA UUCCACGCAUAGCAGAAACAACUCAUACGCAGUGAUCAUCACUAGCACUUCAUCGUACUA CGUGUUCUACAUCUACGUGGGGGUGGCCGAUACUCUGUUGGCAAUGGGAUUCUUUAGAG GGCUGCCUCUGGUGCAUACUCUGAUCACUGUGUCCAAGAUCCUCCACCACAAGAUGCUCC ACUCCGUGCUUCAGGCCCCUAUGUCAACUCUCAACACCCUCAAGGCCGGAGGUAUUCUUA AUCGCUUUUCCAAGGACAUCGCCAUUCUCGAUGACUUGCUUCCCCUGACUAUCUUCGACU UUAUCCAGUUGCUGCUGAUUGUGAUCGGCGCUAUUGCCGUCGUCGCAGUGCUGCAACCGU ACAUCUUUGUGGCUACCGUCCCAGUCAUUGUGGCCUUCAUCAUGCUCAGGGCAUACUUUC UCCAGACCAGCCAGCAGCUCAAGCAGCUCGAAUCCGAAGGCAGAUCGCCGAUCUUCACCC ACCUCGUCACUUCGCUCAAGGGCCUCUGGACCCUGCGCGCCUUCGGUCGCCAGCCGUAUU CCCUGUUCCAUAAAGCACUGAACCUCCAUACUGCGAACUGGUUUCUCUACCUUU CAACCCUGAGGUGGUUCCAGAUGAGAAUCGAGAUGAUCUUUGUGAUCUUCUUUAUCGCU GUGACGUUCAUCUCCAUUCUCACUACCGGCGAGGGAGAGGGCAGAGUGGGGAUUAUCCUC ACGCUGGCCAUGAAUAUCAUGAGCACGCUGCAGUGGGCCGUCAAUAGCAGCAUCGACGUG GACUCCCUGAUGCGGUCCGUGUCGAGAGUGUUUAAGUUCAUCGAUAUGCCUACUGAAGG GAAACCGACCAAGUCGACCAAGCCGUACAAGAAUGGGCAGCUGAGCAAGGUGAUGAUUA UUGAGAACUCCCAUGUGAAGAAGGACGACAUCUGGCCCAGCGGAGGCCAGAUGACCGUGA UGACCGCUAAGUACACUGAGGGUGGAAAUGCCAUUCUUGAGAAUAUCAGCUUC UCGAUCUCGCCGGGACAACGCGUGGGAUUGCUCGGGCGCACUGGCAGCGGCAAAUCCACC CUGCUUAGCGCUUUUCUGAGGCUGCUGAACACUGAAGGUGAAAUUCAAAUCGAUGGAGU GUCGUGGGAUAGCAUCACCCUUCAACAGUGGCGCAAGGCCUUCGGCGUGAUCCCUCAAAA GGUCUUUAUCUUCUCGGGGACGUUCCGGAAAAAUCUCGACCCCUACGAACAGUGGUCAGA CCAAGAGAUUUGGAAAGUCGCAGAUGAGGUCGGACUGCGCUCAGUGAUCGAACAGUUUC CGGGUAAACUUGACUUCGUGCUCGUCGAUGGAGGUUGCGUCCUGUCCCACGGACAUAAGC AGCUGAUGUGUCUGGCGCGCUCGGUCCUCUCCAAAGCGAAGAUCCUGCUGCUCGAUGAAC CGUCCGCCCACCUUGAUCCAGUGACCUAUCAGAUCAUUCGGAGAACUUUGAAGCAAGCCU UCGCUGACUGCACCGUCAUCCUCUGCGAACACCGGAUCGAGGCAAUGCUGGAGUGCCAAC UGGUCAUCGAAGAAAACAAAGUGCGCCAGUAUGACUCGAUCCAAAAACUUCUG AACGAGCGCUCCCUCUUCCGGCAGGCAAUCAGCCCAUCCGACCGCGUGAAGUUGUUCCCU CAUCGGAAUAGCUCCAAAUGCAAAUCGAAGCCGCAGAUCGCUGCCUUGAAAGAAGAAACC GAAGAAGAAGUCCAAGACACUAGGUUGUAGfSEQUDNOfll) SEQ ID NO:12 AUGCAGCGGUCCCCUCUGGAGAAGGCUUCCGUGGUCAGCAAGCUGUUCUUCUCGUGGACC AGACCUAUCCUCCGCAAGGGAUACCGCCAGCGCCUGGAGCUGUCAGAUAUCUACCAGAUC CCAAGCGUGGACUCAGCCGACAAUCUGAGCGAAAAGCUGGAACGGGAGUGGGACCGGGA GCUCGCCUCCAAGAAGAAUCCGAAGUUGAUCAAUGCGCUGCGCAGAUGCUUCUUCUGGCG GUUUAUGUUUUACGGCAUCUUUCUGUAUCUCGGAGAAGUGACCAAAGCCGUGCAGCCGC UGCUCUUGGGUAGGAUCAUUGCUUCGUACGACCCGGACAACAAAGAAGAACGCUCCAUCG ACCUCGGAAUCGGUCUGUGCCUGCUCUUUAUCGUGCGCACUCUCCUGCUGCAUC Page 98 of 121 RECTIFIED SHEET (RULE 91) ISAIEP CGGCGAUCUUCGGACUGCACCACAUCGGCAUGCAAAUGCGGAUCGCAAUGUUCUCACUGA UCUACAAAAAGACUCUGAAGCUCAGCUCCAGAGUGCUGGAUAAGAUCUCGAUCGGGCAAC UCGUCAGCCUGCUGUCGAACAAUCUGAAUAAGUUCGACGAAGGGUUGGCCCUCGCACAUU UCGUGUGGAUCGCACCGCUGCAAGUGGCGCUCCUGAUGGGACUCAUUUGGGAACUGCUCC AAGCCAGCGCGUUUUGCGGACUCGGAUUCCUGAUCGUGCUCGCCCUGUUCCAAGCCGGAC UGGGGCGCAUGAUGAUGAAGUACCGCGAUCAGCGGGCAGGAAAGAUCUCCGAGCGGUUG GUGAUCACUUCCGAAAUGAUCGAGAAUAUUCAGUCCGUGAAGGCCUACUGCUGGGAAGA AGCUAUGGAAAAGAUGAUUGAAAACUUGCGGCAAACUGAGCUGAAAUUGACUCGCAAAG CGGCAUACGUCCGCUACUUCAAUAGCAGCGCCUUCUUCUUUUCGGGCUUUUUCGUGGUGU UUCUGAGCGUGCUGCCCUACGCUCUGAUCAAGGGAAUCAUCCUCCGGAAAAUCUUCACCA CCAUUUCGUUCUGUAUCGUGUUGCGCAUGGCCGUGACUCGCCAGUUCCCCUGGGCGGUGC AGACCUGGUACGACAGCUUGGGGGCAAUCAAUAAGAUUCAAGACUUCUUGCAAAAGCAG AAGACUCUGGAGUACAACCUGACCACCACUGAAGUCGUGAUGGAGAACGUGACC GCCUUUUGGGAAGAGGGUUUUGGAGAACUGUUUGAGAAAGCAAAGCAGAAUAACAACAA CCGCAAGACCUCAAAUGGGGACGAUUCCCUGUUUUUCUCGAACUUCUCCCUGCUCGGAAC ACCCGUGUUGAAGGACAUCAAUUUCAAGAUUGAGAGGGGACAGCUUCUCGCGGUAGCGG CUGGUGCGGGAAAAACUAGCCUCUUGAUGGUGAUUAUGGGGGAGCUUGAGCCC AGCGAGGGGAAGAUUAAACACUCCGGGCGUAUCUCAUUCUGUAGCCAGUUUUCAUGGAU CAUGCCCGGAACCAUUAAAGAGAACAUCAUUUUCGGAGUAUCCUAUGAUGAGUACCGAU ACAGAUCGGUCAUUAAGGCGUGCCAGUUGGAAGAGGACAUUUCUAAGUUCGCCGAGAAG GAUAACAUCGUCUUGGGAGAAGGGGGUAUUACAUUGUCGGGAGGGCAGCGAGCGCGGAU CAGCCUCGCGAGAGCGGUAUACAAAGAUGCAGAUUUGUAUCUGCUUGAUUCACCGUUUG GAUACCUCGACGUAUUGACAGAAAAAGAAAUCUUCGAGUCGUGCGUGUGUAAACUUAUG GCUAAUAAGACGAGAAUCCUGGUGACUUCCAAAAUGGAGCAUCUCAAGAAGGCGGACAA GAUCCUGAUUCUGCAUGAGGGAUCAAGCUAUUUCUACGGAACUUUUUCCGAGCUGCAGA ACCUCCAGCCGGAUUUUAGCUCCAAGCUGAUGGGUUGCGACUCAUUCGACCAAUUCUCGG CUGAGCGGCGGAACUCAAUCCUGACCGAAACCCUGCAUCGCUUCUCCCUUGAGGGAGAUG J UGUCGUGGACUGAGACUAAAAAGCAGUCGUUUAAGCAAACUGGCGAAUUCGGC GAAAAGCGGAAGAAUAGCAUCCUCAACCCAAUCAACAGCAUUCGGAAGUUCAGCAUCGUC CAAAAGACCCCGCUCCAGAUGAACGGCAUUGAAGAGGACUCAGACGAGCCAUUGGAAAGA CGCCUGUCACUGGUCCCAGAUUCGGAGCAGGGUGAAGCAAUUCUGCCUCGGAUCUCGGUC AUCUCGACUGGCCCCACUCUCCAAGCUCGGCGGAGACAGAGCGUGCUUAACUUGAUGACC GUGAACCAGGGUCAGAACAUCCACCGCAAAACCACCGCCUCCACCAGGAAGGUG UCACUGGCCCCUCAAGCCAAUCUGACUGAGUUGGAUAUCUACUCCAGAAGGCUCAGCCAG GAAACCGGACUGGAAAUCUCGGAAGAGAUCAACGAAGAGGAUCUCAAAGAGUGUUUCUU CGACGACAUGGAAUCAAUCCCUGCUGUCACUACUUGGAACACCUAUCUCCGCUACAUUAC CGUGCACAAGUCACUCAUCUUCGUCCUGAUCUGGUGCCUCGUGAUCUUCCUGGCCGAGGU CGCAGCAUCGCUGGUCGUGCUGUGGCUGCUCGGCAACACCCCACUCCAAGACAAAGGCAA CAGCACCCAUUCCCGCAACAACUCCUACGCGGUGAUCAUCACUUCAACUUCGUCCUACUA CGUCUUUUACAUCUACGUGGGCGUGGCGGACACGCUCCUGGCUAUGGGGUUCUUUCGCGG GCUGCCUCUUGUCCACACGCUCAUCACUGUGUCAAAGAUUCUCCACCACAAAAUGCUGCA CUCCGUGCUCCAGGCCCCUAUGUCGACUUUGAACACGCUUAAGGCCGGAGGCAUCCUUAA CAGAUUCUCGAAAGAUAUCGCGAUCUUGGACGAUCUUCUGCCGCUGACUAUCUUUGACUU CAUCCAACUCCUGCUGAUCGUCAUCGGUGCCAUCGCAGUGGUCGCGGUGCUCCAACCGUA CAUUUUCGUGGCGACUGUGCCGGUGAUCGUGGCGUUCAUCAUGCUGCGGGCUUACUUUCU Page 99 of 121 RECTIFIED SHEET (RULE 91) ISAIEP UCAGACCUCACAGCAGCUGAAGCAACUCGAAUCGGAGGGUAGAUCACCAAUCUUUACCCA CCUCGUCACCUCGCUGAAGGGACUCUGGACCCUGCGCGCAUUUGGACGGCAACCGUACUU CGAGACUCUCUUCCAUAAGGCCCUGAAUCUGCAUACGGCGAAUUGGUUUCUUUACCUCUC GACGCUCCGCUGGUUCCAGAUGCGCAUUGAGAUGAUUUUCGUCAUCUUUUUCAUCGCGGU GACCUUCAUCUCCAUCCUCACCACGGGUGAGGGAGAGGGCAGAGUCGGAAUUAUCCUCAC UCUGGCCAUGAACAUCAUGUCCACUCUGCAGUGGGCCGUCAACUCAUCCAUUGACGUGGA CUCGCUGAUGCGCUCCGUGUCGAGAGUGUUCAAGUUCAUCGAUAUGCCGACCGAGGGAAA GCCAACUAAGUCGACCAAGCCGUACAAAAACGGACAGCUGAGCAAGGUCAUGAUCAUCGA AAACUCCCACGUGAAAAAGGAUGACAUCUGGCCGUCCGGUGGACAGAUGACGGUGAAGG AUCUGACUGCGAAGUACACUGAGGGAGGGAAUGCCAUCCUCGAAAACAUCUCAUUCUCAA UCUCCCCUGGACAGAGGGUCGGGCUGCUGGGCCGCACUGGCUCGGGGAAGUCGACUCUUC UUUCGGCAUUUCUGCGCUUGCUCAAUACCGAGGGAGAAAUCCAGAUCGAUGGAGUGUCA UGGGACUCGAUCACCCUGCAGCAGUGGCGCAAGGCUUUUGGCGUCAUCCCGCAAAAGGUG UUCAUCUUCUCGGGCACUUUUAGAAAGAAUCUGGAUCCCUACGAACAGUGGUCAGAUCA UUGGAAAGUCGCAGACGAAGUGGGCCUCCGGUCCGUGAUUGAACAGUUUCCGG GAAAGCUCGACUUCGUGCUUGUGGACGGAGGAUGUGUGCUGAGCCACGGCCACAAACAGC UCAUGUGCCUGGCUCGGUCGGUCCUGUCGAAAGCAAAGAUCCUGCUGCUGGACGAACCGU CGGCACACCUCGAUCCAGUGACGUACCAGAUCAUCCGGCGGACCCUGAAGCAGGCCUUCG CAGACUGCACUGUCAUUUUGUGUGAACACAGAAUCGAAGCUAUGUUGGAGUGCCAGCAG UUCCUGGUCAUCGAAGAAAACAAAGUCCGCCAGUACGAUUCGAUUCAGAAGCUGCUGAAC GAACGGAGCCUCUUCAGACAGGCGAUCAGCCCCAGCGAUCGGGUCAAGUUGUUCCCGCAU CGGAACAGCAGCAAGUGUAAGUCAAAGCCUCAGAUCGCUGCACUCAAAGAAGAGACUGA AGAAGAAGUGCAAGACACCAGACUCUGA($32HDNOAE SEQ ID NO: 13 CGCUCGCCUCUGGAGAAAGCCUCAGUCGUGUCAAAACUGUUCUUUAGCUGGACU CGCCCGAUUCUCCGGAAGGGUUAUAGACAGCGCUUGGAGCUCUCCGACAUCUACCAAAUC CCUUCCGUGGACUCCGCCGACAACCUGUCGGAGAAGCUCGAACGCGAGUGGGACCGGGAA CUCGCGUCCAAAAAGAAUCCAAAACUCAUUAAUGCACUGCGCCGCUGCUUCUUCUGGCGC UUUAUGUUUUACGGUAUCUUUCUCUACCUGGGCGAGGUGACGAAAGCAGUGCAGCCGCU UGGCAGAAUUAUCGCCUCGUACGAUCCGGAUAACAAAGAAGAACGCUCAAUCGC UAUCUACCUCGGUAUCGGAUUGUGCCUGCUUUUCAUCGUGCGCACCCUGUUGCUGCACCC GGCGAUUUUCGGACUCCACCACAUCGGAAUGCAAAUGAGAAUUGCAAUGUUCUCAUUGA UCUACAAAAAGACCCUUAAACUGUCGUCCCGCGUCCUCGACAAGAUUUCAAUCGGCCAGC UGGUGUCGCUUCUUUCGAAUAAUCUUAACAAGUUCGAUGAAGGACUCGCGCUCGCCCAUU UCGUGUGGAUCGCACCACUUCAAGUCGCACUGCUCAUGGGACUGAUUUGGGAGUUGCUGC CCGCCUUUUGCGGCCUGGGAUUCCUGAUCGUCCUGGCUUUGUUCCAGGCUGGAC UGGGCAGAAUGAUGAUGAAGUACCGGGACCAGCGGGCAGGAAAGAUCAGCGAAAGGCUC GUGAUCACUAGCGAAAUGAUCGAGAACAUCCAAUCCGUCAAGGCGUACUGCUGGGAAGA AGCGAUGGAGAAGAUGAUCGAAAAUCUUCGCCAGACCGAACUCAAACUCACUAGAAAGG CUGCCUACGUGCGCUACUUUAACAGCUCAGCAUUUUUCUUCUCCGGAUUUUUCGUGGUGU UCCUGUCGGUGCUGCCAUACGCCCUGAUCAAGGGGAUCAUUCUUCGCAAAAUCUUCACCA CGAUCUCAUUCUGCAUUGUCCUCCGGAUGGCCGUGACGCGGCAGUUCCCUUGGGCAGUGC AAACUUGGUACGAUUCGCUGGGGGCCAUUAACAAGAUUCAAGAUUUUCUUCAAAAGCAG Page 100 of121 RECTIFIED SHEET (RULE 91) ISAIEP GAGUACAAAACCCUGGAGUACAAUCUGACCACUACGGAAGUCGUGAUGGAAAACGUGAC UGCUUUUUGGGAGGAAGGCUUCGGCGAACUUUUUGAAAAGGCAAAGCAAAACAAUAACA ACAGAAAGACGUCAAACGGCGAUGACUCGCUGUUCUUCUCCAAUUUCUCCCUGCUCGGCA CCCCUGUGCUGAAGGACAUCAACUUCAAAAUUGAACGCGGACAGCUGCUGGCCGUGGCGG GAUCGACCGGGGCUGGGAAAACCUCGUUGUUGAUGGUGAUCAUGGGAGAACUCGAACCC UCGGAGGGAAAGAUUAAGCAUAGCGGACGGAUCAGCUUCUGUUCCCAGUUCUCGUGGAU CAUGCCGGGAACCAUUAAGGAAAACAUCAUCUUCGGCGUGUCCUACGACGAGUACCGGUA UAGGUCGGUGAUCAAGGCCUGCCAGUUGGAAGAGGACAUCUCCAAGUUCGCUGAGAAGG ACAACAUCGUGCUCGGUGAAGGGGGCAUUACUCUGUCCGGUGGCCAGCGCGCGAGAAUUU CGCUGGCUCGCGCGGUGUACAAAGAUGCGGAUCUCUAUCUGCUGGAUUCGCCCUUCGGAU ACCUCGAUGUCCUCACGGAGAAGGAGAUCUUCGAAUCGUGCGUGUGCAAGUUGAUGGCG AACAAGACUAGGAUCCUGGUCACUUCCAAGAUGGAGCACUUGAAGAAGGCCGAUAAGAU CUUGAUCCUCCAUGAAGGAUCGAGCUACUUUUACGGAACUUUCUCAGAGCUGCAGAACUU GCAGCCGGACUUCUCAAGCAAACUGAUGGGUUGCGACUCGUUCGACCAGUUUUCGGCAGA ACGGCGGAACUCGAUCCUGACUGAGACUCUGCAUCGCUUUUCGCUGGAAGGCGAUGCCCC UGUGUCCUGGACUGAAACCAAGAAGCAAUCCUUCAAACAAACUGGAGAAUUCGGAGAAA AGCGGAAGAACUCCAUCCUUAACCCCAUCAAUAGCAUCCGGAAGUUCUCAAUCGUCCAAA CGCUGCAGAUGAAUGGCAUCGAAGAAGAUAGCGACGAACCUCUUGAAAGACGGC UGUCCUUGGUGCCAGACUCAGAACAGGGAGAAGCUAUCCUGCCGCGGAUCUCCGUGAUCA GCACCGGACCGACUCUGCAGGCUCGCAGACGCCAGAGCGUGCUCAACCUGAUGACCCACU CCGUGAACCAGGGACAAAACAUCCAUAGAAAGACCACGGCCUCCACCAGAAAAGUCUCCC UGGCACCGCAAGCCAACCUGACUGAACUGGACAUCUACAGCAGAAGGCUCAGCCAAGAAA CCGGACUGGAGAUUUCAGAAGAAAUCAACGAGGAAGAUCUUAAAGAGUGCUUCUUCGAC GACAUGGAAUCGAUCCCAGCCGUGACCACUUGGAAUACCUAUCUGAGAUACAUCACCGUG UCCCUGAUCUUCGUGCUGAUCUGGUGCCUGGUGAUCUUCCUGGCUGAGGUGGCC GCCUCACUGGUGGUGCUUUGGUUGCUGGGGAAUACGCCGCUCCAAGACAAGGGAAACUCC ACGCACUCCAGAAACAACUCGUACGCCGUGAUCAUCACGUCGACUUCGUCGUACUACGUG UUCUACAUCUACGUCGGUGUGGCAGACACUCUCUUGGCGAUGGGCUUUUUCCGGGGACUG CCACUGGUCCACACCCUGAUCACCGUGUCCAAAAUCUUGCACCACAAGAUGCUCCACAGC GUGCUGCAAGCCCCGAUGAGCACCCUGAAUACCCUCAAAGCGGGAGGCAUCCUCAACAGA UUCAGCAAGGACAUCGCCAUCCUCGACGACCUGUUGCCCCUGACCAUCUUCGAUUUCAUC CUUCUCAUCGUGAUCGGGGCAAUCGCUGUCGUGGCGGUGCUGCAGCCGUACAUC UUCGUGGCGACUGUGCCAGUGAUCGUCGCCUUUAUCAUGCUGCGGGCCUACUUUCUCCAA ACUUCCCAACAGCUGAAACAACUGGAGUCGGAGGGCCGCAGCCCUAUCUUCACCCAUCUG AGCCUCAAAGGACUGUGGACUCUGAGGGCUUUCGGGAGGCAGCCAUACUUCGAG ACUCUCUUUCACAAGGCCCUGAAUCUCCAUACGGCAAAUUGGUUUUUGUAUUUGAGUACC CUCCGAUGGUUUCAGAUGCGCAUUGAGAUGAUUUUUGUGAUCUUCUUUAUCGCGGUGAC UUUUAUCUCCAUCUUGACCACGGGAGAGGGCGAGGGACGGGUCGGUAUUAUCCUGACAC UCGCCAUGAACAUUAUGAGCACUUUGCAGUGGGCAGUGAACAGCUCGAUUGAUGUGGAU AGCCUGAUGAGGUCCGUUUCGAGGGUCUUUAAGUUCAUCGACAUGCCGACGGAGGGAAA GCCCACAAAAAGUACGAAACCCUAUAAGAAUGGGCAAUUGAGUAAGGUAAUGAUCAUCG AGAACAGUCACGUGAAGAAGGAUGACAUCUGGCCUAGCGGGGGUCAGAUGACCGUGAAG GACCUGACGGCAAAAUACACCGAGGGAGGGAACGCAAUCCUUGAAAACAUCUCGUUCAGC AUUAGCCCCGGUCAGCGUGUGGGGUUGCUCGGGAGGACCGGGUCAGGAAAAUCGACGUU GCUGUCGGCCUUCUUGAGACUUCUGAAUACAGAGGGUGAGAUCCAGAUCGACGGCGUUU Page 101 of 121 RECTIFIED SHEET (RULE 91) ISAIEP CGUGGGAUAGCAUCACCUUGCAGCAGUGGCGCAAGGCGUUCGGAGUCAUUCCCCAAAAGG UGUUCAUCUUUUCGGGAACCUUCCGCAAGAAUCUGGAUCCGUACGAACAGUGGAGCGACC AAGAGAUUUGGAAAGUGGCAGAUGAAGUGGGAUUGCGGAGCGUCAUCGAACAGUUUCCG GGAAAGCUCGAUUUCGUCCUUGUGGACGGUGGAUGUGUGCUGUCGCACGGCCAUAAGCA GCUGAUGUGUCUCGCCCGCUCGGUGCUGUCAAAGGCGAAGAUCCUCUUGCUGGAUGAGCC CCAUCUGGACCCGGUGACGUACCAGAUCAUUAGACGGACGCUGAAACAGGCAUU CGCGGACUGCACUGUGAUCCUCUGUGAACAUCGGAUCGAGGCCAUGCUGGAGUGUCAACA AUUCUUGGUCAUCGAAGAGAACAAAGUGCGGCAGUACGACAGCAUCCAAAAGCUGCUGA ACGAGAGGUCCCUCUUCCGCCAGGCCAUCUCCCCAUCCGACCGGGUCAAGCUGUUCCCUC ACCGCAACAGCUCAAAGUGCAAAUCCAAACCCCAGAUCGCAGCGCUGAAAGAAGAAACUG AAGAAGAAGUGCAAGACACUAGACUGUGAKSHQHDNOJD SEQ ID NO: 14 AUGCAAAGGUCCCCAUUGGAGAAGGCCUCAGUGGUGUCGAAGCUGUUCUUCUCGUGGACC AGGCCUAUCCUCCGGAAGGGAUACAGACAGCGGCUGGAACUGUCCGAUAUCUACCAGAUC CCCAGCGUGGACAGCGCCGAUAAUCUCAGCGAAAAGCUGGAACGGGAAUGGGACCGCGAA CUCGCUUCGAAGAAGAACCCGAAGCUGAUUAAUGCUCUGCGGAGAUGUUUCUUUUGGCG GUUCAUGUUUUACGGAAUCUUUCUGUACUUGGGAGAGGUCACGAAGGCUGUGCAGCCUC UGCUGCUGGGACGGAUUAUCGCGUCGUAUGACCCCGACAAUAAGGAAGAACGCAGCAUCG CAAUCUACCUGGGCAUCGGAUUGUGCCUGCUGUUCAUCGUGAGAACUCUCCUGCUGCAUC CAGCCAUCUUCGGACUCCACCACAUUGGAAUGCAGAUGAGAAUCGCAAUGUUCUCCCUGA UCUACAAGAAAACGCUCAAGCUCAGCAGCCGCGUGCUCGAUAAGAUCAGCAUCGGUCAAU UGGUGUCCCUGCUGUCGAAUAACCUCAACAAGUUCGACGAAGGGUUGGCCCUCGCUCACU UCGUGUGGAUCGCACCUCUGCAAGUGGCCCUGCUGAUGGGACUGAUUUGGGAGCUGCUGC AGGCUUCCGCUUUCUGCGGCCUGGGAUUUCUUAUCGUGCUUGCUCUGUUCCAGGCGGGAC UGGGACGCAUGAUGAUGAAGUACCGGGACCAACGGGCUGGAAAGAUCAGCGAACGGCUG GUGAUCACUUCCGAAAUGAUUGAGAAUAUCCAGUCAGUCAAGGCGUACUGCUGGGAAGA GGCUAUGGAAAAGAUGAUUGAAAAUCUGAGACAAACCGAGCUGAAGCUGACUCGGAAAG CGGCCUACGUCAGAUACUUCAAUAGCUCAGCUUUCUUUUUCUCGGGGUUUUUCGUCGUGU UCCUGUCGGUGCUUCCCUAUGCCCUGAUUAAGGGCAUCAUUCUGCGCAAGAUCUUCACUA CGAUCUCAUUCUGCAUCGUGCUGCGCAUGGCUGUGACCAGACAAUUCCCGUGGGCCGUGC AAACCUGGUACGAUUCACUGGGAGCCAUCAACAAGAUCCAAGACUUUCUCCAAAAACAGG AGUAUAAGACCCUGGAGUACAACCUGACUACUACCGAGGUGGUGAUGGAGAACGUGACU GCGUUUUGGGAAGAAGGGUUCGGCGAACUGUUUGAAAAGGCCAAGCAGAACAAUAACAA CAGAAAGACUUCAAACGGAGAUGACUCGCUGUUCUUUUCGAACUUCAGCCUGCUGGGUAC GUUGAAAGAUAUCAACUUCAAGAUUGAGAGAGGACAGCUGCUGGCUGUGGCGG CCGGAGCAGGAAAAACUUCACUCCUGAUGGUGAUCAUGGGAGAACUCGAACCGU CAGAGGGGAAGAUUAAACACUCGGGAAGAAUCUCAUUUUGCUCCCAAUUUUCAUGGAUU AUGCCGGGAACCAUUAAAGAAAACAUUAUCUUCGGCGUGUCCUACGACGAGUACCGCUAC AGAUCGGUGAUCAAAGCAUGCCAGCUGGAAGAGGACAUCUCGAAAUUCGCUGAAAAAGA CAAUAUCGUGCUCGGGGAAGGCGGCAUCACCCUCAGCGGAGGACAACGGGCACGGAUUUC GCUCGCACGCGCAGUCUACAAAGACGCCGAUCUCUACCUCUUGGACAGCCCAUUCGGGUA UCUGGACGUGCUCACCGAGAAAGAGAUCUUCGAAAGCUGCGUCUGCAAGCUCAUGGCCAA CAAGACCCGCAUCCUCGUGACGUCGAAGAUGGAACAUCUUAAGAAGGCUGACAAGAUUCU Page 102 of 121 RECTIFIED SHEET (RULE 91) ISAIEP WO 53052 CAUUCUCCAUGAAGGGAGCUCAUACUUCUACGGCACCUUUUCCGAGCUCCAGAAUCUGCA ACCGGACUUCUCGUCCAAGCUGAUGGGCUGCGAUUCGUUUGAUCAGUUCUCCGCCGAGCG GAGAAACAGCAUUCUGACGGAAACCCUGCACCGGUUCUCGCUGGAAGGCGAUGCACCGGU GUCGUGGACCGAAACUAAGAAGCAAUCGUUCAAGCAGACGGGAGAGUUUGGAGAGAAGC ACUCCAUCCUCAACCCGAUCAACAGCAUCCGGAAGUUCAGCAUCGUGCAAAAGA CCCCGCUCCAGAUGAAUGGCAUUGAAGAGGACUCCGACGAACCUUUGGAACGCAGACUGA GCCUCGUGCCGGAUUCAGAACAGGGAGAAGCCAUUCUGCCACGGAUCUCCGUGAUCAGCA CUGGGCCAACUCUCCAAGCACGGCGGAGGCAGUCCGUGCUGAAUCUUAUGACGCACAGCG UGAACCAAGGGCAGAACAUCCAUAGAAAAACGACCGCUUCGACCAGGAAAGUCUCCCUCG CCCCACAAGCUAACCUCACGGAACUGGAUAUCUACUCCCGCAGACUGUCGCAAGAGACUG AGAUCUCCGAAGAGAUUAACGAAGAAGAUCUCAAAGAAUGUUUCUUCGAUGAU AUGGAAUCAAUCCCGGCAGUGACCACUUGGAACACCUACUUGCGCUAUAUCACUGUGCAC AAAAGCCUUAUCUUCGUCCUCAUCUGGUGCCUCGUCAUCUUCCUGGCUGAGGUCGCAGCC UCGCUGGUCGUGCUCUGGUUGCUCGGAAACACUCCGCUGCAGGAUAAGGGGAAUUCGACU CACUCGCGGAACAAUUCGUACGCUGUCAUUAUCACCUCGACGUCGUCAUACUACGUGUUU UACAUCUACGUGGGAGUGGCUGACACUCUGUUGGCUAUGGGGUUCUUUCGCGGCCUGCCA CUGGUCCAUACUCUCAUUACUGUGUCCAAAAUCCUUCAUCACAAGAUGUUGCAUUCAGUG CUGCAAGCACCGAUGUCCACCCUCAAUACCCUUAAGGCUGGCGGGAUUCUCAACCGCUUC UCGAAAGACAUCGCCAUCCUCGAUGAUCUUCUGCCUCUCACCAUCUUUGAUUUCAUCCAG CUGCUCCUGAUCGUGAUCGGAGCGAUUGCCGUGGUGGCAGUGUUGCAGCCGUACAUCUUU GUCGCAACUGUGCCGGUCAUCGUCGCCUUCAUCAUGCUGCGCGCCUACUUCUUGCAAACG UCACAGCAACUGAAGCAGCUUGAAUCCGAGGGAAGAUCACCUAUCUUCACCCACCUCGUG ACUUCGCUGAAGGGGCUGUGGACGCUGCGCGCAUUUGGAAGGCAACCGUACUUCGAGACU UUGUUCCACAAGGCGCUCAAUCUUCACACUGCCAAUUGGUUCUUGUACCUGUCAACGCUG AGAUGGUUUCAGAUGCGGAUCGAAAUGAUCUUCGUGAUCUUCUUUAUCGCGGUGACUUU CAUCUCGAUCCUGACUACCGGAGAGGGAGAAGGACGGGUGGGUAUUAUCCUCACUCUGGC GAUGAACAUCAUGUCGACGCUUCAGUGGGCGGUGAAUAGCUCAAUCGAUGUCGACUCGC UGAUGCGCUCCGUGAGCCGGGUGUUUAAGUUCAUCGACAUGCCAACUGAAGGGAAGCCG ACCAAGUCGACCAAACCGUACAAAAACGGACAGCUCUCCAAGGUGAUGAUUAUCGAGAAU UCCCACGUGAAAAAGGACGACAUCUGGCCAUCCGGUGGACAGAUGACCGUGAAGGACCUG ACCGCGAAGUACACUGAGGGAGGCAACGCAAUCCUUGAGAACAUCAGCUUCUCCAUCUCG CCCGGUCAGAGGGUGGGCCUUCUUGGCCGGACCGGAUCGGGAAAGUCCACUCUUCUGUCG GCCUUUCUUCGCCUCUUGAAUACUGAAGGGGAAAUCCAGAUCGACGGAGUGUCGUGGGA UAGCAUCACUCUGCAGCAGUGGCGGAAAGCGUUUGGAGUAAUCCCCCAAAAGGUCUUUA UCUUUAGCGGAACCUUCCGAAAGAAUCUCGAUCCUUAUGAACAGUGGUCAGAUCAAGAG AUUUGGAAAGUCGCGGACGAGGUUGGCCUUCGGAGUGUAAUCGAGCAGUUUCCGGGAAA ACUCGACUUUGUCCUUGUAGAUGGGGGAUGCGUCCUGUCGCAUGGGCACAAGCAGCUCAU GUGCCUGGCGCGAUCCGUCCUCUCUAAAGCGAAAAUUCUUCUCUUGGAUGAACCUUCGGC CCAUCUGGACCCGGUAACGUAUCAGAUCAUCAGAAGGACACUUAAGCAGGCGUUUGCCGA CUGCACGGUGAUUCUCUGUGAGCAUCGUAUCGAGGCCAUGCUCGAAUGCCAGCAAUUUCU UGUCAUCGAAGAGAAUAAGGUCCGCCAGUACGACUCCAUCCAGAAGCUGCUUAAUGAGA GAUCAUUGUUCCGGCAGGCGAUUUCACCAUCCGAUAGGGUGAAACUUUUUCCACACAGAA AUUCGUCGAAGUGCAAGUCCAAACCGCAGAUCGCGGCCUUGAAAGAAGAGACUGAAGAA CAAGACACGCGUCUUUAAlSEQHDNOJ4) Page 103 of121 RECTIFIED SHEET (RULE 91) ISAIEP 2014/028849 AUGCAGCGGUCCCCGCUCGAAAAGGCCAGUGUCGUGUCCAAACUCUUCUUCUCAUGGACU CGGCCUAUCCUUAGAAAGGGGUAUCGGCAGAGGCUUGAGUUGUCUGACAUCUACCAGAU CCCCUCGGUAGAUUCGGCGGAUAACCUCUCGGAGAAGCUCGAACGGGAAUGGGACCGCGA ACUCGCGUCUAAGAAAAACCCGAAGCUCAUCAACGCACUGAGAAGGUGCUUCUUCUGGCG GUUCAUGUUCUACGGUAUCUUCUUGUAUCUCGGGGAGGUCACAAAAGCAGUCCAACCCCU GUUGUUGGGUCGCAUUAUCGCCUCGUACGACCCCGAUAACAAAGAAGAACGGAGCAUCGC GAUCUACCUCGGGAUCGGACUGUGUUUGCUUUUCAUCGUCAGAACACUUUUGUUGCAUCC CUUCGGCCUCCAUCACAUCGGUAUGCAGAUGCGAAUCGCUAUGUUUAGCUUGAU CUACAAAAAGACACUGAAACUCUCGUCGCGGGUGUUGGAUAAGAUUUCCAUCGGUCAGU UGGUGUCCCUGCUUAGUAAUAACCUCAACAAAUUCGAUGAGGGACUGGCGCUGGCACAU UUCGUGUGGAUUGCCCCGUUGCAAGUCGCCCUUUUGAUGGGCCUUAUUUGGGAGCUGUU GCAGGCAUCUGCCUUUUGUGGCCUGGGAUUUCUGAUUGUGUUGGCAUUGUUUCAGGCUG GGCUUGGGCGGAUGAUGAUGAAGUAUCGCGACCAGAGAGCGGGUAAAAUCUCGGAAAGA CUCGUCAUCACUUCGGAAAUGAUCGAAAACAUCCAGUCGGUCAAAGCCUAUUGCUGGGAA GAAGCUAUGGAGAAGAUGAUUGAAAACCUCCGCCAAACUGAGCUGAAACUGACCCGCAA GGCGGCGUAUGUCCGGUAUUUCAAUUCGUCAGCGUUCUUCUUUUCCGGGUUCUUCGUUG UCUUUCUCUCGGUUUUGCCUUAUGCCUUGAUUAAGGGGAUUAUCCUCCGCAAGAUUUUC ACCACGAUUUCGUUCUGCAUUGUAUUGCGCAUGGCAGUGACACGGCAAUUUCCGUGGGCC GUGCAGACAUGGUAUGACUCGCUUGGAGCGAUCAACAAAAUCCAAGACUUCUUGCAAAA GCAAGAGUACAAGACCCUGGAGUACAAUCUUACUACUACGGAGGUAGUAAUGGAGAAUG UGACGGCUUUUUGGGAAGAGGGUUUUGGAGAACUGUUUGAGAAAGCAAAGCAGAAUAAC AACAACCGCAAGACCUCAAAUGGGGACGAUUCCCUGUUUUUCUCGAACUUCUCCCUGCUC GGAACACCCGUGUUGAAGGACAUCAAUUUCAAGAUUGAGAGGGGACAGCUUCUCGCGGU AGCGGGAAGCACUGGUGCGGGAAAAACUAGCCUCUUGAUGGUGAUUAUGGGGGAGCUUG AGCCCAGCGAGGGGAAGAUUAAACACUCCGGGCGUAUCUCAUUCUGUAGCCAGUUUUCAU GGAUCAUGCCCGGAACCAUUAAAGAGAACAUCAUUUUCGGAGUAUCCUAUGAUGAGUAC CGAUACAGAUCGGUCAUUAAGGCGUGCCAGUUGGAAGAGGACAUUUCUAAGUUCGCCGA GAAGGAUAACAUCGUCUUGGGAGAAGGGGGUAUUACAUUGUCGGGAGGGCAGCGAGCGC GGAUCAGCCUCGCGAGAGCGGUAUACAAAGAUGCAGAUUUGUAUCUGCUUGAUUCACCG UACCUCGACGUAUUGACAGAAAAAGAAAUCUUCGAGUCGUGCGUGUGUAAACU UAUGGCUAAUAAGACGAGAAUCCUGGUGACAUCAAAAAUGGAACACCUUAAGAAGGCGG ACAAGAUCCUGAUCCUCCACGAAGGAUCGUCCUACUUUUACGGCACUUUCUCAGAGUUGC AAAACUUGCAGCCGGACUUCUCAAGCAAACUCAUGGGGUGUGACUCAUUCGACCAGUUCA GCGCGGAACGGCGGAACUCGAUCUUGACGGAAACGCUGCACCGAUUCUCGCUUGAGGGUG AUGCCCCGGUAUCGUGGACCGAGACAAAGAAGCAGUCGUUUAAGCAGACAGGAGAAUUU GGUGAGAAAAGAAAGAACAGUAUCUUGAAUCCUAUUAACUCAAUUCGCAAGUUCUCAAU CGUCCAGAAAACUCCACUGCAGAUGAAUGGAAUUGAAGAGGAUUCGGACGAACCCCUGG AGCGCAGGCUUAGCCUCGUGCCGGAUUCAGAGCAAGGGGAGGCCAUUCUUCCCCGGAUUU CGGUGAUUUCAACCGGACCUACACUUCAGGCGAGGCGAAGGCAAUCCGUGCUCAACCUCA UGACGCAUUCGGUAAACCAGGGGCAAAACAUUCACCGCAAAACGACGGCCUCAACGAGAA AAGUGUCACUUGCACCCCAGGCGAAUUUGACUGAACUCGACAUCUACAGCCGUAGGCUUU CGCAAGAAACCGGACUUGAGAUCAGCGAAGAAAUCAAUGAAGAAGAUUUGAAAGAGUGU UUCUUUGAUGACAUGGAAUCAAUCCCAGCGGUGACAACGUGGAACACAUACUUGCGUUA CAUCACGGUGCACAAGUCCUUGAUUUUCGUCCUCAUCUGGUGUCUCGUGAUCUUUCUCGC Page 104 of121 RECTIFIED SHEET (RULE 91) ISAIEP CGCAGCGUCACUUGUGGUCCUCUGGCUGCUUGGUAAUACGCCCUUGCAAGACAA UUCUACACACUCAAGAAACAAUUCCUAUGCCGUGAUUAUCACUUCUACAAGCUC GUAUUACGUGUUUUACAUCUACGUAGGAGUGGCCGACACUCUGCUCGCGAUGGGUUUCU UCCGAGGACUCCCACUCGUUCACACGCUUAUCACUGUCUCCAAGAUUCUCCACCAUAAGA UGCUUCAUAGCGUACUGCAGGCUCCCAUGUCCACCUUGAAUACGCUCAAGGCGGGAGGUA UUUUGAAUCGCUUCUCAAAAGAUAUUGCAAUUUUGGAUGACCUUCUGCCCCUGACGAUC UUCGACUUCAUCCAGUUGUUGCUGAUCGUGAUUGGGGCUAUUGCAGUAGUCGCUGUCCU CCAGCCUUACAUUUUUGUCGCGACCGUUCCGGUGAUCGUGGCGUUUAUCAUGCUGCGGGC CUAUUUCUUGCAGACGUCACAGCAGCUUAAGCAACUGGAGUCUGAAGGGAGGUCGCCUA UCUUUACGCAUCUUGUGACCAGUUUGAAGGGAUUGUGGACGUUGCGCGCCUUUGGCAGG CAGCCCUACUUUGAAACACUGUUCCACAAAGCGCUGAAUCUCCAUACGGCAAAUUGGUUU UUGUAUUUGAGUACCCUCCGAUGGUUUCAGAUGCGCAUUGAGAUGAUUUUUGUGAUCUU CUUUAUCGCGGUGACUUUUAUCUCCAUCUUGACCACGGGAGAGGGCGAGGGACGGGUCG GUAUUAUCCUGACACUCGCCAUGAACAUUAUGAGCACUUUGCAGUGGGCAGUGAACAGC UCGAUUGAUGUGGAUAGCCUGAUGAGGUCCGUUUCGAGGGUCUUUAAGUUCAUCGACAU GCCGACGGAGGGAAAGCCCACAAAAAGUACGAAACCCUAUAAGAAUGGGCAAUUGAGUA AGGUAAUGAUCAUCGAGAACAGUCACGUGAAGAAGGAUGACAUCUGGCCUAGCGGGGGU CAGAUGACCGUGAAGGACCUGACGGCAAAAUACACCGAGGGAGGGAACGCAAUCCUUGA AAACAUCUCGUUCAGCAUUAGCCCCGGUCAGCGUGUGGGGUUGCUCGGGAGGACCGGGUC AGGAAAAUCGACGUUGCUGUCGGCCUUCUUGAGACUUCUGAAUACAGAGGGUGAGAUCC ACGGCGUUUCGUGGGAUAGCAUCACCUUGCAGCAGUGGCGGAAAGCGUUUGGA GUAAUCCCCCAAAAGGUCUUUAUCUUUAGCGGAACCUUCCGAAAGAAUCUCGAUCCUUAU GAACAGUGGUCAGAUCAAGAGAUUUGGAAAGUCGCGGACGAGGUUGGCCUUCGGAGUGU AAUCGAGCAGUUUCCGGGAAAACUCGACUUUGUCCUUGUAGAUGGGGGAUGCGUCCUGU CGCAUGGGCACAAGCAGCUCAUGUGCCUGGCGCGAUCCGUCCUCUCUAAAGCGAAAAUUC UUCUCUUGGAUGAACCUUCGGCCCAUCUGGACCCGGUAACGUAUCAGAUCAUCAGAAGGA CACUUAAGCAGGCGUUUGCCGACUGCACGGUGAUUCUCUGUGAGCAUCGUAUCGAGGCCA UGCUCGAAUGCCAGCAAUUUCUUGUCAUCGAAGAGAAUAAGGUCCGCCAGUACGACUCCA AGCUGCUUAAUGAGAGAUCAUUGUUCCGGCAGGCGAUUUCACCAUCCGAUAGG GUGAAACUUUUUCCACACAGAAAUUCGUCGAAGUGCAAGUCCAAACCGCAGAUCGCGGCC UUGAAAGAAGAGACUGAAGAAGAAGUUCAAGACACGCGUCUUCACCAUCACCAUCACCAU CACCAUCACCAUUAA (SEQ ID N0215) SEQ ID NO:16 AUGGCCACUGGA UCAAGAACCUCACUGCUGCUCGCUUUUGGACUGCUUUGCCUGCCCUGGU UGCHAGflAGGAUCGGCUUUCCCGACCAUCCCACUCUCCAUGCAGCGGUCCCCGCUCGAAAA GGCCAGUGUCGUGUCCAAACUCUUCUUCUCAUGGACUCGGCCUAUCCUUAGAAAGGGGUA UCGGCAGAGGCUUGAGUUGUCUGACAUCUACCAGAUCCCCUCGGUAGAUUCGGCGGAUAA CCUCUCGGAGAAGCUCGAACGGGAAUGGGACCGCGAACUCGCGUCUAAGAAAAACCCGAA GCUCAUCAACGCACUGAGAAGGUGCUUCUUCUGGCGGUUCAUGUUCUACGGUAUCUUCUU GUAUCUCGGGGAGGUCACAAAAGCAGUCCAACCCCUGUUGUUGGGUCGCAUUAUCGCCUC GUACGACCCCGAUAACAAAGAAGAACGGAGCAUCGCGAUCUACCUCGGGAUCGGACUGUG UUUGCUUUUCAUCGUCAGAACACUUUUGUUGCAUCCAGCAAUCUUCGGCCUCCAUCACAU CGGUAUGCAGAUGCGAAUCGCUAUGUUUAGCUUGAUCUACAAAAAGACACUGAAACUCU Page 105 of121 RECTIFIED SHEET (RULE 91) ISAIEP GGGUGUUGGAUAAGAUUUCCAUCGGUCAGUUGGUGUCCCUGCUUAGUAAUAAC CUCAACAAAUUCGAUGAGGGACUGGCGCUGGCACAUUUCGUGUGGAUUGCCCCGUUGCAA GUCGCCCUUUUGAUGGGCCUUAUUUGGGAGCUGUUGCAGGCAUCUGCCUUUUGUGGCCU GGGAUUUCUGAUUGUGUUGGCAUUGUUUCAGGCUGGGCUUGGGCGGAUGAUGAUGAAGU AUCGCGACCAGAGAGCGGGUAAAAUCUCGGAAAGACUCGUCAUCACUUCGGAAAUGAUC AUCCAGUCGGUCAAAGCCUAUUGCUGGGAAGAAGCUAUGGAGAAGAUGAUUGA AAACCUCCGCCAAACUGAGCUGAAACUGACCCGCAAGGCGGCGUAUGUCCGGUAUUUCAA UUCGUCAGCGUUCUUCUUUUCCGGGUUCUUCGUUGUCUUUCUCUCGGUUUUGCCUUAUGC CUUGAUUAAGGGGAUUAUCCUCCGCAAGAUUUUCACCACGAUUUCGUUCUGCAUUGUAU UGCGCAUGGCAGUGACACGGCAAUUUCCGUGGGCCGUGCAGACAUGGUAUGACUCGCUUG GAGCGAUCAACAAAAUCCAAGACUUCUUGCAAAAGCAAGAGUACAAGACCCUGGAGUAC AAUCUUACUACUACGGAGGUAGUAAUGGAGAAUGUGACGGCUUUUUGGGAAGAGGGUUU UGGAGAACUGUUUGAGAAAGCAAAGCAGAAUAACAACAACCGCAAGACCUCAAAUGGGG ACGAUUCCCUGUUUUUCUCGAACUUCUCCCUGCUCGGAACACCCGUGUUGAAGGACAUCA AUUUCAAGAUUGAGAGGGGACAGCUUCUCGCGGUAGCGGGAAGCACUGGUGCGGGAAAA ACUAGCCUCUUGAUGGUGAUUAUGGGGGAGCUUGAGCCCAGCGAGGGGAAGAUUAAACA CUCCGGGCGUAUCUCAUUCUGUAGCCAGUUUUCAUGGAUCAUGCCCGGAACCAUUAAAGA GAACAUCAUUUUCGGAGUAUCCUAUGAUGAGUACCGAUACAGAUCGGUCAUUAAGGCGU GCCAGUUGGAAGAGGACAUUUCUAAGUUCGCCGAGAAGGAUAACAUCGUCUUGGGAGAA GGGGGUAUUACAUUGUCGGGAGGGCAGCGAGCGCGGAUCAGCCUCGCGAGAGCGGUAUA CAAAGAUGCAGAUUUGUAUCUGCUUGAUUCACCGUUUGGAUACCUCGACGUAUUGACAG AAAUCUUCGAGUCGUGCGUGUGUAAACUUAUGGCUAAUAAGACGAGAAUCCUG GUGACAUCAAAAAUGGAACACCUUAAGAAGGCGGACAAGAUCCUGAUCCUCCACGAAGG AUCGUCCUACUUUUACGGCACUUUCUCAGAGUUGCAAAACUUGCAGCCGGACUUCUCAAG CAAACUCAUGGGGUGUGACUCAUUCGACCAGUUCAGCGCGGAACGGCGGAACUCGAUCUU GACGGAAACGCUGCACCGAUUCUCGCUUGAGGGUGAUGCCCCGGUAUCGUGGACCGAGAC AAAGAAGCAGUCGUUUAAGCAGACAGGAGAAUUUGGUGAGAAAAGAAAGAACAGUAUCU UGAAUCCUAUUAACUCAAUUCGCAAGUUCUCAAUCGUCCAGAAAACUCCACUGCAGAUGA AUGGAAUUGAAGAGGAUUCGGACGAACCCCUGGAGCGCAGGCUUAGCCUCGUGCCGGAU UCAGAGCAAGGGGAGGCCAUUCUUCCCCGGAUUUCGGUGAUUUCAACCGGACCUACACUU CAGGCGAGGCGAAGGCAAUCCGUGCUCAACCUCAUGACGCAUUCGGUAAACCAGGGGCAA AACAUUCACCGCAAAACGACGGCCUCAACGAGAAAAGUGUCACUUGCACCCCAGGCGAAU UUGACUGAACUCGACAUCUACAGCCGUAGGCUUUCGCAAGAAACCGGACUUGAGAUCAGC AUCAAUGAAGAAGAUUUGAAAGAGUGUUUCUUUGAUGACAUGGAAUCAAUCCC AGCGGUGACAACGUGGAACACAUACUUGCGUUACAUCACGGUGCACAAGUCCUUGAUUU UCGUCCUCAUCUGGUGUCUCGUGAUCUUUCUCGCUGAGGUCGCAGCGUCACUUGUGGUCC UCUGGCUGCUUGGUAAUACGCCCUUGCAAGACAAAGGCAAUUCUACACACUCAAGAAACA AUUCCUAUGCCGUGAUUAUCACUUCUACAAGCUCGUAUUACGUGUUUUACAUCUACGUA GGAGUGGCCGACACUCUGCUCGCGAUGGGUUUCUUCCGAGGACUCCCACUCGUUCACACG CUUAUCACUGUCUCCAAGAUUCUCCACCAUAAGAUGCUUCAUAGCGUACUGCAGGCUCCC AUGUCCACCUUGAAUACGCUCAAGGCGGGAGGUAUUUUGAAUCGCUUCUCAAAAGAUAU UGCAAUUUUGGAUGACCUUCUGCCCCUGACGAUCUUCGACUUCAUCCAGUUGUUGCUGAU CGUGAUUGGGGCUAUUGCAGUAGUCGCUGUCCUCCAGCCUUACAUUUUUGUCGCGACCGU UCCGGUGAUCGUGGCGUUUAUCAUGCUGCGGGCCUAUUUCUUGCAGACGUCACAGCAGCU UAAGCAACUGGAGUCUGAAGGGAGGUCGCCUAUCUUUACGCAUCUUGUGACCAGUUUGA PagelO6of121 RECTIFIED SHEET (RULE 91) ISAIEP WO 53052 AGGGAUUGUGGACGUUGCGCGCCUUUGGCAGGCAGCCCUACUUUGAAACACUGUUCCACA AAGCGCUGAAUCUCCAUACGGCAAAUUGGUUUUUGUAUUUGAGUACCCUCCGAUGGUUU CAGAUGCGCAUUGAGAUGAUUUUUGUGAUCUUCUUUAUCGCGGUGACUUUUAUCUCCAU CUUGACCACGGGAGAGGGCGAGGGACGGGUCGGUAUUAUCCUGACACUCGCCAUGAACAU UAUGAGCACUUUGCAGUGGGCAGUGAACAGCUCGAUUGAUGUGGAUAGCCUGAUGAGGU CCGUUUCGAGGGUCUUUAAGUUCAUCGACAUGCCGACGGAGGGAAAGCCCACAAAAAGU ACGAAACCCUAUAAGAAUGGGCAAUUGAGUAAGGUAAUGAUCAUCGAGAACAGUCACGU GAAGAAGGAUGACAUCUGGCCUAGCGGGGGUCAGAUGACCGUGAAGGACCUGACGGCAA AAUACACCGAGGGAGGGAACGCAAUCCUUGAAAACAUCUCGUUCAGCAUUAGCCCCGGUC AGCGUGUGGGGUUGCUCGGGAGGACCGGGUCAGGAAAAUCGACGUUGCUGUCGGCCUUC UUGAGACUUCUGAAUACAGAGGGUGAGAUCCAGAUCGACGGCGUUUCGUGGGAUAGCAU CACCUUGCAGCAGUGGCGGAAAGCGUUUGGAGUAAUCCCCCAAAAGGUCUUUAUCUUUA GCGGAACCUUCCGAAAGAAUCUCGAUCCUUAUGAACAGUGGUCAGAUCAAGAGAUUUGG AAAGUCGCGGACGAGGUUGGCCUUCGGAGUGUAAUCGAGCAGUUUCCGGGAAAACUCGA CUUUGUCCUUGUAGAUGGGGGAUGCGUCCUGUCGCAUGGGCACAAGCAGCUCAUGUGCCU GGCGCGAUCCGUCCUCUCUAAAGCGAAAAUUCUUCUCUUGGAUGAACCUUCGGCCCAUCU GGACCCGGUAACGUAUCAGAUCAUCAGAAGGACACUUAAGCAGGCGUUUGCCGACUGCAC GGUGAUUCUCUGUGAGCAUCGUAUCGAGGCCAUGCUCGAAUGCCAGCAAUUUCUUGUCA UCGAAGAGAAUAAGGUCCGCCAGUACGACUCCAUCCAGAAGCUGCUUAAUGAGAGAUCA UUGUUCCGGCAGGCGAUUUCACCAUCCGAUAGGGUGAAACUUUUUCCACACAGAAAUUCG UCGAAGUGCAAGUCCAAACCGCAGAUCGCGGCCUUGAAAGAAGAGACUGAAGAAGAAGU UCAAGACACGCGUCUUUAA(SEQUDNOJ6) AUGCAGCGGUCCCCGCUCGAAAAGGCCAGUGUCGUGUCCAAACUCUUCUUCUCAUGGACU CGGCCUAUCCUUAGAAAGGGGUAUCGGCAGAGGCUUGAGUUGUCUGACAUCUACCAGAU CCCCUCGGUAGAUUCGGCGGAUAACCUCUCGGAGAAGCUCGAACGGGAAUGGGACCGCGA ACUCGCGUCUAAGAAAAACCCGAAGCUCAUCAACGCACUGAGAAGGUGCUUCUUCUGGCG GUUCAUGUUCUACGGUAUCUUCUUGUAUCUCGGGGAGGUCACAAAAGCAGUCCAACCCCU GUUGUUGGGUCGCAUUAUCGCCUCGUACGACCCCGAUAACAAAGAAGAACGGAGCAUCGC GAUCUACCUCGGGAUCGGACUGUGUUUGCUUUUCAUCGUCAGAACACUUUUGUUGCAUCC AGCAAUCUUCGGCCUCCAUCACAUCGGUAUGCAGAUGCGAAUCGCUAUGUUUAGCUUGAU CUACAAAAAGACACUGAAACUCUCGUCGCGGGUGUUGGAUAAGAUUUCCAUCGGUCAGU UGGUGUCCCUGCUUAGUAAUAACCUCAACAAAUUCGAUGAGGGACUGGCGCUGGCACAU UUCGUGUGGAUUGCCCCGUUGCAAGUCGCCCUUUUGAUGGGCCUUAUUUGGGAGCUGUU GCAGGCAUCUGCCUUUUGUGGCCUGGGAUUUCUGAUUGUGUUGGCAUUGUUUCAGGCUG GGCUUGGGCGGAUGAUGAUGAAGUAUCGCGACCAGAGAGCGGGUAAAAUCUCGGAAAGA CUCGUCAUCACUUCGGAAAUGAUCGAAAACAUCCAGUCGGUCAAAGCCUAUUGCUGGGAA GAAGCUAUGGAGAAGAUGAUUGAAAACCUCCGCCAAACUGAGCUGAAACUGACCCGCAA GUAUGUCCGGUAUUUCAAUUCGUCAGCGUUCUUCUUUUCCGGGUUCUUCGUUG UCUUUCUCUCGGUUUUGCCUUAUGCCUUGAUUAAGGGGAUUAUCCUCCGCAAGAUUUUC ACCACGAUUUCGUUCUGCAUUGUAUUGCGCAUGGCAGUGACACGGCAAUUUCCGUGGGCC ACAUGGUAUGACUCGCUUGGAGCGAUCAACAAAAUCCAAGACUUCUUGCAAAA GCAAGAGUACAAGACCCUGGAGUACAAUCUUACUACUACGGAGGUAGUAAUGGAGAAUG Page 107 of 121 RECTIFIED SHEET (RULE 91) ISAIEP UGACGGCUUUUUGGGAAGAGGGUUUUGGAGAACUGUUUGAGAAAGCAAAGCAGAAUAAC AACAACCGCAAGACCUCAAAUGGGGACGAUUCCCUGUUUUUCUCGAACUUCUCCCUGCUC GGAACACCCGUGUUGAAGGACAUCAAUUUCAAGAUUGAGAGGGGACAGCUUCUCGCGGU AAGCACUGGUGCGGGAAAAACUAGCCUCUUGAUGGUGAUUAUGGGGGAGCUUG GCGAGGGGAAGAUUAAACACUCCGGGCGUAUCUCAUUCUGUAGCCAGUUUUCAU GGAUCAUGCCCGGAACCAUUAAAGAGAACAUCAUUUUCGGAGUAUCCUAUGAUGAGUAC CGAUACAGAUCGGUCAUUAAGGCGUGCCAGUUGGAAGAGGACAUUUCUAAGUUCGCCGA GAAGGAUAACAUCGUCUUGGGAGAAGGGGGUAUUACAUUGUCGGGAGGGCAGCGAGCGC GCCUCGCGAGAGCGGUAUACAAAGAUGCAGAUUUGUAUCUGCUUGAUUCACCG UUUGGAUACCUCGACGUAUUGACAGAAAAAGAAAUCUUCGAGUCGUGCGUGUGUAAACU UAUGGCUAAUAAGACGAGAAUCCUGGUGACAUCAAAAAUGGAACACCUUAAGAAGGCGG ACAAGAUCCUGAUCCUCCACGAAGGAUCGUCCUACUUUUACGGCACUUUCUCAGAGUUGC AAAACUUGCAGCCGGACUUCUCAAGCAAACUCAUGGGGUGUGACUCAUUCGACCAGUUCA GCGCGGAACGGCGGAACUCGAUCUUGACGGAAACGCUGCACCGAUUCUCGCUUGAGGGUG AUGCCCCGGUAUCGUGGACCGAGACAAAGAAGCAGUCGUUUAAGCAGACAGGAGAAUUU GGUGAGAAAAGAAAGAACAGUAUCUUGAAUCCUAUUAACUCAAUUCGCAAGUUCUCAAU CGUCCAGAAAACUCCACUGCAGAUGAAUGGAAUUGAAGAGGAUUCGGACGAACCCCUGG AGCGCAGGCUUAGCCUCGUGCCGGAUUCAGAGCAAGGGGAGGCCAUUCUUCCCCGGAUUU CGGUGAUUUCAACCGGACCUACACUUCAGGCGAGGCGAAGGCAAUCCGUGCUCAACCUCA UGACGCAUUCGGUAAACCAGGGGCAAAACAUUCACCGCAAAACGACGGCCUCAACGAGAA AAGUGUCACUUGCACCCCAGGCGAAUUUGACUGAACUCGACAUCUACAGCCGUAGGCUUU CGCAAGAAACCGGACUUGAGAUCAGCGAAGAAAUCAAUGAAGAAGAUUUGAAAGAGUGU UUCUUUGAUGACAUGGAAUCAAUCCCAGCGGUGACAACGUGGAACACAUACUUGCGUUA CAUCACGGUGCACAAGUCCUUGAUUUUCGUCCUCAUCUGGUGUCUCGUGAUCUUUCUCGC UGAGGUCGCAGCGUCACUUGUGGUCCUCUGGCUGCUUGGUAAUACGCCCUUGCAAGACAA AGGCAAUUCUACACACUCAAGAAACAAUUCCUAUGCCGUGAUUAUCACUUCUACAAGCUC GUAUUACGUGUUUUACAUCUACGUAGGAGUGGCCGACACUCUGCUCGCGAUGGGUUUCU UCCGAGGACUCCCACUCGUUCACACGCUUAUCACUGUCUCCAAGAUUCUCCACCAUAAGA UGCUUCAUAGCGUACUGCAGGCUCCCAUGUCCACCUUGAAUACGCUCAAGGCGGGAGGUA UUUUGAAUCGCUUCUCAAAAGAUAUUGCAAUUUUGGAUGACCUUCUGCCCCUGACGAUC UUCGACUUCAUCCAGUUGUUGCUGAUCGUGAUUGGGGCUAUUGCAGUAGUCGCUGUCCU CCAGCCUUACAUUUUUGUCGCGACCGUUCCGGUGAUCGUGGCGUUUAUCAUGCUGCGGGC CUAUUUCUUGCAGACGUCACAGCAGCUUAAGCAACUGGAGUCUGAAGGGAGGUCGCCUA UCUUUACGCAUCUUGUGACCAGUUUGAAGGGAUUGUGGACGUUGCGCGCCUUUGGCAGG CAGCCCUACUUUGAAACACUGUUCCACAAAGCGCUGAAUCUCCAUACGGCAAAUUGGUUU UUGUAUUUGAGUACCCUCCGAUGGUUUCAGAUGCGCAUUGAGAUGAUUUUUGUGAUCUU CUUUAUCGCGGUGACUUUUAUCUCCAUCUUGACCACGGGAGAGGGCGAGGGACGGGUCG GUAUUAUCCUGACACUCGCCAUGAACAUUAUGAGCACUUUGCAGUGGGCAGUGAACAGC GAUGUGGAUAGCCUGAUGAGGUCCGUUUCGAGGGUCUUUAAGUUCAUCGACAU GCCGACGGAGGGAAAGCCCACAAAAAGUACGAAACCCUAUAAGAAUGGGCAAUUGAGUA AGGUAAUGAUCAUCGAGAACAGUCACGUGAAGAAGGAUGACAUCUGGCCUAGCGGGGGU CAGAUGACCGUGAAGGACCUGACGGCAAAAUACACCGAGGGAGGGAACGCAAUCCUUGA AAACAUCUCGUUCAGCAUUAGCCCCGGUCAGCGUGUGGGGUUGCUCGGGAGGACCGGGUC AGGAAAAUCGACGUUGCUGUCGGCCUUCUUGAGACUUCUGAAUACAGAGGGUGAGAUCC AGAUCGACGGCGUUUCGUGGGAUAGCAUCACCUUGCAGCAGUGGCGGAAAGCGUUUGGA Page 108 of 121 RECTIFIED SHEET (RULE 91) ISAIEP GUAAUCCCCCAAAAGGUCUUUAUCUUUAGCGGAACCUUCCGAAAGAAUCUCGAUCCUUAU GAACAGUGGUCAGAUCAAGAGAUUUGGAAAGUCGCGGACGAGGUUGGCCUUCGGAGUGU AAUCGAGCAGUUUCCGGGAAAACUCGACUUUGUCCUUGUAGAUGGGGGAUGCGUCCUGU CGCAUGGGCACAAGCAGCUCAUGUGCCUGGCGCGAUCCGUCCUCUCUAAAGCGAAAAUUC UUCUCUUGGAUGAACCUUCGGCCCAUCUGGACCCGGUAACGUAUCAGAUCAUCAGAAGGA CACUUAAGCAGGCGUUUGCCGACUGCACGGUGAUUCUCUGUGAGCAUCGUAUCGAGGCCA UGCUCGAAUGCCAGCAAUUUCUUGUCAUCGAAGAGAAUAAGGUCCGCCAGUACGACUCCA AGCUGCUUAAUGAGAGAUCAUUGUUCCGGCAGGCGAUUUCACCAUCCGAUAGG GUGAAACUUUUUCCACACAGAAAUUCGUCGAAGUGCAAGUCCAAACCGCAGAUCGCGGCC UUGAAAGAAGAGACUGAAGAAGAAGUUCAAGACACGCGUCUUUAA($3)HDNOJ7) SEQ ID NO: 18 _ AUGGCCACUGGAUCAAGAACCUCACUGCUGCUCGCUUUUGGACUGCUUUGCCUGC CCUGGUUGCAAGAAGGAUCGGCUUUCCCGACCAUCCCACUCUCC(flxflDNOfl& SEQIDNO:w AUGGCAACUGGAUCAAGAACCUCCCUCCUGCUCGCAUUCGGCCUGCUCUGUCUCC CAUGGCUCCAAGAAGGAAGCGCGUUCCCCACUAUCCCCCUCUCG (SEQ ID NO:19) SEQ ID NO: 20 CGGGUGGCAUCCCUGUGACCCCUCCCCAGUGCCUCUCCUGGCCCUGGAAGUUGCC GUGCCCACCAGCCUUGUCCUAAUAAAAUUAAGUUGCAUCAAGCU Page 109 of 121 RECTIFIED SHEET (RULE 91) ISAIEP 2014/028849 Equivalents The specification is most thoroughly understood in light of the teachings of the references cited within the specification. The embodiments within the specification provide an illustration of ments of the invention and should not be construed to limit the scope of the invention. The skilled artisan readily recognizes that many other embodiments are encompassed by the invention. All publications and patents cited in this disclosure are incorporated by reference in their entirety. To the extent the material incorporated by reference contradicts or is inconsistent with this specification, the specification will supersede any such material. The on of any references herein is not an admission that such references are prior art to the present invention.
Unless otherwise ted, all numbers expressing quantities of ingredients, reaction ions, and so forth used in the specification, including claims, are to be understood as approximations and may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the ation of the doctrine of equivalents to the scope of the claims, each cal parameter should be construed in light of the number of significant digits and ordinary rounding approaches. The recitation of series of numbers with differing s of significant digits in the specification is not to be construed as implying that s with fewer significant digits given have the same precision as numbers with more significant digits given.
The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,3, (Cat least one,” and “one or more than one.” The use of the term “or” in the claims is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the atives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or.” Unless otherwise indicated, the term “at least” preceding a series of elements is to be understood to refer to every element in the series. Those skilled in the art will recognize, or Page 110 of 121 2014/028849 be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following .
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ry skill in the art to which this invention s. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described.
The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to te such publication by virtue of prior invention.
Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.
Other embodiments of the invention will be apparent to those d in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be ered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.
Page 111 olel

Claims (20)

CLAIMS We claim:
1. An in vitro transcribed mRNA comprising a coding sequence at least 80% identical to SEQ ID NO: 3 for use in treating cystic fibrosis in a mammal.
2. The mRNA for use according to claim 1, wherein the coding sequence is at least 90% identical to SEQ ID NO: 3.
3. The mRNA for use according to claim 1, wherein the coding sequence is 100% identical to SEQ ID NO: 3.
4. The mRNA for use according to any one of the preceding claims, wherein the mRNA comprises a 5’ untranslated region (UTR), a 3’ UTR, a signal peptide coding sequence, a cap structure and/or a tail structure.
5. The mRNA for use according to claim 4, n the 5’-UTR comprises SEQ ID NO: 4 and/or the 3’-UTR comprises SEQ ID NO: 5.
6. The mRNA for use according to claim 4 or 5, wherein the tail structure is a poly-A tail of at least 70, 100, 120, 150, 200, or 250 residues in length.
7. The mRNA for use according to any one of claims 4-6, wherein the cap structure is a cap1 structure.
8. The mRNA for use ing to any one of the preceding claims, wherein the mRNA comprises one or more nonstandard tide(s), optionally wherein the one or more nonstandard nucleotide(s) is/are chosen from 5-methyl-cytidine, uridine, and 2-thiouridine.
9. The mRNA for use according to any one of the preceding claims, wherein the mRNA is to be administered to the lung of the mammal by inhalation, asal administration, aerosolization, or nebulization.
10. The mRNA for use according to any one of the preceding claims, wherein the mRNA comprises a coding sequence which encodes a human cystic fibrosis transmembrane conductance regulator (CFTR) protein of SEQ ID NO:1, optionally wherein the human CFTR protein is expressed in the epithelial cells of the lung.
11. The mRNA for use according to any one of the preceding claims, wherein the mRNA is administered with a carrier.
12. The mRNA for use ing to claim 11, wherein the carrier comprises an organic cation, such as a cationic lipid or a cationic c r.
13. The mRNA for use according to claim 12, wherein the cationic c polymer is selected from the group consisting of polyethyleneimine (PEI), protamine, PEGylated protamine, poly-L-lysine (PLL), and PEGylated PLL.
14. The mRNA for use according to claim 13, wherein the PEI is branched PEI with a molecular weight ranging from 10 kDa to 40 kDa.
15. The mRNA for use according to any one of claims 11-14, wherein the carrier is a liposome.
16. A composition comprising an mRNA and a carrier, wherein the mRNA is an in vitro transcribed mRNA and has a coding sequence at least 80% identical to SEQ ID NO: 3.
17. The composition of claim 16, wherein the carrier comprises an organic cation, such as a ic lipid or a cationic organic polymer.
18. The composition according to claim 17, wherein the cationic organic polymer is selected from the group consisting of polyethyleneimine (PEI), ine, PEGylated protamine, poly-L- lysine (PLL), and PEGylated PLL.
19. The composition according to claim 18, wherein the PEI is branched PEI with a molecular weight ranging from 10 kDa to 40 kDa.
20. The ition of claim 16, wherein the carrier is a liposome. Pages 115 to 121 are ionally blank Pages 115 to 121 are ionally blank Pages 115 to 121 are ionally blank Pages 115 to 121 are ionally blank Pages 115 to 121 are ionally blank Pages 115 to 121 are ionally blank Pages 115 to 121 are ionally blank
NZ711657A 2013-03-14 2014-03-14 Cftr mrna compositions and related methods and uses NZ711657B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ751462A NZ751462A (en) 2013-03-14 2014-03-14 Cftr mrna compositions and related methods and uses

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361783663P 2013-03-14 2013-03-14
US61/783,663 2013-03-14
PCT/US2014/028849 WO2014153052A2 (en) 2013-03-14 2014-03-14 Cftr mrna compositions and related methods and uses

Publications (2)

Publication Number Publication Date
NZ711657A NZ711657A (en) 2021-01-29
NZ711657B2 true NZ711657B2 (en) 2021-04-30

Family

ID=

Similar Documents

Publication Publication Date Title
US20230302039A1 (en) Cftr mrna compositions and related methods and uses
NZ711657B2 (en) Cftr mrna compositions and related methods and uses
HK40005353A (en) Cftr mrna compositions and related methods and uses
HK1220137B (en) Cftr mrna compositions and related methods and uses
EA047691B1 (en) mRNA CFTR COMPOSITIONS AND RELATED METHODS AND APPLICATIONS